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ABSTRACT 
Cancer is one of the leading causes of death in the world, arising when cells accumulate 
genomic mutations that render them incapable of controlling their own proliferation and survival. 
While substantial improvements in patient outcome have been achieved over the years, 
completely eliminating tumorigenic cells remains a significant challenge, and some cancer types 
(such as pancreatic cancer) have not shown meaningfully improved patient survival rates despite 
our advancements in understanding cancer cell biology and treatment. 
Genetic targeting approaches to the treatment of cancer have yielded some success, but 
have shown rather disappointing results overall. In contrast to the diversity of genetic aberrations 
within tumor cells (making treatment difficult), cancers share common phenotypes that are more 
universally targetable. As cancers evolve within their biological environment to become 
aggressive, the net effects of their genetic alterations lead to 1) decreased sensitivity to cell death 
cues, 2) altered oxidative state and redox-dependent signaling, and 3) dramatically increased 
demand for energy production and biosynthesis (altered metabolism).  
The work of this study shows that in pancreatic cancer cells reversible metabolic 
adaptation alters oxidative stress sensitivity and triggers persistent drug resistance, demonstrating 
the interplay of the above three cellular activities. Further experimentation identifies the 
mitochondrial protein apoptosis-inducing factor (AIF) as an essential signaling node functioning 
at the convergence of all three of these processes. In response to cellular metabolic cues, AIF 
controls the ability of the mitochondria to produce energy required for tumorigenic growth, 
invasion, and survival while functioning as mitochondrial translation factor. Distinct from this 
pivotal metabolic role, AIF serves as a transmitter of extra-mitochondrial redox signaling cues 
regulating pro-tumor gene expression programs that are lethal without AIF. Finally, AIF exhibits 
 iv 
involvement in atypical death pathways associated with the cell death regulators PGAM5 and 
XIAP. Remarkably, these AIF activities are functionally dissociable and demonstrate the 
multifunctional nature of AIF in control of tumorigenesis. 
Overall this study defines a variety of diverse AIF activities at the intersection of multiple 
tumorigenic phenotypes, furthering our understanding of how cancer cells converge upon 
different aggressive characteristics and revealing potential vulnerabilities for therapeutic 
intervention. 
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I. INTRODUCTION 
Mitochondria: Energy production, redox signals, and cell death 
Mitochondrial structure and function 
Long recognized for their roles as the powerhouses of the eukaryotic cell, mitochondria 
are key mediators of metabolism, homeostasis, survival, and death. In addition to providing 
cellular energy in the form of adenosine triphosphate (ATP), mitochondria also generate heat, 
regulate calcium storage and signaling, and house pro-apoptotic factors that are released into the 
cytosol to execute cell death programs following apoptotic stimuli [1]. Mitochondria are 
significant producers of reactive oxygen species (ROS), which are potentially toxic byproducts 
of cellular respiration that also function as second messengers to control signaling pathways that 
promote cellular homeostasis [2]. Together these diverse activities balance the fate of the cell, 
and their dysregulation is associated with a wide variety of pathologies, underscoring the 
fundamental impact of mitochondria upon human physiology and disease. 
As shown in Figure 1.1, mitochondria are comprised of two membranes that define their 
suborganellar compartments. The outer mitochondrial membrane (OMM) separates the 
mitochondria from the cytosol and is permeable to small molecules (e.g., H2O, ATP, pyruvate), 
while the inner mitochondrial membrane (IMM) is a highly selective diffusion barrier between 
the intermembrane space (IMS) and the matrix. The matrix houses numerous metabolic 
processes including the TCA cycle, amino acid transamination, β-oxidation of fatty acids, and 
the initial stages of the urea cycle. ATP production via respiration occurs at the IMM, which is 
folded into cristae that increase IMM surface area and create localized pH pockets that drive 
respiration (discussed below). 
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Figure 1.1. Mitochondrial structure and metabolism. 
Mitochondria consist of two membranes (OMM and IMM) separating the IMS and the matrix, 
with the IMM folded into cristae. Inset: Following complex I-mediated oxidation of NADH, 
electrons are shuttled to complex III via ubiquinone/coenzyme Q (Q) and then to complex IV via 
cytochrome c (cyt c) with O2 as the terminal electron acceptor. As electrons are shuttled through 
the ETC, complexes I, III, and IV pump protons from the matrix to the IMS to establish a proton 
gradient that is used by complex V to power ATP synthesis. 
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Aerobic and anaerobic metabolism 
Much of the cell’s fuel for ATP synthesis is derived from glucose. Upstream of 
mitochondrial ATP production, glucose is oxidized into two molecules of pyruvate during 
glycolysis as nicotinamide adenine dinucleotide (NAD
+
) is reduced to NADH, yielding a 
relatively small amount of ATP. Subsequently pyruvate can be imported into the mitochondria 
for complete oxidation into CO2 to produce substantially greater ATP quantities, or, depending 
on cellular metabolic needs, pyruvate may be reduced to lactate in the cytosol. Under conditions 
of abundant oxygen, pyruvate is broken down to CO2 while its electrons reduce O2 in order for 
mitochondria to generate ATP (Figure 1.2A). In oxygen-deprived anaerobic cells, such as rapidly 
contracting skeletal muscle or hypoxic tumor cells, ATP is produced entirely from glycolysis. In 
this situation, instead of delivery into the mitochondria, pyruvate is converted to lactate so that 
NAD
+
 can be regenerated for continued glycolytic activity (Figure 1.2B). 
Mitochondrial ATP production 
Mitochondria are the main providers of ATP in eukaryotic cells. Among the many 
biochemical pathways of the cell, various fuel sources (carbohydrates, amino acids, lipids) are 
broken down to their basic building blocks (CO2, H2O, NH3, etc.), while the energy released 
from these processes is used to power mitochondrial ATP synthesis. During the breakdown of 
reduced fuels, metabolites are enzymatically oxidized while their electrons are used to reduce 
NAD
+
 to NADH or flavin adenine dinucleotide (FAD) to FADH2. In the mitochondria, the 
electrons carried by NADH and FADH2 are delivered into a series of protein complexes within 
the IMM known as the electron transport chain (ETC, alternatively called the respiratory chain). 
The ETC establishes a proton gradient across the IMM by means of redox reactions culminating 
in the reduction of O2 to H2O. Establishment of the proton gradient, a thermodynamically 
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difficult process requiring an input of free energy, is driven by the passage of electrons through 
cofactors of progressively increasing reduction potential. As electrons are transported through 
these assemblies, complexes I, III, and IV sequester potential energy by pumping protons (H
+
) 
across the IMM from the matrix to the IMS. During oxidative phosphorylation (OXPHOS), ATP 
synthase (also known as complex V) harnesses this free energy by delivering protons across the 
IMM in the opposite direction, from high (IMS side) to low concentration (matrix side). Proton 
flux through complex V powers its ATP synthase activity, catalyzing the formation of ATP from 
ADP (adenosine diphosphate) and inorganic phosphate (Pi). The flow of electrons through the 
ETC and its coupling to ATP synthesis are diagrammed in Figure 1.1. 
 
Figure 1.2. Glucose metabolism under aerobic and anaerobic conditions. 
A) When O2 is present, pyruvate is fully oxidized during the TCA cycle and used to generate 
ATP in the mitochondria. B) In the absence of O2, pyruvate is converted to lactate in order for 
the cell to regenerate NAD
+
 for continued glycolysis-derived ATP production. 
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Figure 1.3. Cellular redox balance. 
A) ROS regulate a variety of cell signaling pathways involved in metabolism and angiogenesis, 
growth, survival, and proliferation. B) Effects of altered ROS levels upon cell fate and 
tumorigenesis.  Types of ROS generators and ROS scavengers are indicated. Different signaling 
molecules (MAPKs, NF-κB, PI3K, HIFs) can promote ROS or detoxify ROS to the benefit of 
tumorigenesis. 
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Mitochondria and reactive oxygen species 
As potentially toxic by-products of cellular respiration, ROS are formed primarily by the 
aberrant leakage of electrons from the ETC. Mitochondrial ROS occur when electrons liberated 
from the respiratory chain partially reduce molecular oxygen to form superoxide anions, which 
are subsequently converted to hydrogen peroxide by mitochondrial superoxide dismutases 1 and 
2 (SOD1, SOD2). Through the activity of glutathione peroxidase, hydrogen peroxide can then be 
neutralized during its reduction to H2O. In addition to their production during normal 
mitochondrial respiration, ROS are also rapidly generated to high levels during ETC malfunction 
that is observed in cases of mitochondrial DNA mutation, complex I deficiency, or chemical 
ETC inhibition [3-5]. Additional sources of endogenous ROS include plasma membrane 
NADPH oxidase complexes, peroxisomes, and endoplasmic reticula, and cells may intentionally 
generate ROS in response to various stimuli including TNFα, EGF, IL-1β, hypoxia, and 
irradiation [6, 7]. 
High levels of ROS are biologically deleterious (Figure 1.3), leading to lipid 
peroxidation, protein damage, and enzymatic deactivation due to the oxidation of redox-sensitive 
cofactors. Critically, ROS cause oxidative damage to nucleic acids including base oxidation and 
strand breaks, creating potentially tumorigenic DNA lesions. In addition to their role in tumor 
initiation, high ROS levels are also involved with tumor progression, chronic inflammation, 
neurodegeneration, diabetes, and aging, among a host of other chronic conditions [8]. 
Historically ROS have been viewed as inevitable byproducts of metabolic reactions, but 
in the past two decades their essential roles in signal transduction to regulate normal cellular and 
physiological processes have become apparent [9]. Under normal cellular conditions, ROS are 
maintained at small amounts, as the ETC generates relatively low levels that are easily 
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neutralized by antioxidant enzymes.  In healthy cells, a residual amount of ROS that escape 
enzymatic breakdown persists, and despite their potential for toxicity, these low ROS levels are 
predominantly beneficial (Figure 1.3). At basal levels ROS are essential for basic cell processes 
including proliferation, viability, and differentiation [10]. Moreover, while excessive ROS levels 
induce cellular toxicity, ROS overload is in fact often an intentionally produced active 
component of various programmed cell death pathways that are physiologically beneficial (e.g., 
apoptosis). 
Mitochondrial control of cell death 
While actively respiring mitochondria are the predominant energy producers of the cell, 
mitochondria are also central to cell death, functioning as cellular stress sensors at the 
convergence of various cell death pathways. Although many distinct death pathways have been 
defined in various cell types and contexts, cell death is traditionally classified into three broad 
categories: apoptosis, autophagy, and necrosis [11]. These mechanisms are described in detail in 
appendix A. 
Apoptosis (Greek, "falling away"), the most common and well-studied type of cell death, 
was named for the characteristic morphology of cells condensing and breaking into smaller 
apoptotic bodies that are phagocytosed by neighboring cells [12]. In contrast to premature or 
accidental cell death (necrosis), the quiet incorporation of apoptotic bodies into phagocytes 
allows immune evasion without inducing inflammation [13]. Biochemical hallmarks of apoptosis 
include the activation of pro-apoptotic Bcl-2 protein family members,  caspase cleavage and 
activation, permeabilization of the mitochondrial membrane, flipping of phosphatidylserine 
membrane lipids, high ROS levels, DNA fragmentation and degradation, and rupture of the cell 
membrane [14]. Apoptosis is a routine event in multicellular organisms (>1 million cells per 
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second in humans), promoting normal development (e.g., organ morphogenesis and lymphocyte 
maturation) and eliminating diseased cells, e.g., those infected with pathogens or that have 
accumulated irreparable and potentially tumorigenic mutations [15, 16]. 
When cell death is a physiological necessity or cells become potentially tumorigenic, 
apoptosis is the most frequent biological outcome. Depending on stimulus and context, apoptosis 
can be activated through either an extrinsic or intrinsic pathway (Figure 1.4). Extrinsic apoptosis 
involves the binding of an external signaling ligand with its cognate receptor, in turn inducing 
toxic pathways within the cell. Intrinsic apoptosis is activated by cellular stresses such as 
radiation or chemical damage that are detected by the mitochondria, which respond by releasing 
apoptotic molecules that activate death pathways in the cytosol. Both extrinsic and intrinsic 
pathways are mediated by cascades of cysteine-aspartate proteases called caspases. Caspases 
activated by proteolytic cleavage serve as the executioners of apoptosis [17]. 
In the extrinsic pathway, cells respond to external signaling molecules that bind 
membrane-bound TNF receptors (TNFRs), leading to caspase activation and cell death. In 
contrast, the intrinsic pathway is activated by nonspecific internal stresses that directly or 
indirectly lead to changes in mitochondrial membrane permeability. Under nonstress conditions, 
the pro-survival proteins Bcl-2 and Bcl-XL maintain mitochondrial membrane integrity by 
inhibiting their pro-apoptotic family members Bax, Bak, and Bid [18]. When the cell death 
pathway is induced, apoptotic proteins are activated through a variety of mechanisms relieving 
these inhibitory interactions. An example of this mitochondrial death protein activation can occur 
via the tumor suppressor p53. Following lethal signals, p53 is stabilized and can induce apoptotic 
genes as a nuclear transcription factor but also promote cell death proteins through direct 
interactions with Bcl-2 family members at the mitochondria [19]. Following apoptotic insult, 
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Bax and Bak oligomerize, causing the formation of pores in the OMM that increase its 
permeability [20]. Once the mitochondrial membrane has permeabilized, various death factors 
are released into the cytosol including Smac (second mitochondria-derived activator of caspases) 
and the ETC molecule cytochrome c [21]. Upon release from the mitochondria, Smac binds X-
linked inhibitor of apoptosis (XIAP), neutralizing its ability to inhibit caspases, while cytosolic 
cytochrome c binds Apaf-1 and induces its oligomerization, forming the death complex known 
as the apoptosome [22].  The apoptosome recruits procaspase-9 and induces its cleavage into 
active caspase-9, which subsequently activates caspases-3 and 7 to mediate cellular disassembly 
[23]. 
Apoptosis-inducing factor: a microcosm of mitochondrial function 
Overview of AIF architecture and activities 
Common to the regulation of the diverse activities of the mitochondria is the NADH-
dependent oxidoreductase known as apoptosis-inducing factor (AIF). As its name suggests, AIF 
was first characterized in the context of cell death [24]; however later studies have established 
the death-associated role of AIF is secondary to its widespread mitochondrial activities in 
controlling cellular metabolic and redox homeostasis [25, 26]. 
AIF (also known as AIFM1 and PCDC8) is a ubiquitously expressed gene mapped to the 
X chromosome in mice and humans [27]. Phylogenetic analyses have revealed strong 
conservation of AIF among mammals with ~90% sequence identity, while AIF and AIF-like 
proteins originating from a universal common ancestor are found in eukaryotes, bacteria, and 
archaea [28-30]. The human AIF gene encodes a 613-amino acid (67 kDa) precursor polypeptide 
(Figure 1.5A) with an N-terminal mitochondrial localization sequence (MLS) that is cleaved at 
residue 54 upon mitochondrial import. This mature 62 kDa form of AIF (Δ1-54 AIF, Figure  
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Figure 1.4. Extrinsic and intrinsic pathways of apoptosis. 
The extrinsic apoptotic pathway is mediated by TNFs (e.g., Fas ligand) and TNFRs (e.g., Fas 
receptor), which recruit the adaptor molecule FADD to activate caspase-8. The intrinsic 
pathway, occurring through the mitochondria, involves OMM permeabilization followed by the 
release of cytochrome c and activation of caspase-9. Both pathways converge upon caspase-3 
and caspase-7 activation. AIF can be released from the mitochondria and subsequently 
translocate to the nucleus in a caspase-independent manner. 
 
1.5A) is tethered to the IMM by a small hydrophobic segment with the soluble protein surfaces 
extending into the IMS [24, 31]. Following import into the mitochondria, AIF acquires its 
oxidoreductase activity through the incorporation of an FAD moiety (Figure 1.5B) and adopts a 
glutathione reductase fold. Upon cell death stimuli and OMM permeabilization, AIF undergoes a 
second round of proteolytic cleavage at position 102 by cathepsins and/or calpains, freeing AIF 
from its IMM tether [24, 28, 31-33]. The liberated cytosolic form of AIF (Δ1-102 AIF, 57 kDa, 
Figure 5A) is targeted to the nucleus via its nuclear localization sequence (NLS), and its C-
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terminal domain binds DNA to initiate chromatin condensation and DNA fragmentation 
characteristic of cellular demise [24, 34]. 
Role of AIF in cell death 
AIF was first identified in 1996 as a soluble factor released from mouse mitochondria 
during apoptosis, causing isolated nuclei to undergo chromatin condensation and 
internucleosomal DNA fragmentation [35]. During this time knowledge of apoptotic signaling 
was limited, and the ability of AIF to trigger features of apoptosis independently of caspase 
activation (Figure 1.4) was an unprecedented discovery in the field of cell death research. Under 
conditions of cell death, OMM permeabilization induces the release of mitochondria-localized 
AIF into the cytosol (Figure 1.4), followed by its translocation to the nucleus and nonspecific 
DNA binding [24, 31, 32, 36-43]. In the nucleus AIF recruits additional factors including 
endonuclease G, cyclophilin A, and/or H2AX to form active DNAse complexes that induce 
chromatinolysis and DNA degradation [40, 41, 43]. The precise mechanistic details of this 
process remain unclear.  
AIF-mediated toxicity is regulated by a variety of cell death inhibitors during various 
phases of the apoptotic cascade including Bcl-2, the heat shock protein Hsp70, and XIAP. AIF 
was first identified in the context of Bcl-2-mediated protection from apoptosis, and its release 
from the mitochondria is attenuated when Bcl-2 inhibits OMM permeabilization [24, 35]. 
Through its interaction with Apaf-1, Hsp70 promotes apoptotic resistance by suppressing the 
apoptosome complex and ensuing caspase activation [44, 45]. In a caspase-independent manner, 
Hsp70 also binds AIF, preventing its relocation to the nucleus [46, 47]. XIAP is an endogenous 
inhibitor of caspases but also functions as an E3 ubiquitin ligase [48]. Duckett and colleagues 
identified AIF as a binding partner of XIAP and target for ubiquitination [49]. Contrary to the 
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canonical association of ubiquitin modification with proteasomal targeting, XIAP-mediated 
ubiquitination of AIF at lysine 255 interferes with the ability of AIF to bind DNA and induce 
chromatin degradation [50]. It is notable that since AIF-mediated death is caspase independent, 
the actual mechanisms by which AIF causes toxicity more closely resemble necroptosis 
(appendix A). 
Interestingly, we have identified the mitochondrial phosphatase PGAM5 as an AIF-
associated factor that triggers a novel death pathway leading to mitophagic cell death. Similar to 
AIF, PGAM5 is ubiquitinated and inhibited by XIAP through a non-degradative mechanism 
[53]. This indicates the existence of a regulatory triad comprising AIF, PGAM5, and XIAP that 
could regulate the balance of cell death and survival. Therefore while AIF is not commonly a 
significant factor for the execution of “classical” apoptosis, AIF is likely to play a role in atypical 
death mechanisms associated with XIAP and PGAM5. Further exploration of this death triad and 
its control through non-canonical ubiquitination represents a significant area of research that may 
further explain how cells determine decisions of cell fate. 
Despite an extensive number of studies defining the mechanisms by which AIF mediates 
cellular toxicity and its utility as a cell death marker [24, 31, 32, 36-43], the ability of AIF to kill 
is often insignificant [49, 51-54]. Rather, AIF activity is essential for the cell to die only under 
limited stimuli and to a narrow range of cell types, primarily neurons and cardiomyocytes in 
response to hypoxia-ischemia, DNA damage, and excitotoxicity [55-58]. Therefore, in sharp 
contrast to its name and initial characterization, AIF does not function as a universal effector of 
cell death. 
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Figure 1.5. Domains and structure of AIF. 
A) AIF is translated into a precursor polypeptide containing a mitochondrial localization 
sequence (MLS), two FAD-binding domains, an NADH binding domain, two nuclear 
localization sequences (NLS), and a C-terminal (Ct) DNA-binding domain. AIF is cleaved at the 
indicated positions during processing and mitochondrial release. B) Three-dimensional structure 
of AIF. Protein-bound FAD is shown in yellow. Image from the RCSB PDB (www.rcsb.org) of 
PDB ID 4BV6 [59]. 
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Role of AIF in cell survival and homeostasis 
Concurrently with studies of cell death mechanisms, AIF was also shown to possess an 
intrinsic redox activity dependent on FAD and NAD(P)H, similar to bacterial oxidoreductases, 
and that is independent of its death activity [24, 60]. AIF can catalyze the oxidization of both 
NADH and NADPH while reducing O2 to superoxide in vitro [60], but the role of this 
NAD(P)H-oxidase activity in vivo is not well understood. These findings indicated additional 
activities distinct from AIF-mediated cell death and would first bring its dual nature to light. The 
enzymatic activity of AIF has been linked to control of mitochondrial structure and function [60, 
61], and while a complete picture of how AIF promotes mitochondrial homeostasis remains 
elusive, it has become increasingly clear that the predominant cellular role of AIF maintains 
survival. The physiological significance of AIF in control of cell homeostasis and survival has 
been demonstrated in studies of AIF-null mice [26, 62], targeted AIF deletion experiments [63, 
64], and cases of AIF mutation in humans [65-68] leading to a variety of mitochondrial 
respiratory chain and redox balance disorders. Inactivation of the AIF gene in mice causes 
embryonic lethality [62, 69], whereas the Harlequin mouse model exhibits severe and 
progressive neurodegeneration as a consequence of decreased AIF protein expression (>80%) in 
all tissues [26]. Tissue-specific AIF deletion studies demonstrated a series of physiological 
defects including skeletal muscle atrophy and dilated cardiomyopathy resulting from severe 
mitochondrial dysfunction and loss of cristae structure [63, 64]. More recent studies in humans 
have identified AIF mutations that lead to respiratory chain malfunction with a spectrum of 
clinical manifestations including mitochondrial encephalomyopathy [65], prenatal 
ventriculomegaly [66], and Cowchock syndrome [68]. While largely descriptive, these studies 
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collectively illustrate a role for AIF as a central regulator of cellular metabolism and redox 
balance. 
Consistent with the phenotypes shared by AIF deficiency and mitochondrial respiratory 
chain disorders, ablation of AIF causes a loss of complex I of the ETC, resulting in impaired 
OXPHOS [25]. AIF is neither a part of complex I nor found to interact with any ETC subunits, 
but it has been suggested that AIF can transfer electrons from NADH to ubiquinone, functioning 
as a supplemental NADH oxidase to the ETC [70]. Other groups have reported that AIF mediates 
respiratory chain biogenesis by facilitating the co-translational mitochondrial import and 
stabilization of the ETC import factor CHCHD4 [71, 72]. It has been proposed that AIF serves as 
a sensor of cellular redox conditions, controlling mitochondrial respiration and/or cell death in 
response to the metabolic and oxidative environment [73]. These findings establish the centrality 
of AIF to control of the mitochondrial respiratory chain and energy production, and confirm AIF 
as a significant mediator of cell survival and homeostasis. 
AIF functions as a pro-tumor molecule 
Metabolism and redox control in cancer 
Cancer arises when cells accumulate genomic mutations that render them incapable of 
controlling their own proliferation. To exhibit aggressive and invasive characteristics, cancer 
cells rewire their metabolic pathways in such a way that they produce high levels of both energy 
and macromolecular supplies supporting further proliferation. Otto Warburg first observed that 
cancer cells increase their glucose consumption despite sufficient O2 levels relative to normal 
cells, hypothesizing that defective mitochondrial respiration contributes to tumorigenesis [74]. 
While elevated glucose consumption is a common characteristic of tumor cells, it is now well-
established that many cancer cells rely on both glycolysis and mitochondrial energy metabolism 
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[75]. As Warburg noted, such changes indeed often involve a substantial increase in glycolytic 
activity (“aerobic glycolysis”), but rather than stemming from defective respiration, elevated 
glycolysis serves to supply the pentose phosphate pathway with intermediates used for 
macromolecule biosynthesis (Figure 1.6). These metabolic reprogramming events come at the 
cost of mitochondrial energy production, and the subsequent loss of metabolic leeway sensitizes 
cancer cells to metabolic perturbation relative to normal cells [76]. This “metabolism addiction” 
makes the disruption of cancer cells’ delicate metabolic balance an attractive therapeutic goal. 
 
Figure 1.6. Metabolic fates of glucose. 
Glucose may be catabolized to pyruvate during glycolysis, producing ATP, or glycolytic 
intermediates may enter biosynthesis reactions through the pentose phosphate pathway. If further 
glycolysis is required, pyruvate is converted to lactate. Alternatively pyruvate can be fully 
oxidized in the mitochondria to produce ATP. Metabolism addiction in cancer cells can result 
from the balancing act of upregulating these pathways simultaneously. 
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In addition to metabolic alterations supplying fuels necessary for aggressive growth, 
cancer cells also exhibit a moderate increase in ROS levels relative to normal cells that drive 
growth-promoting signaling events [77] and promote oxygen-independent metabolism in 
hypoxic tumor regions inaccessible to vasculature [78]. There exists a threshold for increased 
ROS, and this elevation of the cellular redox state must be carefully controlled since high ROS 
levels are lethal [79] (Figure 1.3). ROS-dependent signaling regulated by the mitogen-activated 
protein kinase (MAPK) family of proteins [80] is a significant example of how ROS levels 
impact cell fate. MAPKs operate as central signaling hubs to control a wide range of cellular 
activities in response to ROS and many other stimuli. Under conditions of elevated ROS, the 
MAPK known as c-Jun N-terminal kinase (JNK) can be activated through phosphorylation by 
upstream kinases (MAP2Ks) and relief of MAPK phosphatase (MKP)-mediated inhibition [80]. 
While it is recognized that exceptions exist, the generally held view is that in response to the 
cell’s oxidative stress level, low levels of JNK activity promote proliferation, whereas high 
levels of JNK activity induce apoptosis [81]. Cancer cells elevate ROS to levels that drive pro-
survival and proliferative activities through JNK and numerous other redox-sensitive signaling 
pathways. Although elevated ROS levels promote tumorigenic signal transduction, these 
increased ROS cause cancer cells to exhibit increased sensitivity to oxidative stress-induced 
toxicity relative to normal cells. Therefore there exists therapeutic potential for targeting redox 
balance in cancer treatment [82]. 
Tumorigenic activities of AIF 
The pro-survival activity of AIF and its role in controlling metabolic and redox 
homeostasis in healthy cells is well positioned to be exploited by cancer cells in order to promote 
growth, invasiveness, and chemoresistance [51, 52, 54]. Indeed, increased AIF protein levels are 
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observed in a variety of cancer types including esophageal, skin, colorectal, gastric, lymphatic, 
pancreatic, and prostate cancers [51, 52, 83-88], suggestive of a prominent role in tumorigenesis. 
Despite its initial characterization as a death-associated molecule, the possibility of elevated AIF 
functioning as a tumor suppressor is unlikely. First, the requirement for AIF in cell death is 
exceedingly cell type and context specific: AIF-mediated toxicity is essential for cell death 
primarily in neurons and cardiomyocytes and in response to specific stimuli including hypoxia-
ischemia, oxidative stress, DNA damaging agents, engagement of death receptors, and 
excitotoxins [55-58]. Second, in rare cases that AIF may induce lethality, endogenous AIF 
inhibitors (XIAP, Hsp70, Bcl-2) are also expressed at high levels in cancer [89-92] and could 
neutralize potentially toxic effects of AIF elevation. It is more likely that instead of a major role 
for AIF death function, the pro-survival activities of AIF would serve to mediate tumor-
permissive metabolic and oxidative states. 
How might the presence of AIF promote tumorigenesis? A supportive role of AIF in 
cancer would likely derive from its ability to regulate ETC/OXPHOS, which gains significance 
as cells become more aggressive and reliant on mitochondrial function. When tumors undergoing 
aerobic glycolysis reach advanced stages, cancer cells often continue to rely on mitochondria as 
a source of energy production [93] and suffer a metabolic disadvantage when mitochondrial 
function is lost. Indeed, several recent studies have identified paramount roles for OXPHOS in 
promoting the invasiveness of cancer cells [94-96]. A second mechanism for AIF support of 
cancer might involve increased ROS levels through AIF-mediated catalysis, which would serve 
as signaling molecules to promote proliferation and survival. 
The work of Urbano et al. [54] was the first to demonstrate a pro-tumor role for AIF. 
Following ablation of AIF, Porter and colleagues observed reductions of complex I subunits and 
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decreased ROS levels in colorectal, breast, and lung cancer cell lines. These changes 
corresponded to impairments in both growth and resistance to chemical oxidative stress and 
DNA damaging agents in a manner dependent on the enzymatic activity of AIF. This 
demonstrated for the first time that apoptosis-inducing factor can function as an anti-apoptotic 
molecule that supports—rather than suppresses—tumorigenesis, likely through control of 
cellular metabolism and/or ROS-mediated survival signaling. 
AIF enzymatic activity supports advanced prostate cancer 
The work of our laboratory has further defined tumorigenic roles for the enzymatic 
activity of AIF in the context of advanced prostate cancer [51]. In a mouse model of prostate 
tumorigenesis [97], loss of the tumor suppressor PTEN in prostate tissue leads to increased AIF 
protein levels, indicating a possible role in the development of prostate tumorigenesis. Extending 
these data to human studies, increased AIF expression is observed at both the RNA and protein 
levels in prostate tumors relative to normal tissue. Notably, AIF protein levels become 
significantly more abundant with disease progression, and together these data show AIF levels 
can serve as a marker for disease and may promote prostate cancer (PCa) progression. 
To test this hypothesis, AIF was stably suppressed in the PCa cell lines PC3, DU145, and 
LNCaP. While LNCaP cells are sensitive to androgen deprivation (a means of PCa treatment), 
PC3 and DU145 have developed resistance and are considered a model of further disease 
progression. Sensitivity to a variety of chemical death agents was unaffected following AIF 
ablation, further confirming the hypothesis that AIF is not a significant inducer of death in 
cancer. While proliferation was unaffected under nutrient-rich conditions in vitro, suppression of 
AIF severely impaired invasion, migration, and growth in Matrigel™ substrate. This AIF-
dependent growth support was observed in PC3 and DU145 (advanced cells) but not LNCaP 
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cells. Xenograft studies of AIF-mediated tumorigenesis in mice were then conducted using PC3 
cells, demonstrating that AIF is critical for tumor growth in vivo. 
Metabolic assessment of PCa cells revealed that AIF-dependent growth support is 
directly related to its metabolic contribution. AIF knockdown led to decreased levels of complex 
I in PC3 and DU145 cells, yet subunits examined were unaffected in LNCaP cells. Notably, this 
was the first report of a context in which AIF does not regulate complex I. AIF-deficient PCa 
cells with decreased complex I also exhibited increased glucose consumption, increased lactate 
secretion, and decreased oxygen consumption. Together these data indicate that following 
suppression of AIF, mitochondrial OXPHOS expectedly decreases and is accompanied by an 
increase in glycolysis. The significance of this glycolytic elevation to survival was confirmed by 
sensitivity to glycolytic disruption, as cells treated with the glycolysis inhibitor 2-deoxyglucose 
exhibited substantially greater amounts of death when AIF was suppressed. Consistent with other 
metabolic analyses, these effects were only observed in PC3 and DU145 cells, while LNCaP 
cells were unaffected. 
To determine if these observations are due to the enzymatic activity of AIF, cells were 
restored with either wild-type (WT) AIF or AIF with T263A/V300A mutations (TVA), which 
cause catalytic impairment. Restoration of AIF-deficient PC3 cells with WT-AIF but not TVA-
AIF restored the metabolic and growth effects of AIF deficiency to control levels, demonstrating 
that the NADH-oxidase activity of AIF supports metabolism benefitting the growth and 
invasiveness of advanced prostate cancer cells. It is notable while only WT-AIF can restore 
growth and metabolism, both WT-AIF and TVA-AIF can restore complex I. This suggests that 
the enzymatic activity of AIF is not significant to complex I levels yet remains a critical factor 
for cellular metabolism, and the nature of metabolic switching following AIF ablation is not 
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limited to the effects of complex I expression alone. Altogether these experiments demonstrate 
the essential role of AIF enzymatic activity to the progression of PCa and prompt further 
investigation into AIF metabolic and redox activity in cancer. 
Open questions and research objectives 
Expanding studies of AIF metabolic activity to additional cancer types 
Previous work in our laboratory [51] defined a novel pro-tumor metabolic role for the 
enzymatic activity of AIF in PCa. A natural question that arises is whether AIF expression and/or 
activity contribute to other cancer types, or if AIF is uniquely important to the development of 
limited cancers such as PCa and colorectal cancer [51, 54]. AIF expression and metabolic 
contribution to PCa both increase with disease progression. Extending this observation to other 
cancer types, does this suggest that AIF is important specifically to advanced-stage cancers? 
This hypothesis forms the basis for our investigation of AIF activity in pancreatic ductal 
adenocarcinoma (PDAC), a disease almost universally advanced at diagnosis and consequently 
one of the most lethal malignancies across the world. Due to the anatomical position of the 
pancreas, tumors cannot be seen or felt during routine exams, and early detection methods for 
disease are scarce. Because symptoms typically do not manifest until the cancer has 
metastasized, tumors often become unresectable before diagnosis, and long-term survival after 
resection is poor. Moreover, current treatment options fail to prolong survival beyond several 
months that are accompanied by severe side effects, with PDAC mortality nearly identical to 
incidence [98]. The identification of AIF as a contributory factor for PDAC pathogenesis would 
extend its role beyond the context of PCa and also implicate AIF as a potential therapeutic target. 
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Pancreatic cancer as a setting to identify and predict which cells are sensitive to AIF 
PDAC is one of the most bioenergetically sensitive and metabolically diverse known 
diseases [76]. In recent years several groups have subtyped PDAC based on gene expression 
signatures, oncogene addiction, and drug responses, which have been coined as classical, 
quasimesenchymal, and exocrine-like [99] and are described in Appendix B. Another study by 
Daemen et al. [100] demonstrated metabolic subtypes with strong correlation to the above 
groups. The “slow proliferating” metabolic subtype is especially low in carbohydrates and amino 
acids with substantially longer doubling times compared to the other two subtypes. The other 
two subtypes are classified as “glycolytic,” corresponding to the quasimesenchymal subtype, and 
“lipogenic,” corresponding to the classical subtype. The glycolytic subtype exhibits elevated 
activities of glycolysis and pentose phosphate pathways (PPP), whereas the lipogenic subtype 
displays increased lipid levels and, importantly, increased ETC/OXPHOS and mitochondrial 
redox activity. 
Based upon our laboratory’s previous work, AIF-mediated metabolism and growth 
support is clearly cell type-specific [51], but how/why AIF controls complex I and glucose 
metabolism in some cells but not others remains an open question. AIF is proposed to function as 
a metabolic/redox sensor of the mitochondria [73], and it therefore stands to reason that AIF 
activity may be regulated by the metabolic conditions and needs of the cell. The study of AIF 
among PDAC subtypes may reveal if AIF exhibits a subgroup preference, similar to PCa, and 
perhaps more importantly, demonstrate how AIF functions in different metabolic environments 
and elucidate predictive factors for AIF sensitivity. 
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A widespread role for the enzymatic activity of AIF 
AIF is established to participate in both cell death and metabolism. AIF metabolic 
activity is limited to specific cell types, and essential roles for AIF in cellular toxicity are even 
more elusive. Do all AIF activities vary by cell type and context, or might AIF exhibit some yet 
to be identified universal cellular activity? 
The significance of AIF enzymatic activity to mitochondrial homeostasis and survival has 
been demonstrated in a variety of descriptive studies [26, 62-68], and a possible widespread 
function may lie in the ability of AIF to produce ROS. The enzymatic activity of AIF has been 
demonstrated to generate superoxide in vitro [60], but AIF-mediated redox regulation in cells is 
an area largely unexplored. Altered ROS levels and ROS types control a variety of signaling 
pathways and cellular functions, and AIF-dependent differences in phenotypes among cells can 
be explained by cell type-specific methods of ROS regulation (e.g., types and levels of 
antioxidants, other ROS producers, and/or endogenous regulators of redox signaling pathways). 
Such observations would confirm the long-speculated role of AIF as a central regulator of 
cellular oxidant signaling. 
The implications of AIF as a signaling molecule 
The identification of AIF as a control point for signal transduction would serve as a 
mechanistic milestone in understanding how AIF regulates cellular homeostasis, and explain 
how AIF can control nuclear gene expression from within the mitochondria. In the context of 
cancer, redox mechanisms through which AIF mediates tumorigenesis have yet to be identified. 
AIF levels increase in cancer, but upregulation typically does not exceed two- to threefold [51, 
52]. This might represent a change that supports pro-tumor metabolic and redox activity but 
without inducing ROS overload or toxicity in the nucleus. Increased AIF levels could drive 
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redox signaling activity in cancer that promotes drug resistance [54], metabolism [51], or other 
tumorigenic properties such as metastasis (Figure 1.7). 
How AIF metabolic and redox activities are integrated in cells remains an open question. 
Cellular metabolic and oxidative states are intertwined. Examples of the complex relationship 
between metabolism and oxidative stress include the production of NADPH (during PPP, a 
pathway branching from glycolysis) that regenerates glutathione for antioxidant defenses, and 
ROS production by actively respiring mitochondria. AIF-mediated regulation of ROS and redox 
signaling could occur through complex I, AIF itself, or both (Figure 1.7). Further definition of 
AIF ablation-sensitive and insensitive cell types (e.g., PC3 vs. LNCaP) followed by comparison 
of metabolic vs. redox activities among cells would be a starting point to delineating AIF-
associated metabolic regulation and control of oxidative state. If AIF-mediated redox signaling is 
independent of complex I and metabolism, then changes in cellular oxidative state should be 
observed in cells both sensitive and insensitive to AIF ablation. Additionally, experiments 
assessing redox effects of AIF suppression while retaining mitochondrial respiratory chain 
activity would further confirm whether AIF activities are related or independent. 
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Figure 1.7. Involvement of AIF in cellular redox signaling. 
AIF-mediated ROS production may result from the regulation of complex I and/or AIF 
enzymatic activity. Cellular ROS regulate a variety of genetic programs mediated by various 
signaling molecules. 
Summary of research 
The work of this study explores the metabolic and redox activities of AIF and their 
relationship in the context of both normal and tumorigenic cells. While AIF is not typically 
critical for cell death, experiments of this work demonstrate an involvement of AIF with PGAM5 
and XIAP. PGAM5 suppresses XIAP-mediated ubiquitination of AIF, and XIAP and PGAM5 
oppose one another to mediate cell death-survival balance. Studies of metabolically 
reconditioned PDAC cells show that metabolic adaptation plays a significant role in the 
acquisition of increased tumorigenesis through the mitochondria, indicating a likely role for AIF 
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growth and survival of PDAC cells through a metabolic mechanism that depends on cellular 
metabolic needs. OXPHOS-dependent PDAC cells require the metabolic activity of AIF for 
growth and survival, whereas glycolytic cells that do not rely on OXPHOS are metabolically 
insensitive to AIF. This suggests that basal metabolic state governs AIF-dependent growth 
support and demonstrates for the first time a potential explanation for different AIF sensitivity 
among cell types. Building upon these findings, the ability of AIF to mediate oxidative stress-
induced signaling is then assessed in a broad panel of both normal and cancer cells. Regardless 
of AIF-mediated metabolic control, AIF is required for oxidative stress-induced activation of the 
MAP kinases JNK1, p38, and ERK. The role of AIF as a novel signal transduction protein is 
confirmed through its ability to trigger the metastatic event known as cadherin switch through 
JNK1, and genetic reversal of the cadherin switch in the absence of AIF is lethal. Finally, the 
abilities of AIF to regulate redox signaling and metabolism are shown to be functionally 
uncoupled, demonstrating novel routes through which AIF mediates growth and survival and 
underscoring their significance to human health and disease. 
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II. REVERSIBLE ADAPTATION OF PANCREATIC CANCER CELLS TO 
GLYCOLYSIS INHIBITION INDUCES A PERSISTENT INCREASE IN DRUG 
RESISTANCE 
Abstract 
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest forms of cancer, due in 
part to altered metabolism that contributes to invasion and drug resistance. PDAC cells are 
among the most metabolically diverse and adaptable cancer types, and a better understanding of 
how metabolic adaptation impacts drug resistance may be used to further identify molecular 
targets. Here we demonstrate that while several PDAC cell types exhibit resistance to glycolytic 
inhibition with 2-deoxyglucose (2DG), MIA PaCa-2 cells are highly sensitive with a strong 
dependence upon glycolysis for survival. Prolonged exposure to 2DG causes MIA PaCa-2 cells 
to adapt by upregulating mitochondrial activity, which is accompanied by increased ROS and 
oxidative stress sensitivity, altered growth and invasion, and increased drug resistance. 
Remarkably, these metabolic and growth effects reverse when conditions of glycolytic 
suppression are relieved. However, increased drug resistance persists when cells are removed 
from 2DG pressure. This demonstrates that metabolism directly regulates drug resistance and 
that transient metabolic alterations can lead to long-term effects upon chemoresistance. 
Introduction 
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies across 
the world, with mortality nearly identical to incidence. Because symptoms are often detected late 
into disease progression, tumors become unresectable prior to diagnosis, and long-term survival 
after resection is poor, with current treatment options failing to prolong survival beyond several 
months [101]. 
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Relative to other cancers, PDACs often encounter more demanding in vivo metabolic 
constraints that stem from hypovascular and fibrotic microenvironments leading to hypoxia and 
limited nutrient availability. Therefore PDAC cells acquire metabolic capabilities not seen in 
other cancer types. These metabolic changes contribute significantly to invasion and resistance to 
treatment [76, 102]. 
PDAC is one of the most bioenergetically sensitive and metabolically diverse known 
diseases [76]. In order to grow aggressively and invade through the body, cancer cells undergo 
metabolic reprogramming events producing both energy and macromolecular supplies at high 
levels supporting further proliferation and resistance to treatment. Otto Warburg first observed 
that relative to normal cells, cancer cells exhibit highly increased glycolytic activity under 
conditions of abundant oxygen. It was hypothesized that defective mitochondrial respiration is a 
cause for this “aerobic glycolysis” and contributes to tumorigenesis [74]. However, it is clear 
now that many cancer cells rely on both glycolysis and mitochondrial energy metabolism [75]. 
Cancer cells additionally exhibit increased ROS levels relative to normal cells that drive 
growth-promoting signaling events [77] and promote oxygen-independent metabolism in 
hypoxic tumor regions inaccessible to vasculature [78]. However, because high ROS levels are 
lethal, cancer cells often exhibit increased sensitivity to oxidative stress-induced toxicity relative 
to normal cells. ROS elevation in cancer is attributed in part to altered metabolism [79, 103]. 
PDAC is stratified into three subtypes (classical, quasimesenchymal, and exocrine-like) 
according to gene expression signatures, oncogene addiction, and drug responses [99]. Notably, 
these subtypes correspond to defined metabolic phenotypes [100]. The quasimesenchymal 
subtype exhibits a dependence upon glycolysis for growth and survival, while the classical 
subtype displays increased lipid levels, ETC/OXPHOS, and mitochondrial redox activity. 
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Drug responses and mean survival rates differ significantly among subtypes (Appendix 
B) and are likely due to intrinsic differences in metabolic characteristics. Here we show that 
glycolytic PDAC cells subjected to prolonged glycolysis inhibition undergo metabolic changes 
that lead to increased mitochondrial activity and dependence. These alterations confer resistance 
to a variety of chemotherapeutic agents, and cells remarkably revert back to a glycolytic 
phenotype following relief of anti-glycolytic conditions. Interestingly, while the metabolic 
phenotype can reverse, drug resistance persists. Altogether this demonstrates by proof of 
principle that PDAC cells undergoing transient metabolic adaptations can acquire long-term drug 
resistance. 
Materials and methods 
Materials 
MEM, DMEM, RPMI 1640, GlutaMAX, trypsin, fetal bovine serum (FBS), and 
phosphate buffered saline (PBS) were from Thermo Scientific; QuantiChrom™ Glucose Assay 
Kit was from BioAssay Systems; Matrigel™ was from BD Biosciences; Matrigel Recovery 
Solution was from Corning; all other materials were from Sigma. 
Cell culture 
PANC-1, BxPC-3, HPAF-II, and MIA PaCa-2 cells were from ATCC (kind gift of Dr. 
Sanku Mallik, NDSU). Cells were grown in an atmosphere of 95% air and 5% CO2 at 37 °C. All 
media was supplemented with 2 mM GlutaMAX. Cell lines were grown and cultured with the 
following media formulations: PANC-1 cells in DMEM supplemented with 10% FBS; MIA 
PaCa-2 in DMEM supplemented with 10% FBS and 2.5% horse serum; BxPC-3 in RPMI 1640 
supplemented with 10% FBS; HPAF-II in MEM supplemented with 10% FBS. 
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Metabolic conditioning with 2-deoxyglucose 
MIA PaCa-2 cells were exposed to 500 μM 2DG for 72 h and then at progressively 
increasing concentrations every 3-4 d until cells grew in 10 mM 2DG. Once cells were in 10 mM 
2DG, cells were treated with progressively increasing concentrations of 2DG in cycles of 3-4 d 
of 2DG exposure and 3-4 d of growth in the absence of 2DG. Once cells (MP2-D) could be 
cultured in 50 mM 2DG for 48 h without substantial toxicity (~3 mo of treatment), cells were 
cultured in alternating normal media conditions and media containing 50 mM 2DG. Fractions of 
cells from these cultures were then grown in normal media without 2DG for ~3 mo to generate 
MP2-DW cells. 
Drug treatments 
Cells seeded at equal densities were treated with 0-50 mM 2-deoxyglucose (2DG) for 0-
96 h, 1 μM gemcitabine for 72 h, 10 μM FCCP for 48, 10 μM oligomycin A for 24 h, 90 μM 
tBHQ for 24 h, 10 mM N-acetylcysteine for 24 h, 1 μg/mL docetaxel for 48 h, 1 μM paclitaxel 
for 48 h, or 100 μg/mL etoposide for 24 h. 
Cell viability 
Cells treated as indicated above were harvested by trypsinization, washed, and 
resuspended in PBS containing 2 µg/mL propidium iodide. Cell viability was determined by 
flow cytometry. 
Measurements of mitochondrial ΔΨm and abundance 
Staining for mitochondrial membrane potential was carried out as described previously 
[104] by resuspending harvested cells in PBS containing 200 nM TMRM followed by flow 
cytometry. Staining for mitochondrial abundance was carried out by incubating cells with 100 
nM MitoTracker™ Red at 37 °C for 20 min. Cells were then harvested and resuspended in PBS, 
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followed by assessment of stain intensity using an Accuri C6 flow cytometer. Mitochondrial 
heterogeneity was defined as the sum of right and left histogram peak shoulders. 
ROS measurements 
Cells were incubated with 2.5 μM MitoSOX™ Red (for mitochondrial superoxide), or 10 
μM CM-H2DCFDA (for general cellular ROS) at 37 °C for 20 min. Cells were then harvested 
and resuspended in PBS, followed by assessment of stain intensity using an Accuri C6 flow 
cytometer. 
Glucose consumption measurements 
Cells were harvested by trypsinization, washed, resuspended in fresh medium, and seeded 
at equal densities in replicate 6-well plates. Cells were grown at 37 °C for 72 h. Media was then 
collected from each well, and total glucose was measured using the QuantiChrom™ Glucose 
Assay Kit (BioAssay Systems). Total cell number in each sample was determined by Coulter™ 
counting. To determine glucose consumed per cell, total glucose consumption per sample was 
divided by its corresponding cell count. 
Phase contrast microscopy 
Images were captured by phase contrast microscopy using the 10× and 20× objectives of 
a Nikon TS100F microscope equipped with a Nikon DS-Fi1 digital camera detection system and 
NIS Elements 4.0 software. 
Matrigel™ experiments 
Equal volumes of cold Matrigel™ were added to each well in 24-well plates and then 
allowed to solidify at 37 °C for 1 h. Cells were added to Matrigel™ layers at equal densities and 
exposed to substrate conditions for up to 5 days in the absence or presence of GEM. Detached 
cells were collected and quantified by Coulter™ counting; attached cells were extracted from 
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substrate using Matrigel recovery solution (Corning) and quantified by Coulter™ counting. 
Percent viability was defined as the number of attached cells divided by total cells. Glucose 
assay was performed as described above. 
Cell growth rate measurements 
Cells were harvested by trypsinization, washed, resuspended in fresh medium, and seeded 
at equal densities in replicate 6-well plates. Cells were harvested and quantified by Coulter™ 
counting every 24 h for 96 h. 
Scratch assay 
Cells were harvested by trypsinization, washed, resuspended in fresh media, and seeded 
in replicate 6-well plates. Cells were allowed to attach overnight, and a single scratch was made 
through the middle of each well using a P200 pipette tip [105]. Cells were immediately washed, 
fresh media was added, and each scratch was imaged. Cells were then incubated for 24 h before 
final assessment of scratch width. All images were captured by phase contrast microscopy using 
the 10× objective of a Nikon TS100F microscope equipped with a Nikon DS-Fi1 digital camera 
detection system and NIS Elements 4.0 software.     
Results 
Assessment of metabolic plasticity and drug resistance in pancreatic cancer cells 
Pancreatic cancer is a highly aggressive disease with 5-year survival rates of only 5-10%. 
Based on factors such as KRAS activation, in vivo microenvironments, and fluctuations in 
nutrient and oxygen availability, PDAC cells exhibit a remarkable metabolic plasticity that has 
been implicated as a cause of intense therapeutic resistance [76, 102, 106]. To assess the ability 
of PDAC cells to adapt to metabolic perturbation, four pancreatic cancer cell lines (PANC-1, 
BxPC-3, HPAF-II, MIA PaCa-2) were treated with 2-deoxyglucose (2DG), an inhibitor of 
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glycolysis. Cells able to meet the metabolic demands of growth and survival under conditions of 
impaired glycolysis will therefore display increased resistance to treatment. Following treatment 
cells showed various sensitivities to glycolysis inhibition (Figure 2.1A). PANC-1 and BxPC-3 
cells demonstrated high levels of survival (>80%) when treated with 2DG, while HPAF-II cells 
exhibited moderate survival rates of ~70%. In contrast, MIA PaCa-2 cells were highly sensitive 
to 2DG, with only ~20% survival following glycolytic disruption (Figure 2.1A). This 
demonstrates a variety of metabolic requirements among PDAC cell types that agrees with 
previous findings [52, 100]. 
Metabolism is a significant contributor to the survival and aggressiveness of PDAC cells. 
Therefore we questioned if sensitivity to glycolytic disruption is related to therapeutic resistance. 
Gemcitabine (GEM) is a nucleoside analog and the current first-line treatment for patients [107]. 
Viability following GEM treatment was then evaluated using PANC-1 and MIA PaCa-2 cells, 
which exhibit the highest resistance and highest sensitivity to 2DG (Figure 2.1A), respectively. 
MIA PaCa-2 cells were substantially more sensitive to GEM than PANC-1 cells, with a 
difference of >30% in GEM resistance between cell types (Figure 2.1B). 
Acquired resistance to glycolytic disruption is accompanied by an upregulation of 
mitochondrial activity 
Since MIA PaCa-2 cells show the highest sensitivity both to metabolic disruption and 
GEM treatment among cell types used (Figure 2.1), this raised the question of whether the two 
are related. Therefore we generated MIA PaCa-2 cells resistant to 2DG. MIA PaCa-2 cells were 
exposed to progressively increasing 2DG concentrations over a period of ~3 months until cells 
exhibited no significant death at 50 mM 2DG for 48 h. Quantification of control non-conditioned  
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Figure 2.1. Sensitivity of PDAC cells to glycolysis inhibition and gemcitabine. 
The indicated cell types were seeded at equal densities and treated with either A) 50 mM 2-
deoxyglucose or B) 1 uM gemcitabine for 72 h, followed by PI stain and flow cytometry. Data 
are shown as average ± standard deviation. 
 
cells (MP2) vs. 2DG-conditioned cells (MP2-D) demonstrated that MP2-D cells are capable of 
survival in 2DG for more time (Figure 2.2A) and at higher concentrations (Figure 2.2B). 
In order to survive glycolysis inhibition, cells must acquire energy through alternative 
means, in particular by upregulating mitochondrial ATP production [108]. Therefore MP2 and 
MP2-D cells were assessed for mitochondrial activity by staining with tetramethylrhodamine 
ester (TMRM, an indicator of mitochondrial membrane potential). When MP2 cells were stained  
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Figure 2.2. Establishment of MP2-D cells. 
Cells were seeded at equal densities and then treated with A) 50 mM 2-deoxyglucose for 0-96 h 
or B) 0-50 mM 2-deoxyglucose for 72 h, followed by PI staining and flow cytometry. Data are 
shown as average ± standard deviation. 
 
with TMRM, populations of low, medium, and high stain intensity were observed (Figure 2.3A). 
Staining of MP2-D cells revealed increased fractions with high membrane potential (Figure 
2.3A, B). Mitochondria are more efficient producers of ATP than the pathway of glycolysis, and 
this ~10% increase in mitochondrial activity is approximately that which would be predicted to 
compensate for glycolytic deficiency. To determine if this increase in mitochondrial activity is 
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due to an increase in mitochondrial biogenesis, cells were stained with MitoTracker™ Red, an 
indicator of mitochondrial abundance. Interestingly, average stain intensity did not increase in 
MP2-D cells (Figure 2.3A). However, histogram peaks were narrower with fewer cell 
populations deviating from the mean in MP2-D samples when compared with MP2 controls 
(Figure 2.3A). This indicates a decrease in mitochondrial heterogeneity (Figure 2.3C), 
suggesting that cells become more selective for active mitochondria. The magnitude of this 
difference (~10%) agrees with TMRM experiments demonstrating increased mitochondrial 
activity in MP2-D cells. Notably, this ability of cells to upregulate mitochondrial activity shows 
that the mitochondria of MIA PaCa-2 cells are not impaired despite a metabolic preference for 
glycolysis. The reason MIA PaCa-2 cells fail to survive acute 2DG treatment remains an open 
question. 
Cells that undergo a metabolic shift from glycolysis to OXPHOS will exhibit decreased 
glucose consumption and altered sensitivity to metabolic inhibitors. Glucose consumption was 
therefore assessed, showing decreased levels in MP2-D cells (Figure 2.4A). Similar changes in 
glucose uptake levels were observed when cells were exposed to Matrigel™ growth substrate 
(Figure 2.4B), which approximates an in vivo environment. These data suggest decreased levels 
of glycolysis in MP2-D cells, a phenotype that would be expected for cells exhibiting increased 
mitochondrial activity to survive 2DG treatment. 
MP2 and MP2-D cells were then treated with two inhibitors of mitochondrial 
metabolism. Carbonylcyanide-p-trifluoromethoxyphenylhydrazone (FCCP) is a lipophilic weak 
acid that shuttles protons across membranes, leading to impairment of the proton gradient 
generated by the ETC and a subsequent loss of mitochondrial ATP production. Oligomycin A 
inhibits ATP synthase by blocking its proton channel. MP2-D cells exhibited significantly 
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increased death following treatment with either agent (Figure 2.4C, D), further demonstrating a 
shift from glycolysis to OXPHOS in MP2-D cells. 
 
Figure 2.3. Acquired 2DG resistance leads to increased mitochondrial activity. 
Cells were stained with either TMRM or MitoTracker™ Red and then assessed by flow 
cytometry. A) Representative histograms. B) Percentages of cells exhibiting high TMRM stain 
intensities. C) Mitochondrial heterogeneity was determined by the sum of high and low outliers 
of cell samples stained with MitoTracker™ Red. Data are shown as average ± standard 
deviation. 
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Figure 2.4. 2DG-conditioned cells shift from glycolysis to OXPHOS dependence for 
survival. 
Glucose consumption was assessed A) in vitro and B) in Matrigel™ substrate using the 
QuantiChrom™ Glucose Assay Kit (BioAssay Systems). C) Cells were treated with control 
vehicle or 10 μM FCCP for 48 h, stained with PI, and assessed by flow cytometry. D) Cells were 
treated with either control vehicle or 10 μM oligomycin A for 24 h and then assessed as in (C). 
Data are shown as average ± standard deviation. 
 
2DG-resistant cells exhibit increased ROS and oxidative stress sensitivity 
Mitochondria are a major source of intracellular ROS due to leakage of electrons from 
the ETC. During tumorigenesis increased ROS levels can stimulate signaling pathways 
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promoting growth and survival, but can also induce toxicity if the cellular threshold is exceeded 
(Figure 1.3). Since MP2-D cells contain more active mitochondria than control MP2 cells, we 
questioned if ROS levels and/or redox sensitivity were also altered. Cells were stained with 
MitoSOX™ Red, an indicator of mitochondrial superoxide, followed by flow cytometry. 
Relative to MP2 cells, MP2-D cells exhibited ~40% greater mitochondrial superoxide levels 
(Figure 2.5A). Cells were then stained with chloromethyl-2',7'-dichlorodihydrofluorescein 
diacetate (CM-H2DCFDA), a general detector of many ROS species not including superoxide 
that could indicate the extramitochondrial redox state. Similar to staining with MitoSOX™, cells 
showed increased ROS levels by >50% greater than controls following metabolic reconditioning 
(Figure 2.5B). Overall these data suggest that MP2-D cells contain increased mitochondrial and 
cytosolic ROS levels. 
Since MP2-D cells have substantially higher levels of ROS, this raises the possibility that 
cells are closer to an oxidative stress-induced death threshold than controls. To test this 
hypothesis cells were treated with the oxidative stress agent tert-butylhydroquinone (tBHQ). 
Measurements of viability demonstrated resistance in control cells, but almost no survival 
(<10%) in MP2-D cells (Figure 2.5C), suggesting a dramatically increased sensitivity to 
oxidative stress that agrees with increased ROS levels. 
Having observed that MP2-D cells show a severe sensitivity to oxidative stress, we then 
tested the inverse hypothesis that cells are more resistant to antioxidant treatment. While 
antioxidants can protect against ROS-induced cell death [109], neutralization of ROS at high 
amounts can also induce toxicity due to decreased pro-survival signaling [110]. Cells were 
treated with N-acetylcysteine (NAC), a ROS scavenger, at lethal concentrations. While MP2 
cells showed reduced survival following NAC treatment, MP2-D cells were resistant to NAC 
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(Figure 2.5D), further demonstrating altered ROS responses in MP2-D cells. Altogether these 
data show that MP2-D cells increase ROS levels that can impact survival, either due to increased 
oxidative stress, decreased antioxidant defenses, or both. 
 
Figure 2.5. 2DG-conditioned cells exhibit increased ROS levels and sensitivity to oxidative 
stress. 
Cells were stained with either A) MitoSOX™ Red or B) CM-H2DCFDA and then assessed by 
flow cytometry. C) Cells were treated with control vehicle or 90 μM tBHQ for 24 h, stained with 
PI, and assessed by flow cytometry. D) Cells were treated with either control vehicle or 10 mM 
NAC for 24 h and then assessed as in (C). Data are shown as average ± standard deviation. 
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2DG-induced metabolic reconditioning alters cell growth and migration 
Since acquired resistance to 2DG alters mitochondrial metabolism and cellular redox 
state, we then hypothesized that metabolic changes would impact tumorigenic phenotypes. In 
support of this hypothesis, MP2-D cells exhibited morphological differences from controls. MP2 
cells showed web-like structures with projections extending to contact neighboring cells, while 
MP2-D cells formed clustered cobblestone structures (Figure 2.6A). Cells were then seeded in 
Matrigel™ substrate and further visualized. Control cells formed large, dense structures with 
numerous arm-like projections and tight cell-cell contacts, whereas MP2-D cells dispersed across 
the substrate with fewer projections and looser intercellular positioning (Figure 2.6B). 
 
Figure 2.6. Acquired resistance to glycolysis inhibition induces morphological changes. 
Cells were seeded at equal densities and then imaged using confocal microscopy A) in vitro or 
B) in Matrigel™ substrate. 
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Changes in morphology are indicative of altered cell behavior. To determine if MP2-D 
cells are likely to exhibit different tumorigenic properties, MP2 and MP2-D cells were seeded at 
equal densities and then quantified after 5 days. Quantification of MP2-D cells revealed reduced 
numbers compared to controls, indicating a moderately reduced proliferation rate (Figure 2.7A). 
Migration of cells was then assessed by scratch assay. Following mechanical wound of cells at 
high densities, cells migrate across the wound and towards each at different rates, indicating 
different migratory properties. When MP2 and MP2-D were subjected to the wound-healing 
assay, MP2-D cells rapidly migrated across the wells at substantially higher rates than controls 
(Figure 2.7B), completely covering the wound within 48 hours (data not shown). This increased 
migration of MP2-D cells is in contrast to decreased proliferation, suggesting that acquired 
resistance to glycolysis inhibition promotes motility but not growth rates. 
Metabolic and growth effects of 2DG conditioning are reversible 
Metabolic alterations in PDAC are highly diverse, and changes in response to different 
metabolic stresses occur at levels not seen in other cancer types [76]. To determine if it is 
possible to restore the MP2-D phenotype to that of MP2 cells, MP2-D cells were withdrawn 
from 2DG and cultured in normal media for the same period of time as 2DG conditioning (~3 
months). After ~3 months following 2DG withdrawal, cells were then treated with 2DG followed 
by viability assay. Remarkably, cells previously conditioned to prolonged 2DG exposure and 
then withdrawn (MP2-DW) exhibited a significant reduction in resistance to 2DG (Figure 2.8A), 
suggesting a reversion to a glycolytic phenotype. To determine if mitochondrial activity was 
affected, cells were then treated with oligomycin A and assessed for cell death levels. Consistent 
with changes observed with 2DG treatment, MP2-DW cells showed reduced levels of death 
compared to MP2-D cells when mitochondrial ATP production was impaired (Figure 2.8B). 
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Figure 2.7. 2DG-conditioned cells exhibit altered proliferation and migration. 
A) Cells were seeded and equal densities and then quantified after 96 h. B) Cells plated at high 
density were subjected to mechanical wound and then allowed to heal for 24 h followed by phase 
contrast microscopy. Data are shown as average ± standard deviation. 
 
The effects of 2DG withdrawal upon proliferation in vitro were then assessed. Cells were 
seeded at equal densities and quantified every 24 h for 4 d. MP2 cells exhibited doubling times 
of ~24, and MP2-D cells showed moderately reduced rates of proliferation with doubling times 
of ~28 h (Figure 2.8C). Consistent with a metabolic reversion to glycolysis similar to MP2 cells, 
MP2-DW cells displayed doubling times of ~24 h that were identical to controls (Figure 2.8C). 
Cells were next assessed for proliferation rates under Matrigel™ growth conditions. Cells 
were seeded at equal densities and then incubated for 5 d prior to extraction and quantification. 
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MP2-D cells grew to populations of <50% of controls (Figure 2.8D), consistent with decreased 
doubling times (Figure 2.8C). However, MP2-DW cells with restored metabolism exhibited 
increased rates of proliferation in substrate (Figure 2.8D), further demonstrating the reversibility 
of 2DG conditioning. 
 
Figure 2.8. The metabolic and growth effects of acquired resistance to glycolysis inhibition 
are reversible. 
A) Cells were left untreated or treated with 50 mM 2DG for 48 h, stained with PI, and assessed 
by flow cytometry. B) Cells treated with control vehicle or 10 μM oligomycin A for 24 h were 
subjected to PI staining and flow cytometry. C) Cells were seeded and equal densities and then 
quantified every 24 h for 96 h. D) Cells were seeded at equal densities in Matrigel™ and 
incubated for 5 d. Cells were then extracted and quantified. Data are shown as average ± 
standard deviation. 
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2DG conditioning causes the acquisition of persistent drug resistance 
Having derived 2DG-resistant MIA PaCa-2 cells and characterized altered metabolism 
and growth, we then wondered if resistance to glycolysis inhibition was related to GEM 
sensitivity (Figure 2.1B). Therefore MP2 and MP2-D cells were treated with GEM and subjected 
to viability assay. Interestingly, 2DG conditioning caused a ~15% increase in resistance to GEM 
in vitro (Figure 2.9A), demonstrating that metabolic alterations can play a significant role in 
survival following treatment.  Since MP2-D cells displayed increased GEM resistance in vitro, 
 
 
Figure 2.9. 2DG conditioning increases GEM resistance that is unaffected by reversion to a 
glycolytic phenotype. 
A) Cells were treated with control vehicle or 1 μM GEM for 72 h and then assessed for viability 
levels by PI stain and flow cytometry. B) Cells were seeded at equal densities in Matrigel™ 
substrate and then allowed to incubate overnight. Cells were then treated with control vehicle or 
1 μM GEM for 72 h. Attached and detached cells were then extracted and quantified.  Viability 
was defined by cells remaining attached by total cells. Data are shown as average ± standard 
deviation. 
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we next assessed viability in Matrigel™ substrate and the potential for reversibility in MP2-DW 
cells. MP2, MP2-D, and MP2-DW cells were seeded in Matrigel™ and then treated with GEM 
for 3 d. Similar to in vitro experiments, 2DG-conditioned cells displayed elevated GEM 
resistance (Figure 2.9B), but at greater levels than cells treated in vitro (>25%). Strikingly, GEM 
resistance remained increased in MP2-DW cells (Figure 2.9B) despite metabolic and growth 
reversions (Figure 2.8). 
To determine if this increased drug resistance is specific to GEM or extends to other 
death-inducing molecules, cells were additionally treated with three agents commonly used in 
cancer treatment. Paclitaxel and docetaxel interfere with microtubules during cell division 
through different mechanisms [111], and etoposide is a topoisomerase inhibitor [112]. Notably, 
MP2-D cells exhibited increased resistance to all three agents (Figure 2.10) at varying 
magnitudes (~10-30% increases relative to controls). Similar to GEM treatment, cells did not 
decrease resistance to docetaxel following metabolic reversion (Figure 2.10). In contrast, 
resistance to paclitaxel and etoposide significantly decreased in MP2-DW cells relative to MP2-
D cells. This indicates that withdrawal from 2DG conditioning does not lead to a general pro-
survival effect but promotes survival in a manner depending on therapeutic mechanism. 
Altogether these data raise the intriguing possibility that undergoing transient metabolic 
alterations can have long-term consequences upon drug resistance. 
Discussion 
Metabolism and tumorigenesis  
Collectively these data demonstrate the effects of forced glycolytic downregulation upon 
metabolism, proliferation, migration, and chemoresistance in PDAC cells. Our experiments 
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suggest that mitochondria can promote tumorigenesis and resistance to therapy, further 
highlighting the importance of mitochondrial function to disease progression. 
Mitochondrial defects in cancer cells are not uncommon, and elevated rates of glycolysis 
are frequently observed in tumors. However, elevated glycolysis is usually not due to 
mitochondrial impairment but occurs to promote macromolecule biosynthesis. MIA PaCa-2 cells 
are an example of a cancer cell line exhibiting a classical Warburg phenotype. This cell type 
does not appear to exhibit mitochondrial impairment, but why mitochondria are not readily 
employed to produce energy remains unknown. 
 
Figure 2.10. Adaptation to glycolysis inhibition increases resistance to docetaxel, paclitaxel 
and etoposide. 
A) Cells were treated with control vehicle or the indicated drugs (docetaxel,  1 μg/ml for 48 h; 
paclitaxel, 1 μM for 48, etoposide, 100 μg/mL for 24 h) and then assessed for viability levels by 
PI stain and flow cytometry. Data are shown as average ± standard deviation. 
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Table 2.1. Characteristics of metabolically reconditioned PDAC cells. 
 MP2 MP2-D MP2-DW 
Glycolysis dependence High Low High 
Mitochondrial activity Low High Low 
Doubling time 24 h 28 h 24 h 
GEM resistance * **** **** 
Docetaxel resistance * **** **** 
Paclitaxel resistance * **** *** 
Etoposide resistance * **** ** 
Glycolysis dependence is defined by sensitivity to 2DG (Figure 2.8A), mitochondrial activity is 
defined by sensitivity to FCCP and oligomycin A (Figure 2.8B), and doubling time was 
determined as shown in Figure 2.8C. Drug resistance levels were assessed as shown in Figures 
2.9 and 2.10. Values were scaled to the difference between MP2 and MP2-D cells and ranked as 
follows: * 0-25%, ** 25-50%, *** 50-75%, **** 75-100%. 
 
2DG-adapted cells exhibit altered growth and drug resistance 
MIA PaCa-2 cells adapted to 2DG demonstrated decreased glucose consumption, 
increased mitochondrial activity, and increased sensitivity to mitochondrial inhibitors. As would 
be expected with increased mitochondrial activity, ROS levels were additionally elevated to 
levels that strongly sensitized cells to oxidative stress. Furthermore, proliferation rates decreased 
while migratory characteristics were enhanced. 
Notably, metabolic and growth changes were reversible when 2DG pressure was 
relieved, while changes in drug resistance persisted (Table 2.1). This suggests that short-term 
metabolic alterations can have lasting effects on tumorigenesis. For example, cells undergoing an 
energetically demanding situation (e.g., matrix invasion) may upregulate mitochondrial activity 
that is accompanied by increased drug resistance, and this acquired resistance is unchanged when 
cells revert to glycolysis (e.g., under hypoxic conditions). 
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This study is the first to generate 2DG-resistant human cells, showing that sustained 
glycolytic inhibition leads to increased therapeutic resistance that does not subside following 
metabolic reversion to a glycolytic phenotype. This further demonstrates the close interplay of 
metabolism and chemoresistance, indicating an additional tumorigenic mechanism that could 
guide therapeutic intervention. Altogether this work defines a pivotal role for transient 
tumorigenic metabolic adaptations to the progression of advanced disease. 
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III. BASAL METABOLIC STATE GOVERNS AIF-DEPENDENT GROWTH SUPPORT 
IN PANCREATIC CANCER CELLS 
Abstract 
Apoptosis-inducing factor (AIF), named for its involvement in cell death pathways, is a 
mitochondrial protein that regulates metabolic homeostasis and plays a contributory role to the 
development of cancer through its enzymatic activity. Having previously implicated AIF as pro-
tumor factor selectively beneficial to advanced PCa, we assessed the role of AIF in the context of 
pancreatic cancer, a disease setting that most often presents at an advanced stage by the time of 
diagnosis. Archival gene expression data revealed a modest elevation of AIF transcript levels in 
subsets of pancreatic tumor specimens, suggesting a possible role in disease progression. AIF 
expression was then suppressed in a panel of five pancreatic cancer cell lines that display diverse 
metabolic phenotypes. AIF ablation selectively crippled the growth of cells in vitro in a manner 
that directly correlated with the loss of mitochondrial respiratory chain subunits and altered 
glucose metabolism, and these effects were exacerbated in the presence of Matrigel™ substrate. 
This suggests a critical metabolic role for AIF to pancreatic tumorigenesis, while the spectrum of 
sensitivities to AIF ablation depends on basal cellular metabolic phenotypes. Altogether these 
data indicate that AIF supports the growth and survival of metabolically defined pancreatic 
cancer cells and that this metabolic function may derive from a novel mechanism so far 
undocumented in other cancer types. 
Introduction 
In the context of prostate cancer, AIF preferentially supports metabolism benefitting the 
aggressiveness of advanced-stage cells. Given these previous findings, we questioned the role of 
AIF in the pathogenesis of pancreatic ductal adenocarcinoma (PDAC), a disease which almost 
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always reaches an advanced stage before diagnosis [98]. As mentioned in Chapters 1 and 2, late 
detection of PDAC makes it one of the most lethal cancers with a grim 5-year survival rate of 5-
10% [101]. As tumors progress to advanced stages, reliance upon specific metabolic pathways 
for growth and survival increases substantially while cells become vulnerable to death by 
metabolic disruption, a trait known as metabolism addiction. As one of the most metabolically 
diverse and bioenergetically sensitive forms of cancer, mitochondrial function is often crucial to 
pancreatic tumorigenesis [76, 94], suggesting a possible role for AIF metabolic activity in 
supporting the growth and survival of PDAC cells.   
Here AIF is identified as a major contributor to the growth-promoting metabolic state of 
pancreatic tumor cells. The contribution of AIF to PDAC metabolism in a panel of cell lines was 
directly related to their basal metabolic preferences. While cells that employ both glycolysis and 
mitochondrial energy metabolism rely on AIF for survival, those that rely only upon glycolysis 
cannot benefit from AIF metabolic activity. Through a mechanism that appears distinct from that 
observed in prostate cancer, AIF facilitates a metabolic balance that maintains survival. Further, 
this role could extend to normal tissues and may explain the selective sensitivity to AIF 
suppression among cell types. Altogether these findings suggest that AIF is a significant support 
molecule to the development and progression of specific pancreatic cancer specimens and further 
shed light upon the ability of AIF to function in a pro-tumor fashion. 
Materials and methods 
 Materials 
MEM, DMEM, RPMI 1640, DMEM/F12, GlutaMAX, horse serum, insulin, transferrin, 
epidermal growth factor, trypsin, 4-12% bis-tris polyacrylamide gels, and nitrocellulose 
membranes were obtained from Life Technologies; fetal bovine serum (FBS), phosphate 
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buffered saline (PBS), and Pierce ECL 2 Western Blotting Substrate were from Thermo 
Scientific; QuantiChrom™ Glucose Assay Kit was from BioAssay Systems; Matrigel™ was 
from BD Biosciences; Matrigel Recovery Solution was from Corning; protease inhibitor tablets 
were from Roche Applied Science; all other materials were from Sigma. Antibodies were 
obtained as follows: anti-AIF (Santa Cruz Biotechnology, sc-13116), anti-complex I 39 kDa 
(Life Technologies, 459100), anti-complex I 20 kDa (Life Technologies, 459210), anti-complex 
I 17 kDa (Life Technologies, A21359), anti-COX IV (Life Technologies, A21347) anti-β-actin 
(Sigma, A5316), and peroxidase-conjugated anti-mouse (Amersham Biosciences, NA931V).  
Oncomine data analysis 
Data sets examining AIF mRNA expression in pancreatic tumors versus normal 
pancreatic tissue from 7 studies [113-119] were analyzed using Oncomine [120]. Statistical 
calculations and normalization techniques are given by the Oncomine website 
(http://www.oncomine.org). 
Cell culture 
PANC-1, BxPC-3, HPAF-II, HPAC, and MIA PaCa-2 cells were from ATCC (kind gift 
of Dr. Sanku Mallik, NDSU). HEK293T cells were as described [51]. Cells were grown in an 
atmosphere of 95% air and 5% CO2 at 37 °C. All media was supplemented with 2 mM 
GlutaMAX. Cell lines were grown and cultured with the following media formulations: 
HEK293T and PANC-1 cells in DMEM supplemented with 10% FBS; MIA PaCa-2 in DMEM 
supplemented with 10% FBS and 2.5% horse serum; BxPC-3 in RPMI 1640 supplemented with 
10% FBS; HPAF-II in MEM supplemented with 10% FBS; and HPAC in a 1:1 mixture of 
DMEM and Ham’s F12 medium supplemented with 5% FBS, 2 μg/mL insulin, 5 μg/mL 
transferrin, 40 ng/mL hydrocortisone, and 10 ng/mL epidermal growth factor. 
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Lentivirus production and infection 
FG12-derived plasmids for targeting of AIF and LacZ by RNA interference (RNAi) have 
been rigorously assessed and used as described [51, 121, 122]. Lentiviral packaging plasmids 
pRRE, pRSV-rev, and pHCMV-G are as described [123]. RNAi plasmids and equal amounts of 
lentiviral packaging plasmids were transfected into HEK293T cells using the calcium phosphate 
precipitation method [124]. Supernatants of transfected HEK293T cultures were then filtered 
through 0.45-μm PVDF Millex-HV filters (Millipore) and concentrated by centrifugation at 
20,000 x g for 90 min at 4 °C. Viral pellets were resuspended in PBS and then incubated 
overnight at 4 °C prior to use. Cell lines were then infected as described [51]. PANC-1 and MIA 
PaCa-2 cells were infected with lentiviruses carrying shLacZ-GFP or shAIF-GFP, after which 
infection was verified by fluorescence microscopy and flow cytometry with an Accuri C6 flow 
cytometer. BxPC-3, HPAC, and HPAF-II cells were infected with lentiviruses carrying shLacZ-
puro or shAIF-puro and then selected using 2 μg/mL puromycin. 
Cell viability 
Cells were seeded in equal replicate densities in 6-well plates and allowed to attach 
overnight. Cells were then left untreated or treated with 1 µg/mL actinomycin D, 1 µM 
gemcitabine, or 50 mM 2-deoxyglucose for 24-72 h. Cells were then harvested by trypsinization, 
washed, and resuspended in PBS containing 2 µg/mL propidium iodide. Cell viability was 
determined by flow cytometry. 
SDS-PAGE and immunoblot 
Cells were harvested by trypsinization, washed, and resuspended in radioimmune 
precipitation assay lysis buffer (PBS containing 1% Nonidet P-40, 0.5% sodium deoxycholate, 
0.1% sodium dodecyl sulfate, 1 mM dithiothreitol, 1 mM phenylmethanesulfonyl fluoride, and 1 
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protease inhibitor mixture tablet per 10 mL). Lysates were then normalized for protein content, 
separated by SDS-PAGE, and transferred to nitrocellulose membranes. Membranes were blocked 
with 5% milk in Tris-buffered saline with 0.1% Tween-20 and incubated with primary antibodies 
for 1 h at room temperature. Membranes were then washed and incubated with peroxidase-
conjugated anti-mouse IgG secondary antibody for 45 min at room temperature, followed by 
washing and visualization using enhanced chemiluminescence with a MyECL imaging system 
(Thermo Scientific). 
Cell growth rate measurements 
Cells were harvested by trypsinization, washed, resuspended in fresh medium, and seeded 
at equal densities in replicate 6-well plates. Cells were harvested and quantified by Coulter™ 
counting after 72 h. Fold change in growth was determined by dividing populations of AIF-
deficient cells by corresponding control populations. 
Scratch assay 
Cells were harvested by trypsinization, washed, resuspended in fresh media, and seeded 
in replicate 6-well plates. Cells were allowed to attach for 12-36 h, and a single scratch was 
made through the middle of each well using a P200 pipette tip [105]. Cells were immediately 
washed, fresh media was added, and each scratch was imaged. Cells were then incubated for 6-
48 h before final assessment of scratch width. All images were captured by phase contrast 
microscopy using the 10× objective of a Nikon TS100F microscope equipped with a Nikon DS-
Fi1 digital camera detection system and NIS Elements 4.0 software.     
Glucose consumption measurements 
Cells were harvested by trypsinization, washed, resuspended in fresh medium, and seeded 
at equal densities in replicate 6-well plates. Cells were grown at 37 °C for 72 h. Media was then 
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collected from each well, and total glucose was measured using the QuantiChrom™ Glucose 
Assay Kit (BioAssay Systems). Total cell number in each sample was determined by Coulter™ 
counting. To determine glucose consumed per cell, total glucose consumption per sample was 
divided by its corresponding cell count. 
Matrigel™ experiments 
Equal volumes of cold Matrigel™ were added to each well in 24-well plates and allowed 
to solidify at 37 °C for 1 h. Cells were harvested, washed, resuspended in fresh medium, and 
seeded in equal densities on solidified Matrigel™ layers. Cells were grown in Matrigel™ for up 
to 21 days with media replenished following each week of growth and imaged using phase 
contrast microscopy as described above. Cells were then extracted from substrate with the 
Matrigel Recovery Solution (Corning), and glucose consumption and growth measurements were 
performed as described above. 
Results 
AIF transcripts are increased in pancreatic cancer 
To determine a potential involvement of AIF in pancreatic cancer, archived expression 
data were retrieved from the cancer gene expression database Oncomine (oncomine.com). 
Archival data from a total of 7 data sets comparing relative AIF expression in pancreatic 
adenocarcinomas to normal pancreatic tissue are currently available [113-119]. When average 
AIF expression was compared between groups (cancer vs. normal) and for each data set, a trend 
towards elevated AIF transcripts in pancreatic cancer tissue was apparent (values ranging from 
essentially unchanged to an increase of 1.54 fold in cancer relative to normal). However, the 
observed increase in average expression was only statistically significant in one of the seven data 
sets, which indicated a 1.45-fold increase in AIF expression in pancreatic cancer tissue ([113], 
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p=0.024; for all other studies p=0.068-0.956). Representative data are shown in Figure 3.1A-D. 
At first glance these data suggested that altered AIF expression is not a global trend in pancreatic 
cancer, but that in a small fraction of tissue cohorts a modest (less than 2-fold) elevation of AIF 
expression can be observed.  
To further explore AIF expression changes in these cohorts of cancer vs. normal tissues 
we compared individual expression data from each sample within each cohort (Figures 3.1E-H). 
Interestingly, in 5 of the 7 data sets there appears a subtype within each cancer group that 
displays elevated AIF expression significantly beyond the 90% confidence interval defined for 
normal tissues [113-116, 119]. This subtype represents ~36% of the total among these five 
cohorts, and while elevated AIF is observed, the magnitude of this elevation remains modest 
(less than 3-fold relative to control tissue). These data are in close agreement with similar 
analyses examining AIF mRNA and protein expression in prostate cancer tissues [51]. Taken 
together these data suggest that while elevated AIF expression is not a global feature of 
pancreatic cancer, there exists a subtype of pancreatic tumors (approximately one-third of the 
total samples assessed) in which AIF expression is significantly elevated. That increased 
expression is modest likely reflects potential toxicity associated with AIF-mediated cell-killing 
when levels exceed a certain threshold [24].   
Establishment of AIF-deficient cell lines 
The above analysis of AIF gene expression data from clinically derived pancreatic cancer 
tissues suggested a connection between elevated AIF expression and subtypes of pancreatic 
tumors. In order to evaluate the role of AIF in the growth and survival of pancreatic cancer cells, 
we generated a panel of AIF-deficient PDAC cell lines. Given the metabolic activity of AIF in 
other systems, we targeted AIF in a panel of five cell types (PANC-1, BxPC-3, HPAC, HPAF-II,  
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Figure 3.1. AIF transcript levels are increased in pancreatic cancer.  
Data comparing AIF mRNA transcript expression in normal pancreatic tissues vs. pancreatic 
tumors was retrieved from the Oncomine database and assessed as shown in representative 
studies [113-115, 119]. A-D) Average relative AIF mRNA expression in normal pancreatic 
tissues vs. pancreatic tumors. E-H) Relative AIF mRNA levels among individual samples within 
each cohort. Fractions of tumor specimens within each cohort exhibiting statistically significant 
AIF expression changes relative to normal tissue are indicated in red. 
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and MIA PaCa-2) that display diverse metabolic characteristics (Figure 3.2). Previously, 
metabolic phenotyping of PDAC cells was rigorously established by gene expression analysis, 
sensitivity to metabolic inhibitors, and metabolite profiling [100]. PANC-1 and BxPC-3 cells 
balance the metabolic requirements derived from glycolysis, pentose phosphate pathway, and 
mitochondrial energy metabolism, while HPAC cells display a pronounced bias towards lipid 
metabolism; HPAF-II cells also require mitochondrial energy pathways but are more reliant upon 
glycolysis than those previously described, and MIA PaCa-2 cells are highly glycolytic (Table 
3.1).   Within this panel of cell lines oncogene status (Table 3.2) varies slightly: all cells except 
 
Figure 3.2. Pancreatic cancer cell lines exhibit distinct metabolic phenotypes. 
PANC-1, BxPC-3, and HPAC cells acquire energy predominantly from mitochondrial OXPHOS. 
Relative to OXPHOS-dependent cells, the glycolytic cell lines HPAF-11 and MIA PaCa-2 cells 
produce most ATP from glycolysis [100].  
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Table 3.1. Metabolic phenotypes are associated with sensitivity to AIF ablation. 
 Relative metabolic phenotype 
[100] Sensitivity to 
glycolytic 
disruption 
Sensitivity to 
AIF ablation 
Glycolysis/PPP 
Fatty acid/ 
OXPHOS 
PANC-1 Moderate Moderate Insensitive Sensitive 
BxPC-3 Moderate Moderate Insensitive Sensitive 
HPAC Low High Insensitive Sensitive 
HPAF-II High Moderate 
Moderately 
sensitive 
Moderately 
sensitive 
MIA PaCa-2 High Low Sensitive Insensitive 
 
Table 3.2. Oncogene status of PDAC cell lines. 
 Patient, age KRAS p53 CDKN2A/p16 Smad4/DPC4 
PANC-1 
Caucasian 
male, 56 
G12D R273H -/- WT 
BxPC-3 
Caucasian 
female, 61 
WT Y220C WT -/- 
HPAC 
Caucasian 
female, 64 
G12D WT 112 amber stop WT 
HPAF-II 
Caucasian 
male, 44 
G12D P151S Δ29-34 WT 
MIA PaCa-2 
Caucasian 
male, 65 
G12C R248W -/- WT 
 
BxPC-3 express mutant KRAS, and all cells except HPAC express mutant p53 [125-131]. 
Silencing of AIF expression by RNAi was achieved through infection with lentiviruses harboring 
short-hairpin RNA (shRNA) sequences targeting either AIF (shAIF) or LacZ (shLacZ) as a 
control. PANC-1 and MIA PaCa-2 cells were infected with lentiviruses that carried GFP 
expression cassettes which served to confirm stable integration and subsequent knockdown of 
targeted genes. Success of lentiviral infection was evaluated by observation of at least 95% GFP 
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positivity using fluorescence microscopy and flow cytometry (Figure 3.3A, B). Due to lower 
infection efficiencies, BxPC-3, HPAC, and HPAF-II cells were infected with lentiviruses 
carrying puromycin resistance as a selectable marker instead of GFP, and stably infected cells 
were derived by treatment with puromycin. To control for differences between lentiviruses 
bearing puromycin resistance vs. GFP, we additionally established PANC-1 cells via puromycin 
selection that were indistinguishable from GFP-infected cells in all assays performed (data not 
shown). To determine the extent of AIF protein ablation in our cell line panel, immunoblot 
analysis was employed, which demonstrated AIF knockdown levels greater than 95% in all cases 
when compared to either uninfected cells or shLacZ negative controls (Figure 3.3C). 
AIF ablation does not affect chemical death induction 
In various cell types, AIF has been suggested to promote both death induction and 
survival in response to toxic chemical triggers. To determine the role of AIF in regulating cell 
death in pancreatic cancer, two death-inducing agents with distinct mechanisms of action were 
employed:  actinomycin D, an inhibitor of protein synthesis; and gemcitabine, a nucleoside 
analog and the first-line treatment for PDAC [107, 132]. Following treatment viability was 
measured by propidium iodide fluorescence exclusion assay. When compared to controls, AIF-
deficient cell lines showed neither increased resistance (to actinomycin D) nor increased 
sensitivity (to gemcitabine) following treatment (Figure 3.4). Similar results were obtained by 
treatment with etoposide, MNNG, arsenic trioxide, menadione, and hydrogen peroxide (data not 
shown). These data demonstrate that AIF does not play a significant regulatory role in the 
promotion of cell death in pancreatic cancer cells, and is consistent with previous studies 
evaluating AIF-mediated cell death [51]. 
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Figure 3.3. Establishment of AIF-deficient PDAC cell lines. 
PANC-1 and MIA PaCa-2 cells were stably infected with shRNA hairpins targeting LacZ or AIF 
with GFP as a selectable marker via lentiviral delivery. GFP positivity of infected cell lines was 
assessed by flow cytometry (A) and fluorescence microscopy (B). Equivalent targeting in BxPC-
3, HPAC, and HPAF-II cells was achieved by puromycin selection; suppression of AIF protein 
expression was verified by immunoblot analysis (C). 
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Figure 3.4. AIF ablation does not impact chemical death induction. 
Equal numbers of cells were harvested, washed, and allowed to attach overnight.  Cells were 
then left untreated (UT) or treated with 1 µg/mL actinomycin D (ActD) for 24 h or 1 µM 
gemcitabine (GEM) for 48-72 h.  Cell viability was then determined by propidium iodide 
staining and flow cytometry.  Data are shown as average ± standard deviation. 
 
AIF selectively supports PDAC cell growth and migration 
In order to determine whether AIF ablation impacts the rate of proliferation of pancreatic 
cancer cells, in vitro growth rates of AIF-deficient PDAC cells were assessed. Equal populations 
of cells were seeded in fresh media and allowed to proliferate for 72 h before quantification by 
Coulter™ counting. Notably, 4 of the 5 cell lines (PANC-1, BxPC-3, HPAC, and HPAF-II) 
showed a reduction in growth rate following ablation of AIF. After 3 days of proliferation, AIF-
deficient PANC-1, BxPC-3, and HPAC cells exhibited ~60% of growth compared to shLacZ 
controls. AIF ablation resulted in a less substantial reduction in proliferation in HPAF-II cells 
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(~75%), while growth was unaffected in MIA PaCa-2 cells (Figure 3.5A). These results are 
distinct from previous observations: in prostate cancer the growth rates of cells are largely 
unaffected by AIF ablation under nutrient-rich conditions in vitro, and it is not until exposure to 
Matrigel™ or growth stress in vivo that AIF-deficient prostate cancer cells exhibit substantial 
reductions in growth. This suggests that AIF is either more important in advanced PDAC vs. 
prostate cancer, and/or functions via alternative/additional mechanisms.   
To further define the role of AIF in controlling the aggressiveness of pancreatic tumor 
cells, the migration of AIF-deficient cells was assessed by scratch assay. High densities of cells 
were plated in replicate and allowed to attach for 12-36 h, and a scratch was made across the 
middle of each well with a P200 pipette tip. Scratch width was assessed immediately following 
cell displacement and 6-48 h later. AIF-deficient PANC-1, BxPC-3, and HPAC cells showed 
reduced migration, while little change was observed in AIF-deficient HPAF-II or MIA PaCa-2 
cells (Figure 3.5B), in agreement with our proliferation rate data. It is notable that while MIA 
PaCa-2-shAIF cells displayed similar migration compared to controls, when plated at the high 
densities used in the migration assay these cells took longer to adhere to plate surfaces. This 
suggests that AIF may be involved in cellular adhesion in this cell type; further studies are 
needed to define this function more clearly and determine the cancer specificity of this 
observation. Altogether, these data indicate that 1) the impact of AIF ablation upon pancreatic 
tumor cells is more severe than that observed in prostate cancer, 2) there is a spectrum of 
sensitivities to AIF ablation that is reflected by changes in cell growth patterns, and 3) AIF 
supports pancreatic tumorigenesis through a mechanism distinct from that shown in prostate 
cancer. 
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Figure 3.5. AIF selectively supports the growth and migration of PDAC cells. 
A) Cells were plated in equal densities in replicate, harvested, and quantified by Coulter™ 
counting after 72 h of growth. Data are shown as average ± standard deviation. B) High densities 
of cells were seeded in replicate wells and allowed to attach for 12-36 h. A single scratch was 
made through the middle of each well, and width was assessed at 0 h (all cell lines), 6 h (HPAC), 
10 h (HPAF-II), 24 h (PANC-1), and 48 h (BxPC-3 and MIA PaCa-2). Representative images 
are shown; all images were captured at 10× magnification. 
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Cellular energy phenotype determines the ability of AIF to promote growth and survival of 
PDAC cells 
Having found that AIF selectively contributes to the rates of both cellular proliferation 
and migration in vitro, we sought to determine how AIF supports cell growth in pancreatic 
cancer and distinguish these effects based on cellular metabolic state. A common feature of cells 
that require AIF for basal metabolic activity is a loss of expression in protein subunits of 
complex I of the respiratory chain [25, 51]. To determine whether respiratory chain regulation is 
related to AIF-mediated cell growth, cells were lysed and probed for complex I subunits by 
immunoblot analysis. Following knockdown of AIF the concomitant changes in respiratory chain 
protein levels were diverse and directly correlated with both metabolic phenotype and changes in 
growth. AIF-deficient PANC-1, BxPC-3, and HPAC cells exhibited substantial reductions in 39-
kDa, 20-kDa, and 17-kDa complex I subunits (Figure 3.6). Interestingly, when AIF was 
suppressed in BxPC-3 cells, the expression of not only complex I subunits but also COX IV was 
reduced (Figure 3.6), a change that has not been previously reported in cancer and may suggest a 
more global alteration in the mitochondrial proteome in this cell type. Changes in respiratory 
chain status were minimal when AIF was depleted from HPAF-II and MIA PaCa-2 cells (Figure 
3.6). These data indicate that loss of complex I in pancreatic cancer cells following AIF ablation 
is dependent on metabolic phenotype. 
A common adaptation following impairment of the mitochondrial respiratory chain is an 
increase in glucose consumption, allowing cells to meet ATP demands directly through 
glycolysis. To further define the role of AIF in pancreatic cancer cells, metabolic changes 
associated with AIF ablation were first evaluated by measuring glucose consumption rates. In 
agreement with the spectrum of respiratory deficiencies observed, AIF-deficient PANC-1, 
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BxPC-3, and HPAC cells consumed ~2-5-fold more glucose than their corresponding controls, 
while HPAF-II-shAIF and MIA PaCa-2-shAIF cells exhibited glucose consumption levels that 
were essentially unchanged when compared to controls (Figure 3.7A). Notably, the magnitudes 
of altered glucose consumption in our panel of cell lines directly correlated with the severity of 
respiratory chain deficiency that followed ablation of AIF (Figure 3.6). This correlation suggests 
that differences in sensitivity to AIF ablation among cell types may stem from differential 
metabolic requirements prior to AIF ablation. For example, due to a pre-existing decrease in 
respiratory chain activity [133], MIA PaCa-2 and HPAF-II cells have already adapted by 
upregulating glycolysis such that further impairment of the respiratory chain via AIF ablation has 
no additional effects upon glucose consumption. 
   
Figure 3.6. AIF selectively controls protein levels of nuclear-encoded respiratory chain 
subunits. 
Following suppression of AIF, respiratory chain status was assessed by immunoblot analysis of 
complex I (39-, 20-, and 17-kDa subunits) and COX IV. Corresponding β-actin immunoblots are 
shown in Figure 3.3. 
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To test this hypothesis and to determine the benefit of AIF-mediated glucose metabolism 
to cell survival, we next inhibited glycolysis in our panel of cell lines by treatment with 2-
deoxyglucose. Glycolytic cell lines will exhibit a higher sensitivity to treatment than those that 
remain capable of using other pathways (OXPHOS, lipid catabolism, glutaminolysis, etc.) to 
compensate for this metabolic deficiency. To assess sensitivity, cell viability was measured using 
propidium iodide staining followed by flow cytometry. Results revealed that while control 
PANC-1 and BxPC-3 cells are entirely resistant to 2-deoxyglucose for the duration of treatment, 
those that lack AIF exhibit substantial sensitivity with only ~40-50% survival following 
treatment (Figure 3.7B). Taken together with the corresponding respiratory statuses of these cell 
lines (Figure 3.6), AIF is likely to regulate a balance between glycolysis and OXPHOS that is 
critical to the growth and survival of PANC-1 and BxPC-3 cells. In contrast, AIF ablation did not 
affect sensitivity to treatment in HPAC cells despite their complex I deficiency and elevated 
glucose consumption levels (Figure 3.7B). This is not surprising given the lipogenic nature of the 
HPAC cell line [100], which allows cells to circumvent the metabolic requirement for AIF and 
complex I but at the expense of their proliferative capacity (Figure 3.5). When compared to the 
resistant PANC-1, BxPC-3, and HPAC cell lines, control HPAF-II and MIA PaCa-2 cells both 
displayed a high basal sensitivity to 2-deoxyglucose, reflecting their dependence on glycolysis 
that is likely due to long-term adaptations to basal mitochondrial dysfunction. AIF ablation 
modestly increased sensitivity to glycolytic disruption in HPAF-II cells, but MIA PaCa-2 cells 
displayed a pre-existing addiction to glycolysis [100, 134] that could not be amplified by AIF 
suppression. This sensitivity was comparable to PANC-1-shAIF and BxPC-3-shAIF cells 
following treatment (Figure 3.7B) and is consistent with glucose consumption data (Figure 
3.7A). In this context loss of AIF has little to no additional metabolic effect, an observation that 
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further confirms the hypothesis that differences in glucose uptake among cell types following 
AIF ablation derive from differences in the intrinsic activities of their respiratory chains. 
 
Figure 3.7. Glycolytic dependence predicts metabolic sensitivity to AIF ablation. 
A) Equal densities of cells were plated in fresh media, and total glucose was measured using the 
QuantiChrom™ Glucose Assay Kit (BioAssay Systems) 72 h after seeding. Total numbers of 
cells in each well were used to determine glucose consumption per cell. B) Cells were seeded in 
equal densities and allowed to attach overnight before treatment with 50 mM 2-deoxyglucose.   
After 48 h cells were collected, and viability was determined by propidium iodide staining and 
flow cytometry. Data are shown as average ± standard deviation. 
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Matrigel™ growth conditions amplify AIF dependence 
Following the observations that AIF supports metabolism benefiting the growth and 
survival of non-glycolytic pancreatic cancer cells in vitro, we next explored the metabolic 
function of AIF in an environment that more closely resembles conditions found in vivo. 
Matrigel
TM
 is a cell growth substrate that consists of matrix protein polymers and proteoglycans 
found in natural extracellular environments and is often used as a model for studying 
tumorigenesis in a setting that approximates in vivo cell growth and survival. To assess the role 
of AIF in the growth and metabolism of pancreatic cancer cells under such conditions, glucose 
consumption and growth were measured following exposure to Matrigel
TM
 substrate. Results 
were strikingly similar to those found in the absence of Matrigel™, except that the differences 
between control and AIF-deficient cells were amplified. When introduced into substrate, cells 
displayed a dependence upon AIF expression for aggressive growth and normal glucose 
consumption. While control PANC-1, BxPC-3, and HPAC cells grew into spheroidal tumor-like 
structures, those without AIF exhibited substantial reductions in both size (Figure 3.8A) and 
proliferation rate (Figure 3.8B). Furthermore, AIF-deficient PANC-1, BxPC-3, and HPAC cells 
consumed ~3-7-fold more glucose than those with AIF (Figure 3.8C), suggesting that glycolysis  
becomes critical for growth and survival under Matrigel
TM
 growth conditions when AIF is 
depleted. In the HPAF-II cell line, which exhibited modest changes in growth and metabolism 
following AIF ablation in vitro, both shLacZ controls and shAIF failed to invade the substrate to 
the extent of other cell lines, yet HPAF-II-shAIF cells showed a substantial reduction in growth 
rate and a 2-fold increase in glucose consumption. Taken together with previous data, this 
suggests that AIF plays a minor role in HPAF-II glucose metabolism under nutrient-rich 
conditions but that this role becomes more important upon exposure to Matrigel
TM
. In contrast, 
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MIA PaCa-2-derived cell lines did not display significant changes (Figure 3.8), consistent with 
in vitro measurements. Following growth in Matrigel™ changes in both glucose uptake and 
growth in substrate were more severe but directly proportional to those found in vitro. 
Altogether, these data indicate that AIF supports the growth and survival of some pancreatic 
cancer cells by facilitating a metabolic balance, and this metabolic function is most beneficial 
OXPHOS-dependent populations. 
Discussion 
AIF elevation in cancer promotes survival without affecting death induction 
When functioning in a pro-death role, AIF can undergo nuclear translocation followed by 
the induction of chromatin condensation and DNA degradation during various forms of cell 
death [135-139]. As a promoter of caspase-independent death, it is formally possible that AIF 
could act in a tumor-suppressive manner. Yet while AIF nuclear translocation has been observed 
in cancer [140, 141], this study and others [51, 54] show that loss of AIF suppresses 
tumorigenesis and that AIF’s nuclear function is unlikely to make a significant contribution to 
death pathways despite overexpression in tumors [51, 83-88]. AIF elevation in cancer is modest 
(typically less than 3-fold), suggesting a threshold exists above which AIF expression is either no 
longer beneficial or actively disadvantageous. Despite this threshold, AIF elevation in cancer is 
both sufficient and necessary for AIF to promote survival through its enzymatic activity [51, 54]. 
Pathogenic AIF mechanisms 
Presently, AIF enzymatic activity has been demonstrated to support tumorigenesis 
through at least two distinct mechanisms. In colorectal cancer cells, AIF elevates the cellular 
oxidative state to protect against chemical stress-induced apoptosis [54]. In prostate cancer, AIF 
promotes  a metabolic  state that  selectively supports  the growth and survival  of cells  that have  
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Figure 3.8. Matrigel™ environment amplifies dependence upon AIF-mediated growth and 
metabolism. 
A) Cells were plated in replicate Matrigel™ layers and allowed to grow for up to 21 days.  
Representative images (captured at 10× magnification) are shown. B) Cells were extracted from 
substrate and quantified by Coulter™ counting. C) Cells were exposed to Matrigel™ conditions 
prior to media collection and total glucose measurements using the QuantiChrom™ Glucose 
Assay Kit (BioAssay Systems). Cells were extracted from substrate with the Matrigel Recovery 
Solution (Corning) and quantified by Coulter™ counting. Total numbers of cells in each well 
were used to determine glucose consumption per cell. Data are shown as average ± standard 
deviation. 
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achieved advanced status [51], suggesting that AIF addiction in cancer manifests as tumors 
become increasingly aggressive. Data presented here agree with a similarly important 
contribution for AIF to pancreatic cancer progression, a disease setting that most often presents 
at an advanced stage by the time of diagnosis. However, in contrast to observations in prostate 
cancer, the selectivity of AIF support of different pancreatic cancer cell types was directly 
related to their cellular energy preferences. 
Differences in AIF sensitivity among cell types 
PANC-1, BxPC-3, and HPAC cells, all of which display a metabolic phenotype not 
solely reliant upon glycolysis (Figure 13B, Table 1, [100]), exhibited a remarkably similar 
reduced growth phenotype (~60% of controls) following AIF ablation that also included 
respiratory chain depletion and elevated glucose consumption levels ranging from ~2-5-fold. 
When introduced into Matrigel™ substrate, more severe changes in both growth (20-30% of 
controls) and glucose uptake (~3-7-fold increases) were observed. PANC-1 and BxPC-3 cell 
lines were also sensitized to glycolytic disruption, suggesting that glycolysis becomes critical for 
survival following AIF ablation. This change was not observed in the HPAC cell line, likely due 
to a metabolic flexibility that derives from its lipogenic phenotype [100]; in this context AIF 
supports aggressive growth, yet cells remain capable of maintaining survival in the absence of 
AIF’s metabolic activities. 
HPAF-II cells, which exhibit a greater dependence on glycolysis than PANC-1, BxPC-3, 
or HPAC cells (Figure 3.7B, Table 3.1, [100]), also showed changes following AIF ablation, 
although less severe. Cells did not lose complex I subunits, nor did they exhibit significantly 
increased glucose consumption in vitro. Despite this apparent lack of metabolic consequence in 
vitro, AIF ablation further increased sensitivity to 2-deoxyglucose while modestly compromising 
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growth. Moreover, introduction to Matrigel™ caused HPAF-II-shAIF cells to elevate glucose 
consumption by 2-fold while significantly reducing growth rate. No changes in either growth or 
glucose metabolism were identified in MIA PaCa-2 cells, which displayed a severe pre-existing 
addiction to glycolysis (Figure 3.7B, Table 3.1, [100]) that could not be further exacerbated by 
AIF ablation. 
AIF is a potential mediator of metabolic flexibility  
While our data suggest that AIF is selectively beneficial to metabolically “flexible” 
PDAC cells that use both glycolysis and OXPHOS for energy production, the basis for the 
selective sensitivity of different cell types to AIF ablation has not been firmly established. It has 
been proposed that AIF functions as a metabolic sensor through binding and oxidizing NADH 
ligands [59]. In light of this hypothesis and extending current data to other cell types, AIF may 
regulate respiratory chain expression and metabolic flux in response to NADH/NAD
+
 
availability (established by the overall metabolic state). By implication, AIF is consequently 
central to a self-regulating metabolic balance. 
Our data suggest that AIF expression is necessary to mediate a metabolic balance in 
certain pancreatic cancer cells (e.g., PANC-1, BxPC-3, and HPAC), and AIF ablation induces 
cellular adaptations that lead to a greater reliance upon glycolysis for survival in these cell types. 
Other cell types that exhibit a pre-existing addiction to glycolysis (e.g., HPAF-II and MIA PaCa-
2) are therefore less sensitive to AIF ablation. This further emphasizes the impact of metabolic 
balance in support of pancreatic tumorigenesis, specifically through the expression of AIF 
(Figure 3.9). 
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Summary 
In this study we established a pro-tumorigenic role for AIF in pancreatic cancer that 
derives from its metabolic activities. The selectivity of AIF dependence in tumorigenesis appears 
independent of oncogene/tumor suppressor status (Table 3.2) and instead stems from the overall 
cellular metabolic state, which results from the cumulative effect of genetic alterations. We 
found a direct relationship between basal metabolic state and dependence upon AIF expression 
(Table 3.1): as cells become aggressive such that they require a critical balance between 
mitochondrial energy metabolism and glycolysis, they become more dependent upon AIF. A 
recent report identified PDAC subtypes based upon metabolic requirements [100]. This extensive 
study characterized the metabolic states of all cell lines used in our study (Table 3.1) as well as 
numerous other cell lines, and their data strongly support our model. These data and our previous 
studies suggest that AIF’s metabolic impact upon tumorigenesis increases with disease 
progression. Previously we showed that AIF promotes a metabolic state permitting progression 
to advanced stages. Based on our current data, we propose that in the most advanced tumor cells 
(such as in PDAC), which critically rely on metabolic reprogramming for growth and survival, 
AIF activity is maximally exploited and becomes entwined within the overall metabolic state, a 
situation in which the only limiting factor to AIF dependence is how the cell utilizes 
mitochondrial energy metabolism.   
Altered AIF expression is not a general feature of cancerous tissues and AIF activity is 
not universally supportive to cancer development and progression. However, in studies presented 
here we have identified a subpopulation of pancreatic cancer samples in which AIF expression is 
elevated, and using a panel of cancer cell lines with defined metabolic phenotypes we have 
correlated AIF activity to basal metabolic state. At present the molecular mechanisms defining 
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AIF sensitivity remain to be elucidated, yet the experiments presented outline a framework for 
determining those cells in which AIF activity is critical, based on criteria such as metabolic 
phenotype and fuel source preference/requirements. The promise of this framework is the 
potential for AIF-mediated therapy. Development of such therapy, either as a stand-alone 
approach or more likely in combination with other modalities, will depend on better 
understanding of AIF mechanism and accurate metabolic assessment, but offers significant 
potential for increasing our treatment arsenal for cancer patients suffering from advanced 
disease. 
Altogether this study highlights the metabolic significance of AIF to PDAC and expands 
the range of AIF function in tumorigenesis.  We found that the basal energetic requirements of 
PDAC cells determine the ability of AIF to support metabolic plasticity that benefits growth and 
survival.   As a metabolic linchpin in cancer, AIF therefore represents a novel therapeutic target. 
 
Figure 3.9. Basal metabolic state governs AIF-dependent growth support. 
AIF is required for complex I and metabolism benefitting the growth and survival of OXPHOS-
dependent cells, but dispensable for metabolism and independent of complex I in glycolytic 
cells. 
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IV. AIF IS A ROTENONE-RESPONSIVE TRANSLATION FACTOR FOR 
MITOCHONDRIAL GENE EXPRESSION BALANCING RESPIRATORY CHAIN 
ACTIVITY WITH GLYCOLYSIS 
Abstract 
AIF is critical for the regulation of metabolism, especially in the context of 
tumorigenesis. Altered metabolism and sensitivity to metabolic disruption are observed 
following AIF ablation, but how AIF regulates energy production remains largely unknown. One 
of the key questions surrounding AIF metabolic activity is why complex I protein levels decrease 
following AIF ablation, and how AIF mechanistically maintains subunits of the ETC. Here we 
define a role for AIF as a mediator of mitochondrial gene expression. AIF interacts with both 
mitochondrial EF-Tu (TUFM) and the mitochondrial ribosome, promoting their association with 
each other. Knockdown of TUFM demonstrates loss of both nuclear and mitochondria-encoded 
proteins, indicating that impairment of mitochondrial translation leads to decreased nuclear 
protein expression in the mitochondria and explains how AIF can control protein levels of the 
ETC encoded both by nuclear and mitochondrial genomes. AIF knockdown and loss of complex 
I alters glucose metabolism, and experiments here demonstrate that levels of a variety of 
glycolysis enzymes increase when AIF expression is suppressed. Altogether these experiments 
identify novel mechanisms through which AIF controls mitochondrial metabolism and extra-
mitochondrial responses to AIF ablation. 
Introduction 
The mitochondrial protein known as AIF has been demonstrated to control complex I and 
cellular metabolism to the benefit of tumorigenesis. However, a mechanistic understanding of 
how AIF serves this metabolic function remains to be determined. Determining how AIF 
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controls levels of ETC subunits would solve a longstanding open question in the field of AIF 
biology and provide a further understanding of the regulation of cellular metabolism. Following 
AIF ablation, select cell types exhibit decreases in subunits of complex I, and a variety of 
explanations can be envisioned. AIF may regulate stability, import, translation, and/or 
transcription of ETC proteins. 
If AIF regulates complex I at the post-translational level, this would suggest that complex 
I is degraded following loss of AIF. This could be due either to improper import and/or assembly 
of complex I. Within cells turnover of defective, old, and/or unnecessary proteins occurs through 
two general mechanisms, involving degradation via either proteasomes or lysosomes. Prior to 
proteasomal degradation, proteins are modified by covalent attachment of ubiquitin residues to 
form polyubiquitin chains. Within polyubiquitin chains, ubiquitin units are linked at lysine 
residue 48, which signals for proteasomal targeting. Ubiquitin linkages at alternative residues 
have also been reported [142], which serve to regulate protein activity rather than degradation. 
Following the attachment of K48-linked polyubiquitin chains to the target protein, the protein is 
recognized by the proteasome and subsequently degraded. During lysosomal degradation, 
proteins and other intracellular components are engulfed into the acidic lysosome and broken 
down by lysosomal hydrolases. Lysosome-mediated degradation of cellular components is often 
mediated by the catabolic cellular recycling process known as autophagy [143]. 
If complex I is degraded either by proteasomes or lysosomes following AIF ablation, this 
would suggest that AIF is essential for respiratory chain stability. Additionally or alternatively, 
AIF may regulate transcription and/or translation of mitochondria-encoded proteins, integrating 
the cellular metabolic environment with mitochondrial activity. Mitochondria contain their own 
circular double-stranded genome encoding 37 genes. Of these 37 genes, 13 encode ETC protein 
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subunits, 22 encode mitochondrial tRNAs, and 2 encode rRNAs. It is thought that mitochondria 
evolved from an ancestral prokaryote that was engulfed by a larger cell and shared a symbiotic 
relationship, with the mitochondrial ancestor eventually losing independence from the host’s 
nuclear genome [144]. Over time mitochondria retained only a handful of their own genes, now 
integrating their expression with nuclear-encoded proteins. If AIF is a necessary factor for 
mitochondrial gene expression, then loss of AIF and subsequent losses of mitochondria-encoded 
proteins would prevent translation, import, and/or assembly of nuclear-encoded ETC subunits, 
which usually happen concurrently. 
Similar to translation in the cytosol, mitochondrial translation involves ribosomes, 
tRNAs, and elongation factors. The mitochondrial ribosome (mitoribosome) functions similarly 
to cytosolic ribosomes, but differs in composition with higher ratios of protein to rRNA. The 
mitochondrial ribosome is comprised of a large 39S subunit and a small 28S subunit, which 
together form a 55S mitoribosome that synthesizes proteins encoded within the mitochondrial 
genome [145]. 
Mitochondrial translation requires accessory factors for the ribosome to synthesize 
proteins. One of these elongation factors known as EF-Tu (known as TUFM in the mitochondria) 
is bound to GDP in its inactive state, and this GDP is released upon binding with EF-Ts (TSFM 
in the mitochondria). As a G-protein, EF-Tu then binds GTP to become active. When complexed 
with GTP, EF-Tu can then bind an aminoacyl-tRNA (aa-tRNA). Subsequently EF-Tu guides the 
aa-tRNA to the ribosome, where the tRNA anticodon binds the codon of ribosome-associated 
mRNA. Correct codon-anticodon pairing then induces the ribosome to activate the GTPase 
domain of EF-Tu, causing GTP hydrolysis. Following GTP hydrolysis, EF-Tu undergoes a 
conformational change that leads to the release of EF-Tu from the aa-tRNA and ribosome. The 
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ribosome then catalyzes the transfer of the growing polypeptide onto the amino acid. The 
liberated EF-Tu (now GDP-bound) is able to be reactivated by EF-Ts and repeat the cycle [146]. 
Here we find that AIF is a critical factor for mitochondrial translation. Ablation of AIF 
does not lead to either proteasomal or lysosomal degradation of complex I, further suggesting an 
absence of protein translation rather than increased turnover. AIF knockdown in our panel of 
PDAC cell lines demonstrates that AIF is required for mitochondria-encoded protein expression 
in specific cell types, similar to our observations of nuclear-encoded subunits. Mechanistic 
examination suggests that AIF stimulates the association of TUFM with the mitoribosome to 
promote translation of mitochondrial genes. The AIF-TUFM-mitoribosome complex is disrupted 
by rotenone, suggesting that AIF serves as an adaptor protein that is sensitive to changing 
metabolic conditions. Loss of AIF metabolic activity leads to the upregulation of the metabolic 
transcription factor c-Myc and a variety of glycolysis enzymes, suggesting altered glycolysis in 
AIF-deficient cells is due to additional changes in nuclear encoded proteins beyond the ETC. 
Altogether these experiments shed light upon how AIF can control the ETC and the effects upon 
nuclear gene expression, furthering our understanding of the regulation of cellular metabolism. 
Materials and methods 
Materials, plasmids and antibodies 
MEM, DMEM, RPMI 1640, DMEM/F12, GlutaMAX, horse serum, insulin, transferrin, 
epidermal growth factor, trypsin, 4-12% bis-tris polyacrylamide gels, and nitrocellulose 
membranes were obtained from Life Technologies; fetal bovine serum (FBS), phosphate 
buffered saline (PBS), Ni-NTA agarose, and Pierce ECL 2 Western Blotting Substrate were from 
Thermo Scientific; protease inhibitor tablets were from Roche Applied Science; all other 
materials were from Sigma. 
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Lentiviral plasmids FG12-shLacZ-GFP, FG12-shAIF-GFP, FG12-shLacZ-puro, and 
FG12-shAIF-puro were described previously [51, 52, 121, 147]. Lentiviral packaging plasmids 
pHCMV-G, pRRE, and pRSV-rev are as described [123]. The pcDNA3.1-Myc/His-MRPL18 
plasmid [148] was kindly provided by Dr. Shu-Bing Qian (Cornell University). To create pEBB-
TUFM-HA, TUFM cDNA was subcloned from pcDNA3 into the pEBB-HA backbone. 
Lentiviral pLKO plasmids were obtained as follows: psPAX2 and pMD2.G-vsv-G from Dr. 
Didier Trono (Addgene plasmids #12260 and 12259); and pLKO.1-puro-scramble [149] from 
Dr. David Sabatini (Addgene plasmid #1864); pLKO.1-puro-shTUFM #1 (TRCN0000280863) 
and pLKO.1-puro-shTUFM #2 (TRCN0000280864) were from Sigma.  
Antibodies were obtained as follows: anti-AIF (Santa Cruz Biotechnology, sc-13116), 
anti-NDUFA9 (Life Technologies, 459100), anti-NDUFB8 (Life Technologies, 459210), anti-
COX IV (Life Technologies, A21347), anti-polyubiquitin conjugated protein (Enzo Life 
Sciences, PW8805), anti-LC3 (Cell Signaling, 12741), anti-TUFM (Thermo, PA5-27511), MT-
ND1 (Abcam, ab181848), anti-MT-CYB (Abcam, ab81215), anti-MT-CO1 (Abcam, ab14705), 
anti-MT-CO2 (Abcam, ab79393), anti-HK1 (Cell Signaling, 2024), anti-HK2 (Cell Signaling, 
2867), anti-PFKP (Cell Signaling, 8164), anti-PFKFB2 (Cell Signaling, 13045), anti-PFKFB3 
(Cell Signaling, 13123), anti-ALDOA (Cell Signaling, 8060), anti-GAPDH (Cell Signaling, 
5174), anti-PGAM1 (Cell Signaling, 12098), anti-ENO1 (Cell Signaling, 3810), anti-ENO2 (Cell 
Signaling, 8171), anti-PKM1/2 (Cell Signaling, 3190), anti-PKM2 (Cell Signaling, 4053), anti-
PDHA1 (Cell Signaling, 3205), anti-PDK1 (Cell Signaling, 3820), anti-LDHA (Cell Signaling, 
3582), anti-c-Myc (Cell Signaling, 5605), anti-β-actin (Sigma, A5316), anti-HA (Covance, 
MMS-101P), peroxidase-conjugated anti-HA (Sigma, H-6533), peroxidase-conjugated anti-
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FLAG (Sigma, A8592), peroxidase-conjugated anti-mouse (Amersham Biosciences, NA931V), 
and HRP-conjugated anti-rabbit IgG (Amersham Biosciences, NA934B). 
Cell culture 
PANC-1, BxPC-3, HPAF-II, HPAC, and MIA PaCa-2 cells were from ATCC (kind gift 
of Dr. Sanku Mallik, NDSU). PC3 and HEK293T cells were as described [51]. Cells were grown 
in an atmosphere of 95% air and 5% CO2 at 37 °C. All media was supplemented with 2 mM 
GlutaMAX. Cell lines were grown and cultured with the following media formulations: 
HEK293T and PANC-1 cells in DMEM supplemented with 10% FBS; MIA PaCa-2 in DMEM 
supplemented with 10% FBS and 2.5% horse serum; BxPC-3 and PC3 in RPMI 1640 
supplemented with 10% FBS; HPAF-II in MEM supplemented with 10% FBS; and HPAC in a 
1:1 mixture of DMEM and Ham’s F12 medium supplemented with 5% FBS, 2 μg/mL insulin, 5 
μg/mL transferrin, 40 ng/mL hydrocortisone, and 10 ng/mL epidermal growth factor. 
Lentiviral production and stable infection of cell lines 
FG12-derived plasmids for targeting of AIF and LacZ by RNA interference (RNAi) have 
been rigorously assessed and used as described [51, 121, 122]. Lentiviral packaging plasmids 
pRRE, pRSV-rev, and pHCMV-G are as described [123]. RNAi plasmids and equal amounts of 
lentiviral packaging plasmids were transfected into HEK293T cells using the calcium phosphate 
precipitation method [124]. Supernatants of transfected HEK293T cultures were then filtered 
through 0.45-μm PVDF Millex-HV filters (Millipore) and concentrated by centrifugation at 
20,000 x g for 90 min at 4 °C. Viral pellets were resuspended in PBS and then incubated 
overnight at 4 °C prior to use. Cell lines were then infected as described [51]. PANC-1 and MIA 
PaCa-2 cells were infected with lentiviruses carrying shLacZ-GFP or shAIF-GFP, after which 
infection was verified by fluorescence microscopy and flow cytometry with an Accuri C6 flow 
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cytometer. BxPC-3, HPAC, and HPAF-II cells were infected with lentiviruses carrying shLacZ-
puro or shAIF-puro and then selected using 2 μg/mL puromycin. 
For establishment of cell lines stably suppressing TUFM, pLKO.1-based lentiviruses 
were generated by transfecting HEK293T cells with pMD.2, psPAX2, and pLKO.1-scramble or 
pLKO.1-shTUFM using the calcium phosphate method. Viral supernatant was collected at 48 h 
and 72 h post-transfection and then filtered using 0.45 μm-pore size Millex HV PVDF filter 
units. Target cells were then incubated with viral supernatant and 8 μg/mL polybrene for 24 h. 
Stably infected cells were selected using 1 μg/mL puromycin. 
Cell lysis, immunoprecipitation, and nickel affinity precipitation 
Cell lysates were prepared in radioimmune precipitation assay (RIPA) lysis buffer (PBS 
containing 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM dithiothreitol, 1 mM 
PMSF, 1 mM sodium fluoride, 1 mM sodium orthovanadate, and 1 protease inhibitor mixture 
tablet per 10 mL). 
For immunoprecipitation experiments, RIPA cell lysates were normalized for protein 
content and then incubated with indicated antibodies for 2 h at 4 °C. Protein G-coupled agarose 
beads were then added and incubated for 1 h. Agarose beads were then recovered by 
centrifugation and washed in RIPA buffer. Precipitated protein was eluted by adding lithium 
dodecyl sulfate sample buffer followed by heating samples at 95 °C for 5 min. Samples were 
then analyzed by immunoblot as described below. 
For nickel affinity precipitation experiments, RIPA cell lysates were normalized for 
protein content and then incubated with Ni-NTA agarose for 2 h at 4 °C. Agarose beads were 
then recovered by centrifugation and washed in RIPA buffer. Precipitated protein was eluted by 
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adding lithium dodecyl sulfate sample buffer followed by heating samples at 95 °C for 5 min. 
Samples were then analyzed by immunoblot as described below. 
Immunoblot analysis 
For immunoblot experiments, protein samples were separated by SDS-PAGE using 4-
12% gradient SDS-polyacrylamide gels followed by electrotransfer to nitrocellulose membranes. 
Membranes were blocked with 5% milk or bovine serum albumin in tris-buffered saline 
containing 0.02 to 0.2% Tween-20 and then incubated with the indicated primary antibodies. 
Membranes were then washed three times and incubated with HRP-conjugated anti-mouse or 
anti-rabbit followed by visualization using enhanced chemiluminescence. 
Replicate immunoblots were quantified at multiple exposures for linearity using 
myImage Analysis™ software (Thermo Scientific). Band intensities for phosphorylated proteins 
were divided by intensities for the corresponding total proteins; all protein values and phospho-
protein/total protein ratios were then normalized to β-actin values. To determine fold changes 
among lanes, all ratios were then normalized to control lanes (leftmost lanes). 
Drug treatments 
Cells were seeded at equal densities and allowed to attach overnight. Cells were then 
treated with either control solvent, 50 μM MG132 for 3-6 h, 0-50 μM chloroquine overnight, or 
100 μM rotenone for 1 h. Following treatment cells were subjected to lysis and immunoblot as 
described above. 
Results 
Complex I is not degraded following AIF ablation 
AIF regulates protein levels of complex I [25, 73], but the mechanisms underlying this 
regulatory process are not well established. One possibility is that AIF could regulate import or 
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folding of complex I. Based upon cell type and metabolic requirements, mitochondria may 
exhibit different sensitivities to defective complex I following loss of AIF. For example, MIA 
PaCa-2 cells are glycolytic and do not appear to acquire significant amounts of ATP from 
mitochondrial ETC/OXPHOS [52]. In this context complex I malfunction would not 
substantially impact metabolism. However, in cells that utilize OXPHOS to obtain energy (e.g., 
PC3 and PANC-1 cells) [51, 52], defective complex I could signal for either proteasomal or 
lysosomal degradation as a mechanism to replace ETC subunits (which is a futile process 
without AIF). 
To test the hypothesis that AIF ablation triggers degradation of complex I, AIF-proficient 
and deficient PC3 cells were used. PC3 cells exhibit complex I deficiency following AIF 
ablation and were therefore treated with MG132, a proteasomal inhibitor. If complex I is 
degraded by the proteasome, MG132 should restore complex I in AIF-deficient cells. 
Immunoblot for ubiquitinated proteins (Figure 4.1) demonstrated substantial protein 
ubiquitination (a signal for proteasomal degradation and indicator of MG132 efficacy) following 
treatment. However, the 39-kDa subunit (NDUFA9) of complex I remained at low levels upon 
proteasomal inhibition (Figure 4.1), suggesting that complex I is not degraded by the proteasome 
when AIF is suppressed. 
An alternative means by which complex I depletion may occur is through lysosomal 
degradation. Autophagy, a cellular process serving to degrade and recycle cellular components, 
uses lysosomes to turn over intracellular molecules and organelles. During this process the 
autophagic protein LC3-I is conjugated with phosphatidylethanolamine, forming LC3-II and 
leading to its association with lysosomes to promote membrane expansion and fusion events. 
LC3-II is then degraded within the lysosome [143]. When lysosomes are neutralized by 
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lysosomotropic agents such as chloroquine, LC3-II accumulates, leading to an increased LC3-
II/LC3-I ratio that can be visualized via immunoblot. Therefore, similar to our experiment with 
MG132, we treated cells with chloroquine to determine if complex I is lysosomally degraded, 
using LC3 as a marker for lysosomal inhibition.  Following treatment with chloroquine, LC3-II 
substantially increased (Figure 4.2) and indicates lysosomal neutralization. However, similar to 
our observations of proteasomal inhibition, suppression of lysosomal activity did not restore 
complex I (Figure 4.2) and suggests that complex I is neither degraded by the proteasome nor 
lysosome following AIF ablation. It is notable that less LC3-II accumulation was observed in 
AIF-deficient cells (Figure 4.2), suggesting a possible involvement of AIF in regulating 
autophagy. 
 
Figure 4.1. Complex I is not degraded by the proteasome following AIF ablation. 
PC3-derived cells were treated with control solvent or 50 μM MG132 for 3 or 6 h, then lysed and 
assessed for the indicated proteins by immunoblot. 
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Figure 4.2. AIF ablation does not induce lysosomal degradation of complex I. 
PC3-derived cells were treated with 0, 10, or 50 μM chloroquine (CQ), lysed, and assessed for 
the indicated proteins by immunoblot. 
 
Proteasomal and lysosomal degradation are the two major general mechanisms for 
protein turnover. Proteases are capable of degrading specific protein targets, but the multitude of 
ETC proteins associated with AIF ablation make this an unlikely mode of complex I deficiency. 
Rather, it appears that complex I is not translated. It remains to be determined how AIF impacts 
ETC subunits at the RNA level. 
AIF regulates mitochondria-encoded protein levels 
Complex I is not degraded following AIF ablation, suggesting that ETC deficiency 
occurs at or prior to protein translation. While most respiratory chain proteins are encoded by the 
nucleus, 13 are encoded within the mitochondrial genome. Therefore we wondered if AIF could 
control protein levels of mitochondria-encoded genes, similar to what is observed for AIF-
dependent control of nuclear-encoded ETC genes [52]. If mitochondrially encoded proteins are 
impaired by AIF ablation, this could lead to a loss of translation and import of nuclear encoded 
proteins. To interrogate the possibility that AIF is involved with mitochondrial gene expression, 
lysates of our panel of AIF-deficient PDAC cells (Chapter 3) were probed for 4 different 
mitochondria-encoded proteins: MT-ND1 (complex I), MT-CYB (complex III), MT-CO1 
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(complex IV), and MT-CO2 (complex IV). Immunoblot analysis revealed that following AIF 
ablation cells exhibited decreased levels of mitochondria-encoded proteins that varied with cell 
type (Figure 4.3A). PANC-1 cells showed decreases in MT-ND1 and MT-CO2; and BxPC-3 
cells demonstrated losses in MT-CYB, MT-CO1, and MT-CO2; while HPAC cells showed 
reduced levels of all 4 proteins assessed following AIF knockdown. HPAF-II and MIA PaCa-2 
cells did not exhibit substantial changes in mitochondria-encoded proteins, similar to a lack of 
response for nuclear-encoded proteins. It is also notable that in general HPAF-II and MIA PaCa-
2 exhibit lower levels of mitochondria-encoded proteins prior to AIF ablation, raising the 
possibility that these two cell types may have fewer and/or less metabolically active 
mitochondria. Altogether, these data show that in specific cell types AIF controls both 
mitochondria- and nuclear-encoded ETC proteins. It is possible AIF may control mitochondrial 
gene expression, and when mitochondrial gene expression is impaired by AIF ablation, 
translation and/or import of nuclear-encoded ETC proteins is halted [150].  
AIF promotes formation of a mitochondrial translation complex containing mitochondrial 
EF-Tu and the mitoribosome 
ETC impairment due to AIF deficiency stems from loss of both nuclear and 
mitochondria-encoded ETC subunits, which is not due to increased protein turnover and rather 
appears to involve control mitochondrial gene expression. Previously we identified the 
mitochondrial ribosomal protein L18 (MRPL18) and the mitochondrial elongation factor Tu 
(TUFM) in a biochemical screen for mitochondrial AIF binding partners [53], providing a 
starting point to explore potential mechanisms through which AIF mediates ETC protein levels. 
Therefore we questioned the ability of AIF to control translation of the respiratory chain, which 
could be in part through interactions with the mitochondrial translation machinery. 
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Figure 4.3. AIF interacts with the mitochondrial translation factor TUFM and controls 
protein levels of mitochondria-encoded genes. 
A) Following suppression of AIF, levels of mitochondria-encoded proteins (MT-ND1, MT-CYB, 
MT-CO1, and MT-CO2) were assessed in the indicated cell types by immunoblot analysis. 
Corresponding β-Actin immunoblots are shown in Figure 3.3. B) HEK293T cells were 
transfected with control plasmids or plasmids encoding HA-tagged TUFM and subjected to co-
immunoprecipitation using an anti-HA antibody followed by immunoblot. 
 
To verify if TUFM physically associates with AIF, HEK293T cells were transfected with 
HA-tagged TUFM followed by immunoprecipitation using an anti-HA antibody. Immunoblot 
analysis demonstrated the presence of AIF in the precipitated samples containing exogenous 
TUFM (Figure 4.4B), showing that TUFM binds endogenous AIF. 
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Figure 4.4. TUFM ablation induces the loss of both mitochondria- and nuclear-encoded 
ETC proteins. 
The indicated cell types were  either uninfected or stably infected with either control lentiviruses 
(shCTL) or lentiviruses harboring TUFM targeting sequences (shTUFM #1, 2), then lysed and 
assessed for the indicated proteins by immunoblot. 
 
To determine the role of TUFM in controlling protein levels of mitochondrial proteins, 
we then stably suppressed TUFM expression using lentivirus-mediated shRNA induction and 
puromycin selection. Three different cell lines exhibiting different ETC responses to AIF 
ablation were targeted: AIF-deficient PC3 cells show decreased ETC subunit levels, whereas 
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AIF-deficient MIA PaCa-2 and HEK293T cells do not show changes in ETC proteins [51-53]. 
To ensure results were not due to nonspecific shRNA targeting effects, two different TUFM 
targeting sequences (shTUFM #1, shTUFM #2) were used in HEK293T cells. Immunoblot for 
TUFM was used to verify stable infection and knockdown (Figure 4.5). AIF levels were 
unaffected following TUFM knockdown, but decreases in complex I subunits NDUFA9 (39 
kDa) and NDUFB8 (20 kDa), COX IV, and MT-CO2 were observed. Similar to mitochondria-
encoded ETC proteins, nuclear-encoded proteins were additionally reduced, demonstrating that 
loss of mitochondrial gene expression triggers the loss of nuclear-encoded ETC subunits. 
Therefore this may explain the loss of nuclear-encoded ETC proteins following AIF ablation. 
Interestingly, decreases in ETC protein levels were substantially more apparent in MIA PaCa-2 
and HEK293T cells, whereas little to no change in ETC proteins was observed in PC3 cells. This 
is particularly notable since PC3 cells, but not MIA PaCa-2 or HEK293T cells exhibit ETC 
deficiency following AIF knockdown. While this observation requires further experimentation to 
provide a mechanistic explanation, it may suggest that AIF can promote mitochondrial protein 
expression without TUFM, but TUFM cannot promote translation without AIF. 
We then tested the possibility that AIF and TUFM could regulate ETC translation 
through interaction with the mitochondrial ribosome. Having previously identified the 
mitoribosomal protein MRPL18 as another AIF-associated factor [53], we then transfected 
HEK293T cells with either empty control plasmids or plasmids encoding FLAG-tagged AIF with 
HA-tagged TUFM and/or 6x-His-tagged MRPL18. The 6x-His tag exhibits a high affinity for 
nickel and can therefore be used for purification/precipitation. Transfected cells were lysed and 
then subjected to nickel affinity precipitation followed by immunoblot for FLAG (AIF) and HA 
(TUFM). Both AIF and TUFM precipitated with MRPL18 (Figure 4.5), suggesting that both 
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proteins are MRPL18 binding partners. Additionally, overexpression of AIF increases TUFM-
MRPL18 binding. Since AIF binds both TUFM (Figure 4.3) and MRPL18 (Figure 4.5), this 
raises the possibility that AIF serves as an adaptor protein promoting delivery of aminoacyl-
tRNAs from EF-Tu to the mitochondrial ribosome, a process that is indispensable for protein 
synthesis. 
Binding of AIF and TUFM with MRPL18 was additionally tested following treatment 
with rotenone, a complex I inhibitor that disrupts respiratory chain function and cellular 
metabolism. The TUFM-MRPL18 interaction was unaffected by treatment, but binding of AIF 
with MRPL18 showed a robust increase in the presence of rotenone. Interestingly, when both 
AIF and TUFM were simultaneously overexpressed with MRPL18, rotenone treatment caused a 
strong reduction in binding of both proteins. The mechanisms and biochemical logic underlying 
this altered binding remain to be determined, but these data demonstrate that the AIF-mediated 
mitochondrial translation complex is sensitive to respiratory chain activity, further suggesting 
that AIF responds to metabolic changes within the cell (Chapter 3). 
 
Figure 4.5. AIF facilitates the formation of a mitochondrial translation complex containing 
TUFM and MRPL18 that is responsive to rotenone. 
HEK293T cells were transfected with the indicated plasmids and then treated with either control 
solvent or 100 μM rotenone, followed by nickel affinity precipitation and immunoblot. 
PD: 6x-His (MRPL18)
WB: anti-HA (TUFM) 
WB: anti-HA (TUFM)
PD: 6x-His (MRPL18)
WB: anti-FLAG (AIF) 
WB: anti-FLAG (AIF) 
- - - - - + + + + +Rotenone 
 92 
Loss of AIF leads to an increase of glycolysis enzymes 
Having identified the existence of an AIF-associated translation complex likely to control 
protein levels of ETC subunits within the mitochondria, we then questioned the mechanism by 
which cells produce ATP in the absence of complex I following AIF knockdown. Previous 
observations of increased glucose consumption and lactate section combined with decreased 
oxygen consumption levels in the absence of AIF [51, 52] strongly suggest a metabolic 
switching event to glycolysis. One mechanism by which cells increase the flux of metabolites 
through different pathways is via changes in protein levels of metabolic enzymes, in particular 
those catalyzing thermodynamically irreversible conversions. Therefore protein levels of 
glycolytic enzymes were assessed in AIF-proficient and deficient PC3 cells, which have been 
thoroughly evaluated for AIF-dependent metabolic phenotypes [51]. 
Enzymes assessed function in both the preparatory and payoff phases of glycolysis, and 
we additionally evaluated the status of enzymes regulating the conversion of pyruvate to acetyl-
CoA for oxidation in the mitochondria, or pyruvate to lactate for sustained glycolysis (Figure 
4.6A). Interestingly, increases in glycolysis enzyme levels in AIF-deficient cells were observed 
throughout the glycolytic pathway (Figure 4.6B, C), with changes ranging from ~2-3-fold that 
are consistent with the magnitude of glucose consumption changes observed in PC3 cells [51]. 
Within the initial stage of glycolysis, changes in levels of at least three enzymes were 
observed (Figure 4.6B, C). Hexokinase (HK) catalyzes the ATP-dependent phosphorylation of 
glucose, which is the rate-limiting first step of glycolysis. Levels of HK1, the most ubiquitously 
expressed HK isoform, approximately doubled following knockdown of AIF, whereas levels of 
the HK2 isoform were unaffected. It is notable that the role of HK2 in coupling glycolysis to 
OXPHOS is thought to drive tumorigenic growth [151], while HK1 is the only HK isoform 
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expressed in cells that rely most heavily upon glucose metabolism, such as the brain and red 
blood cells [152].  
Significant changes were additionally observed at the level of the conversion of fructose-
6-phosphate to fructose-1,6-bisphosphate, which is the commitment step of glycolysis catalyzed 
by phosphofructokinase-1 (PFK-1) and the most heavily regulated step of the pathway [153]. 
Three isozymes of PFK-1 exist in humans [154]: platelet (PFKP), liver (PFKL), and muscle 
(PFKM). PFKL was not expressed at detectable levels in PC3 cells (data not shown), while 
PFKM levels remain to be assessed. However, protein levels of PFKP increased substantially 
following AIF ablation, consistent with elevated glucose consumption and glycolytic activity. 
We additionally noted changes in PFK-2, which is one of the most important regulators of 
glycolysis. PFK-2 is a bifunctional enzyme that mediates both the synthesis and degradation of 
fructose-2,6-bisphosphate (F2,6BP). F2,6BP is a strong allosteric activator of PFK-1, and 
whether PFK-2 predominantly exhibits kinase (F2,6BP synthesis) or phosphatase (degradation) 
activity depends on the cell’s metabolic needs. Two isoforms of PFK-2, known as PFKFB2 and 
PFKFB3, were assessed. Levels of PFKFB2 were unaffected by suppression of AIF, but a robust 
increase in levels of PFKFB3 was observed. Interestingly, PFKFB3 is induced by hypoxia, has 
substantially higher kinase activity than other PFK-2 isoforms [155, 156], and exhibits almost no 
phosphatase activity [157], which strongly suggest that elevated PFKFB3 levels serve to 
promote, and not inhibit, glycolysis. 
Within the payoff phase of glycolysis, changes were found in protein levels of 
phosphoglycerate mutase (PGAM1) and two widely expressed isoforms of enolase (ENO1, 
ENO2). Upregulation of both enzymes serves to promote glycolysis benefitting survival in 
cancer [158-160]. In the context of AIF ablation, elevation of PGAM1 and ENO1/2 are likely to 
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aid in accelerating the conversion of glucose-derived metabolites to pyruvate for increased ATP 
production mediated by phosphoglycerate kinase (PGK1) and pyruvate kinase (PKM). 
Following the oxidation of glucose during glycolysis, the pyruvate product can either be 
converted to acetyl-CoA for subsequent oxidation, or reduced to lactate in order to replenish 
NAD
+
 sustaining further glycolysis. Changes in levels of neither the E1 α1 subunit (PDHA) of 
the pyruvate dehydrogenase complex (PDH) nor the PDH inhibitor PDH kinase 1 (PDK1) were 
observed in AIF-deficient cells. However, protein levels of lactate dehydrogenase (LDHA) 
notably increased, strongly agreeing with increased lactate production following AIF ablation 
[51]. Altogether these data suggest that when AIF is lost from cells, glycolysis is upregulated and 
metabolic flux is shuttled through lactate generation in order to produce ATP in the absence of 
mitochondrial energy production. Moreover, this increased glycolytic activity occurs through the 
elevation of various glycolytic enzymes. 
Glycolysis enzyme levels are regulated through a variety of genetic control mechanisms. 
One of the predominant means cells use to control the expression of glycolysis enzymes is 
through the transcription factor known as c-Myc, a master regulator of metabolism that can 
stimulate glycolysis through the expression of target genes including LDHA, PFK-1, enolase, 
and numerous others [161]. It is notable that these genes increase following AIF ablation which 
could be due to elevated c-Myc activity. Therefore AIF-proficient and deficient cells were 
additionally probed for c-Myc protein levels. Interestingly, c-Myc levels were upregulated in 
response to AIF ablation (Figure 4.6B, C) and may indicate a mechanism through which AIF-
deficient cells upregulate glycolytic activity. Collectively these data further support increased 
glycolytic activity observed in AIF-deficient cells and begin to shed light upon survival 
mechanisms in the absence of AIF. 
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Figure 4.6. AIF ablation increases levels of glycolysis enzymes. 
A) Schematic of glycolysis. Dashed arrows indicated chemical conversations; solid lines indicate 
activation. B) The indicated PC3-derived cells were lysed and probed for the indicated proteins 
by immunoblot. C) Replicate immunoblots  from panel b were quantified and normalized to β-
actin. Data are presented as average ± standard deviation.  
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Discussion 
AIF mediates mitochondrial protein translation 
This study demonstrates for the first time that AIF controls protein levels of not only 
nuclear-encoded ETC subunits but also proteins encoded by the mitochondrial genome. AIF-
mediated control of mitochondria-encoded proteins occurs in specific cell types (e.g., HPAC) but 
not others (e.g., MIA PaCa-2), similar to our observations of nuclear-encoded subunits. These 
differences could stem from differences in mitochondrial activity and/or metabolic requirements 
among cell types (Chapter 3). 
Assessment of the mechanisms underlying AIF ablation-induced metabolic switching 
revealed several intriguing events associated with AIF mitochondrial activity. Following AIF 
suppression, complex I could not be restored either by the proteasomal inhibitor MG132 or the 
lysosomal inhibitor chloroquine. Other than through protein target-specific proteases, 
proteasomal and lysosomal degradation are the two major general mechanisms for protein 
turnover. When AIF is suppressed, complex I is not degraded; rather, it appears likely that 
complex I deficiency occurs because complex I subunits are not translated. 
This hypothesis is supported by our observations of AIF binding with MRPL18 and 
TUFM, which are essential components of the mitochondrial translation machinery. Through 
these interactions AIF could promote mitochondrial translation from the inner membrane. 
Mitoribosomes are frequently localized to the IMM [162, 163], likely because all mitochondria-
encoded proteins are membrane-bound. It appears that AIF forms a complex with TUFM and 
MRPL18 that promotes TUFM-MRPL18 association. This is notable since EF-Tu proteins are 
required to bind ribosomes in order to supply the ribosome with aminoacyl-tRNAs. Therefore if 
AIF is suppressed, decreased TUFM-MRPL18 binding is likely to decrease mitochondrial 
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translation, leading to a reduction in ETC subunits. Subsequently an impairment of 
mitochondria-encoded proteins could cause the cell to halt translation and/or import of nuclear-
encoded ETC subunits. Indeed, knockdown of TUFM induces the loss of both mitochondria- and 
nuclear-encoded proteins. 
Interestingly, TUFM ablation-induced loss of ETC proteins is the most apparent in MIA 
PaCa-2 and HEK293T cells, whereas PC3 cells exhibit lower magnitudes of ETC deficiency. 
This is in contrast with the effects of AIF ablation, which induces ETC deficiency in PC3 cells, 
but not MIA PaCa-2 or HEK293T cells. Reasons for this inverse relationship can only be 
speculated at this point. Perhaps AIF can promote mitochondrial protein expression without 
TUFM, but TUFM cannot promote translation without AIF activity. We hypothesize that AIF 
exhibits lower activity in MIA PaCa-2 cells, which have lower requirements for mitochondrial 
energy production (Chapter 2, 3). Moreover, disruption of mitochondrial activity with rotenone 
disrupts the AIF-mediated translation complex, further supporting the concept of metabolic 
conditions governing AIF activity. This would explain why AIF ablation but not TUFM ablation 
causes the loss of ETC subunits in PC3 cells, while TUFM ablation but not AIF ablation causes 
ETC loss in MIA PaCa-2 and HEK293T cells (exhibiting different metabolic requirements). This 
hypothesis merits further interrogation. 
Metabolic effects of AIF ablation 
When AIF and complex I levels are impaired, cells switch from OXPHOS to glycolysis 
in order to produce ATP. Further assessment of this metabolic switch reveals that a variety of 
glycolytic enzymes are upregulated at the protein levels including HK1, PFKP, PFKFB3, 
PGAM1, ENO1, ENO2, and LDHA. This suggests that increased glycolysis following AIF 
ablation occurs at least in part through elevation of glycolysis enzyme levels. It is also interesting 
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that AIF ablation increases levels of c-Myc, a critical regulator of metabolism. This hints to the 
existence of AIF-dependent signal transduction events regulating metabolism, and to our 
knowledge this is the first report of AIF involvement with an oncogene. 
Summary 
Altogether this study shows that AIF serves as a regulator of mitochondrial translation 
and suggests that ETC deficiency following AIF ablation is triggered by impairments in 
mitochondrial gene expression. Remarkably, AIF appears to promote TUFM-MRPL18 binding 
in order to synthesize mitochondria-encoded proteins, and this activity is sensitive to metabolic 
changes induced by rotenone. When AIF activity is impaired, cells upregulate glycolysis 
enzymes to increase glycolytic flux, a requirement for cells to obtain ATP without proper 
respiratory chain activity. Collectively, these data confirm the ability of AIF to physically 
associate with the mitochondrial translation machinery and identify a potential mechanism 
through which AIF controls protein levels of the mitochondrial respiratory chain. 
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V. THE ENZYMATIC ACTIVITY OF AIF ELEVATES OXIDATIVE STRESS LEVELS 
REGULATING REDOX-SENSITIVE SIGNAL TRANSDUCTION 
Abstract 
Apoptosis-inducing factor (AIF) is a mitochondrial flavoprotein occasionally involved in 
cell death that primarily regulates mitochondrial energy metabolism under normal cellular 
conditions. AIF catalyzes the oxidation of NADH in vitro, yet the significance of this redox 
activity in cells remains unclear. Here we show that through its enzymatic activity AIF is a 
critical factor for the induction of ROS. Moreover, AIF-mediated ROS levels correspond to 
changes in the antioxidant response, suggesting AIF regulates cellular ROS and subsequent 
nuclear responses to oxidative stress. Assessment of the ability of AIF to regulate other redox-
sensitive pathways shows that AIF is required for oxidative stress-induced activation of the 
mitogen-activated protein kinases JNK1, p38, and ERK. Altogether these data demonstrate for 
the first time the ability of AIF to serve as a significant redox signaling protein. 
Introduction 
The known roles of AIF in cell death and survival exemplify the duality of mitochondria 
in life/death decisions: nuclear translocation of AIF is occasionally observed under conditions of 
cell death [24], whereas under non-stress conditions AIF is essential to mitochondrial energy 
production through regulation of the respiratory chain and glucose metabolism [25, 51, 52]. 
Through high levels of ROS production, mitochondria can induce cell death but at low to 
moderate ROS levels promote pro-survival pathways. AIF generates ROS in vitro, but the ability 
of AIF to mediate ROS levels in cells is not well understood. 
The ability of AIF to regulate metabolism and complex I (both capable of altering ROS 
levels), as well as its ROS-generating enzymatic activity, strongly suggests that AIF is likely to 
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play an important role in the regulation of intracellular ROS. While AIF enzymatic activity has 
been shown to produce superoxide anions in vitro, these findings have not been extended to the 
context of an intracellular environment, and the role of AIF enzymatic activity in control of 
cellular ROS levels and its significance to cell biology is not well understood. 
ROS serve as second messengers to promote a variety of redox-sensitive signaling 
pathways. A potential biological purpose for AIF regulation of ROS in cells may be to induce 
these pathways, serving as a transmitter of extra-mitochondrial signaling cues. The contribution 
of AIF enzymatic activity to cellular homeostasis has remained largely elusive, and the ability of 
mitochondria-localized AIF to control intracellular redox signaling has long been speculated 
[54]; yet to date no studies have definitively shown the existence of such pathways. Since 
actively respiring mitochondria are an important ROS source for pro-oxidant signaling, this 
suggests that AIF could sense and/or promote ROS through its NADH-oxidase activity in 
addition to regulating respiratory chain biogenesis. 
We and others have defined contributory roles for AIF metabolic activity to the growth 
and survival of cancer cells, but AIF-mediated redox control and its involvement in the process 
of tumorigenesis are not well understood. Notably, ROS levels have been shown to change with 
loss of AIF, but whether ROS levels increase or decrease appears dependent upon cell type and 
context. For example, Harlequin mice, which express low levels of AIF due to a proviral 
insertion with the Aif promoter, exhibit increased ROS levels leading to cell death and 
neurodegeneration that can be rescued by antioxidant treatment [26]. In contrast, ROS levels 
decrease following AIF knockout in colorectal cancer cells, leading to increased sensitivity to 
apoptosis [54]. Among different cell types, these differences in AIF redox function could be due 
to different ETC protein and activity levels, basal ROS levels influencing the direction of AIF-
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mediated catalysis, or other factors. These findings collectively demonstrate a significant role for 
AIF to cellular redox control, but mechanistic details and pathways involved remain undefined. 
Various purposes for AIF redox activity have been proposed. Urbano et al. [54] posited 
that AIF promotes oxidative stress signaling that can promote the survival of cancer cells, 
whereas Sevrioukova [73] put forth a model in which AIF senses oxidative stress levels and can 
respond (e.g., by regulating complex I, translocating to the nucleus, generating or suppressing 
ROS, etc.) depending on stimulus. Here we tested both models and found that AIF is required for 
various stimuli to induce high ROS levels, and that AIF is additionally required for oxidative 
stress-induced signaling pathways in a variety of cell types. AIF-mediated redox control 
regulates both antioxidant defenses and MAPK phosphorylation, which demonstrate that AIF 
promotes intracellular ROS and for the first time identifies the existence of AIF-dependent signal 
transduction pathways. Based on the diversity of ROS signaling activities, these findings open 
the door to a broad range of potential AIF functions in cell biology and disease. 
Materials and methods 
Materials, plasmids and antibodies 
DMEM, RPMI 1640, DMEM/F12, K-SFM, GlutaMAX, horse serum, insulin, transferrin, 
epidermal growth factor, trypsin, 4–12 % bis-tris polyacrylamide gels, nitrocellulose membranes, 
fetal bovine serum (FBS), phosphate buffered saline (PBS), and Pierce ECL 2 Western Blotting 
Substrate were from Thermo Fisher Scientific; immunoglobulin G-Sepharose was from 
Amersham; all other materials were from Sigma. 
Lentiviral plasmids FG12-shLacZ-puro and FG12-shAIF-puro were described previously 
[51, 52, 121, 147]. To generate RNAi-resistant AIF restoration pSL4-hygro plasmids, AIF cDNA 
was subcloned from pEBB-siMut-AIF
WT
 and pEBB-siMut-AIF
TVA
 [51] into pSL4-hygro [164]. 
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Lentiviral packaging plasmids pHCMV-G, pRRE, and pRSV-rev are as described [123]. 
Additional constructs were kind gifts obtained as follows: pcDNA3-ASK1-HA [165] from Dr. 
Jonathan D. Ashwell; pcDNA3-Flag-MKK7β2-JNK1α1 and pcDNA3-Flag-MKK7β2-JNK2α2 
[166] from Dr. Roger Davis (Addgene plasmids #19726 and 19727). 
Antibodies were obtained as follows: anti-AIF (Santa Cruz, sc-13116), anti-Nrf2 (Santa 
Cruz, sc-13032), anti-HMOX1 (Santa Cruz, sc-136960), anti-GSTM1 (Santa Cruz, sc-517262), 
anti-GGT1 (Santa Cruz, sc-100746), anti-β-actin (Sigma, A5316), anti-α/β-tubulin (Cell 
Signaling, 2148), anti-PCNA (Cell Signaling, 2586), anti-MLK1 (Cell Signaling, 5029), anti-
phospho-MKK4/SEK1 S257 (Cell Signaling, 4514), anti-MKK4/SEK1 (Cell Signaling, 9152), 
anti-phospho-JNK T183/Y185 (Cell Signaling, 4668), anti-JNK (Cell Signaling, 9252), anti-
JNK1 (Cell Signaling, 3708), anti-JNK2 (Cell Signaling, 9258), anti-phospho-p38 T180/Y182 
(Cell Signaling, 9216), anti-p38α (Santa Cruz, sc-535), anti-phospho-ERK T202/Y204 (Cell 
Signaling, 4377), anti-ERK1/2 (Cell Signaling, 9107), anti-DUSP4/MKP2 (Cell Signaling, 
5149), anti-phospho-c-Jun S73 (3270), anti-c-Jun (Cell Signaling, 9165), anti-GAPDH (Cell 
Signaling, 5174), anti-histone H3 (Cell Signaling, 9715), horseradish peroxidase (HRP)-
conjugated anti-Flag (Sigma, A8592), HRP-conjugated anti-HA (Sigma, A6533), HRP-
conjugated anti-mouse IgG (Amersham Biosciences, NA391B), HRP-conjugated anti-rabbit IgG 
(Amersham Biosciences, NA934B), and HRP-conjugated anti-rabbit native IgG (Sigma, R3155). 
Cell culture 
Cells were cultured in an atmosphere of 95% air and 5% CO2 at 37 °C. All media 
formulations were supplemented with 2 mM GlutaMAX. HEK293T and MRC-5 cells were 
cultured in DMEM supplemented with 10% FBS; PC3 and HCT 116 cells in RPMI 1640 
medium supplemented with 10% FBS; MIA PaCa-2 cells in DMEM supplemented with 10% 
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FBS and 2.5% horse serum; and HPAC cells in a 1:1 mixture of DMEM and Ham’s F12 medium 
supplemented with 5 % FBS, 2 μg/mL insulin, 5 μg/mL transferrin, 40 ng/mL hydrocortisone, 
and 10 ng/mL EGF. RWPE-1 cells were cultured in K-SFM (Thermo Scientific, 17005042) 
supplemented with 0.05 mg/mL bovine pituitary extract and 5 ng/mL EGF. Cells were harvested 
by trypsinization, washed in PBS, and seeded at equal densities and then allowed to attach 
overnight prior to all assays. 
Drug treatments 
Cells were subjected to chemical treatments as follows: menadione at 100 μM for 1 h (for 
ROS assays) or 50 μM overnight (for viability assays); antimycin A at 50 μM for 1 h (for ROS 
assays) or 48 h (for viability assays); tBHQ at 90 μM overnight (for Nrf2 and antioxidant gene 
expression assays), 500 μM overnight (for viability assays), or 0-2 mM for 1 h (for phospho-JNK 
assays); and anisomycin at 0-5 μM for 1 h. Following treatment cells were harvested and 
assessed in the indicated assays. 
Transfections 
Plasmids were transfected into cells using Lipofectamine™ 2000 as described by the 
manufacturer. Cells were then harvested 48-72 h following transfection and either lysed as 
described below or quantified by Coulter™ counting. 
ROS measurements 
Following treatments described above, cells were incubated with 2.5 μM MitoSOX™ 
Red (for mitochondrial superoxide), or 10 μM CM-H2DCFDA (for general cellular ROS) at 37 
°C for 20 min. Cells were then harvested and resuspended in PBS, followed by assessment of 
stain intensity using an Accuri C6 flow cytometer. 
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Cell viability 
Following drug treatments described above, attached and floating cells were harvested, 
washed, and resuspended in PBS containing 2 μg/mL propidium iodide. Cell viability was then 
determined by flow cytometry using an Accuri C6 flow cytometer. 
Lentiviral production and stable infection of cell lines   
To establish cell lines stably suppressing or overexpressing AIF, lentiviral particles were 
produced by transfecting equal amounts of pHCMV-G, pRRE, pRSV-rev, and FG12- or pSL4-
derived plasmids into HEK293T cells using the calcium phosphate method [124]. Following 
incubation at 37 °C for 48 h, supernatants were collected, filtered using 0.45 μm-pore size Millex 
HV PVDF filter units (Millipore) and concentrated by centrifugation at 20,000 x g. Viral pellets 
were then resuspended in PBS at 4 °C overnight. Resuspended virus was added to cells in the 
presence of 4 μg/mL polybrene for 4 h at 37 °C in an environment of 93% air and 7% CO2. Cell 
lines used for stable RNAi targeting of AIF were infected with either control lentivirus (shLacZ) 
or lentivirus harboring an AIF target sequence (shAIF) followed by selection with 1 μg/mL 
puromycin. To establish “restoration” cell lines expressing either wild-type AIF or a catalytically 
impaired mutant, cells were infected with empty vector, AIF
WT
, or AIF
TVA
 and then selected with 
500 μg/mL hygromycin B. 
Cell lysis, fractionation, immunoprecipitation, and immunoblot analysis 
Cell lysates were prepared in radioimmune precipitation assay (RIPA) lysis buffer (PBS 
containing 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM dithiothreitol, 1 mM 
PMSF, 1 mM sodium fluoride, 1 mM sodium orthovanadate, and 1 protease inhibitor mixture 
tablet per 10 mL) or Laemmli buffer (62.5 mM tris-HCl pH 6.8, 2% SDS, 10% glycerol, and 5% 
β-mercaptoethanol). 
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For cell fractionation experiments, cytosolic and nuclear extracts were prepared by 
adding hypotonic buffer (20 mM HEPES pH 7.9, 10 mM KCl, 10 mM KCl, 1 mM EDTA, 10% 
glycerol, 1 mM dithiothreitol, 0.2% NP-40, 1 mM PMSF, and 1 protease inhibitor tablet per 10 
mL) to cells with gentle vortexing. Supernatants (constituting the cytosolic fraction) were 
extracted, and nuclear extracts were then prepared by resuspending insoluble fractions in 
extraction buffer (hypotonic buffer containing 20% glycerol and 420 mM NaCl). Fractions were 
then analyzed by immunoblot as described below. 
For immunoprecipitation experiments, RIPA cell lysates were normalized for protein 
content and then incubated with indicated antibodies for 2 h at 4 °C. Protein G-coupled agarose 
beads were then added and incubated for 1 h. Agarose beads were then recovered by 
centrifugation and washed in RIPA buffer. Precipitated protein was eluted by adding lithium 
dodecyl sulfate sample buffer followed by heating samples at 95 °C for 5 min. Samples were 
then analyzed by immunoblot as described below. 
For immunoblot experiments, protein samples were separated by SDS-PAGE using 4-
12% gradient SDS-polyacrylamide gels followed by electrotransfer to nitrocellulose membranes. 
Membranes were blocked with 5% milk or bovine serum albumin in tris-buffered saline 
containing 0.02 to 0.2% Tween-20 and then incubated with the indicated primary antibodies. 
Membranes were then washed three times and incubated with HRP-conjugated anti-mouse or 
anti-rabbit followed by visualization using enhanced chemiluminescence. 
Replicate immunoblots were quantified at multiple exposures for linearity using 
myImage Analysis™ software (Thermo Scientific). Band intensities for phosphorylated proteins 
were divided by intensities for the corresponding total proteins; all protein values and phospho-
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protein/total protein ratios were then normalized to β-actin values. To determine fold changes 
among lanes, all ratios were then normalized to control lanes. 
Quantitative RT-PCR 
Gene expression analysis was carried out as described [167] using the relative standard 
curve method for quantification.  Briefly, real time PCR was carried out on the ABI Prism 7000 
sequence detection system (Applied Biosystems, Foster City, CA). Total RNA was isolated from 
the indicated cell lines using TRIzol reagent according to the manufacturer's instructions. 30 μg 
of RNA isolated from each sample was treated with 30 units of DNase I (Promega) for 30 min at 
37 °C. After DNase I digestion, RNA was purified using an RNeasy mini purification kit 
(Qiagen) following the manufacturer's protocol. An oligo (dT) primer was used in cDNA 
synthesis. 200 ng of RNA was reverse transcribed in a total volume of 50 μl using the TaqMan 
reverse transcription reagents kit (Applied Biosystems). To make a standard curve, serial 
dilutions of RNA from one sample (160, 40, 10, and 2.5 ng/μL final concentrations) were added 
to the RT reaction. Aliquots (3.5 μl) of cDNA were added to a 31.5-μl reaction mixture 
containing 17.5 μl of 2× SYBR® Green PCR Master Mix (Applied Biosystems) and 200–400 
nm primers; quadruplicate samples were prepared for each RNA source. Absence of DNA 
contamination was verified by performing amplification from cDNA without reverse 
transcriptase. The primers for PCR were designed with IDT PrimerQuest software (Integrated 
DNA Technologies, Inc.). Sequences are shown in Table D1. Primers to either β-Actin or 
GAPDH were used in order to determine normalization factors between AIF proficient (shLacZ) 
and AIF deficient (shAIF) cell lines, and variation in β-actin/GAPH levels between cell lines was 
less than 10% in all cases. 
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Results 
AIF promotes cellular ROS via its enzymatic activity 
The known roles of AIF in the regulation of respiratory chain proteins and superoxide 
production suggest that AIF activity may control mitochondrial redox balance. Therefore we 
tested the effects of AIF ablation upon cellular ROS responses, focusing on PC3 and HeLa cells 
that exhibit different respiratory chain responses following knockdown [25, 51]. In order to 
assess the ability of AIF to regulate ROS levels and associated signaling pathways, we began by 
establishing PC3 and HeLa cells in which AIF expression is stably suppressed using a lentiviral 
RNAi approach described previously [51, 52]. Lentiviruses harboring either control sequences 
(shLacZ) or AIF targeting sequences (shAIF) were generated and then used to infect cells. Cells 
were then subjected a second round of lentiviral infection in order to generate AIF restoration 
cell lines stably expressing either an empty vector, wild type AIF (AIF
WT
), or a catalytically 
inactive AIF mutant [51, 54] containing the substitutions T263A and V300A (AIF
TVA
). 
Lentiviral cDNA constructs additionally harbored a silent mutation resistant to shRNA-mediated 
targeting of AIF [51]. 
Following derivation of cell lines (shLacZ + empty, shAIF + empty, shAIF+AIF
WT
, 
shAIF+AIF
TVA
), cellular ROS levels were compared following acute oxidative stress triggers 
using two chemical agents with differing mechanisms of action: menadione, a naphthoquinone 
derivative that potentiates redox cycling and is linked to AIF redox activity [168]; and antimycin 
A, an inhibitor of the ETC targeting complex III. Staining with MitoSOX™ Red (an indicator of 
mitochondrial superoxide levels) demonstrated that menadione induces a rapid increase of 
mitochondrial superoxide in both cell types that requires AIF to different extents. Suppression of 
AIF in HeLa cells did not substantially affect stimulation levels (data not shown), whereas in 
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PC3 cells AIF ablation almost entirely abolished superoxide production. Having observed 
significant changes in PC3 cells, we tested the effect of AIF enzymatic activity on superoxide 
production using our panel of AIF-restored PC3 cells. We observed that AIF
WT
, but not AIF
TVA
 
restored mitochondrial superoxide production following treatment (Figure 5.1A), demonstrating 
that the enzymatic activity of AIF is essential for the increase of mitochondrial superoxide in 
response to acute menadione exposure. To determine if altered mitochondrial ROS production 
was connected to the extramitochondrial redox state of cells, we then measured general cellular 
ROS by detection with chloromethyl-2',7'-dichlorodihydrofluorescein diacetate (CM-H2DCFDA, 
a general detector of many ROS species not including superoxide) following antimycin A 
stimulation. The enzymatic activity of AIF was required for the production of intracellular ROS 
in HeLa cells (Figure 5.1B), whereas PC3 cells exhibited antimycin A-stimulated ROS that were 
independent of AIF (data not shown). 
To determine if AIF-mediated ROS protection is related to sensitivity to the oxidative 
stress triggers examined, viability of PC3 and HeLa cells were then evaluated following 
overnight treatment (Figure 5.1C, D). Consistent with decreased ROS levels following AIF 
ablation, the loss of AIF decreased cell deaths levels when cells were treated with menadione and 
antimycin A. Taken together these data indicate that in both cell types the NADH-oxidase 
activity of AIF facilitates acute ROS generation in response to chemical redox agents, which can 
regulate sensitivity to oxidative stress. 
AIF-mediated ROS activate antioxidant responses under basal and stimulated conditions 
The above data indicate that AIF promotes acute ROS generation. We therefore 
hypothesized that AIF could also regulate basal ROS and low-dose/nonlethal ROS stimulation 
with downstream signaling effects. If AIF-dependent ROS can activate signal transduction 
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pathways, then differences in molecular signaling responses (such the antioxidant response) 
should be observed when AIF is suppressed. To test the role of AIF in control of such signaling 
pathways, we stimulated HeLa and PC3 cells with tert-butylhydroquinone (tBHQ) as an 
exogenous source of ROS to activate redox-sensitive pathways in a mitochondria-independent 
fashion. 
 
Figure 5.1. AIF enzymatic activity regulates cellular ROS. 
A) Effect of AIF enzymatic activity on mitochondrial superoxide production: The indicated cell 
lines were left untreated (UT) or treated with menadione, stained with MitoSOX™ Red, and 
assessed by flow cytometry. B) Effect of AIF enzymatic activity on general cellular ROS 
production: Relative fluorescence intensity was measured by flow cytometry following 
antimycin A treatment and subsequent CM-H2DCFDA staining. C-D) Viability levels of the 
indicated cell types treated with either menadione or antimycin A were determined by PI 
exclusion assay. Data are presented as average ± standard deviation.  *p<0.05. 
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As a measure of cellular response to AIF redox function, activities of the antioxidant 
response (Nrf2 activity and antioxidant gene expression levels) were assessed. Under conditions 
of oxidative stress, the antioxidant transcription factor Nrf2 is stabilized from proteasomal 
degradation and accumulates in the nucleus [169]. Following treatment with tBHQ, nuclear 
accumulation of Nrf2 was dependent upon AIF in HeLa but not PC3 cells (Figure 5.2A, B), 
which may be related to varied AIF-dependent ROS levels observed above (Figure 5.1). To 
further interrogate altered nuclear Nrf2 in HeLa cells, cells were stimulated with tBHQ and/or 
treated with the proteasome inhibitor MG132, followed by immunoblot analysis of total cellular 
protein. AIF-deficient cells demonstrated decreased total Nrf2 levels under both basal and 
stimulated conditions. MG132 increased Nrf2 levels independently of tBHQ, but to a lesser 
extent in AIF-deficient cells (Figure 5.2C). Together these data suggest altered Nrf2 responses in 
HeLa cells result from decreased Nrf2 protein levels, increased Nrf2 degradation rate, or both. 
To further characterize the role of AIF in control of cellular redox activity, we 
additionally assessed levels of Nrf-2 dependent antioxidant genes under basal conditions by RT-
qPCR. In agreement with our measurements of ROS production, substantial changes in mRNA 
transcripts encoding a variety of antioxidant genes under basal conditions were observed in both 
cell types (Figure 5.3A, B). Almost all genes assessed under basal conditions decreased 
following AIF knockdown, whereas one gene increased and notably was different between cell 
types (GGT1 in HeLa cells, GSTM1 in PC3 cells). We further assessed levels of antioxidant 
transcripts following treatment with tBHQ. Following stimulation, either no change or decreased 
upregulation was observed in AIF-deficient cells; and hMOX1 is common for both cell lines as 
the most upregulated and most affected by AIF loss (Figure 5.3C, D). 
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Figure 5.2. AIF-mediated redox signaling regulates Nrf2 levels and translocation.  
A, B) Effect of AIF ablation on Nrf2 translocation: The indicated cell lines were treated with 
control solvent or tBHQ and then fractionated into cytosolic and nuclear extracts followed by 
immunoblot for Nrf2. Tubulin and PCNA were used as loading controls for cytosolic and nuclear 
extracts, respectively. C) Effect of AIF ablation on Nrf2 levels: Cells were treated with control 
solvent or tBHQ in the absence or presence of MG132, lysed, and subjected to immunoblot with 
the indicated antibodies. 
Having observed notable differences in GGT1, GSTM1, and hMOX1 mRNA transcript 
levels that appear cell type-specific, protein levels were then assessed by immunoblot analysis 
(Figure 5.3E), which generally agreed with RT-qPCR data. In HeLa cells, tBHQ induced an 
increase in hMOX1 that was not substantially affected by AIF ablation, whereas GSTM1 was 
generally unaffected by either tBHQ or AIF levels. In contrast, levels of GGT1 increased 
dramatically following AIF ablation in HeLa cells relative to undetectable control levels, both in 
the absence and presence of tBHQ. Consistent with mRNA assessment, AIF-dependent 
antioxidant protein levels in PC3 cells differed  from  HeLa  cells.  Control PC3 cells upregulated  
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Figure 5.3. AIF levels control antioxidant responses. 
A, B) Effect of AIF ablation on basal levels of antioxidant gene transcripts: Quantitative PCR 
(qPCR) was used to determine basal levels of antioxidant transcripts in the indicated cell lines. 
C, D) Effect of AIF ablation on tBHQ-stimulated levels of antioxidant transcripts: Fold 
stimulation of antioxidant transcripts in tBHQ-treated cells relative to vehicle-only controls were 
measured by qPCR. qPCR data were acquired by A.S. Wilkinson. E) Cells treated with control 
solvent or tBHQ were lysed and assessed for levels of the indicated proteins by immunoblot. 
Quantitative data are presented as average ± standard deviation.  *p<0.05. 
 
hGSTM1 hGGT1 hGSR hHMOX1 hNQO1 hHMOX2 hGCLM AIF
F
o
ld
 c
h
a
n
g
e
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
0
2
4
6
8
10
PC3 shLacZ 
PC3 shAIF 
F
o
ld
 c
h
a
n
g
e
C D
A B
* * * * * * *
* * * * * *
GGT1
β-Actin
H
e
L
a
 s
h
L
a
c
Z
H
e
L
a
 s
h
A
IF
H
e
L
a
 s
h
L
a
c
Z
H
e
L
a
 s
h
A
IF
CTL tBHQ
HMOX1
GSTM1
P
C
3
 s
h
L
a
c
Z
P
C
3
 s
h
A
IF
P
C
3
 s
h
L
a
c
Z
P
C
3
 s
h
A
IF
CTL tBHQ
E
 113 
hMOX1 following tBHQ stimulation, but this upregulation was impaired following loss of AIF. 
GSTM1 levels increased under basal conditions following AIF knockdown, and increased further 
under tBHQ-induced conditions, while GGT1 did not show any changes with either tBHQ or 
AIF ablation. Further experimentation is required to account for mechanisms and differences 
between cell types, but data presented here show for the first time the ability of AIF to serve as a 
redox control protein that produces ROS in cells with observable downstream effects. 
In an effort to determine if altered ROS production and redox signaling following AIF 
ablation affect sensitivity to oxidative stress, PC3- and HeLa-derived cell lines were then 
subjected to lethal concentrations of tBHQ and assessed for viability levels. PC3 and HeLa cells 
exhibited notably different sensitivities to tBHQ, which may in part explain different antioxidant 
responses when AIF is suppressed. In both cell types and consistent with the above viability data 
(Figure 5.1C, D), AIF ablation protected against tBHQ-induced cell death (Figure 5.4A, B), 
which may be due to decreased oxidative stress levels (Figure 5.1A, B). This indicates that AIF-
mediated ROS elevation and/or altered antioxidant responses can impact sensitivity to oxidative 
stress following a variety of stimuli. 
Suppression of AIF decreases MAPK phosphorylation 
We then wondered if AIF-mediated ROS signaling impacts pro-tumor proliferative and 
survival pathways. We have shown previously that AIF promotes the growth and invasiveness of 
advanced-stage prostate [51] and pancreatic cancer cells [52]. PC3 cells, an androgen-
independent prostate cancer line commonly used as a model for advanced prostate cancer [170], 
serve as a well-characterized system for studying AIF-dependent tumorigenic activity. AIF 
knockdown substantially reduces the aggressiveness of PC3 cells [51], but the mechanism(s) 
underlying AIF-dependent growth and survival are presently unclear. 
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Figure 5.4. AIF knockdown decreases sensitivity to oxidative stress. 
HeLa- (A) and PC3-derived (B) cell lines were treated with control vehicle or tBHQ and 
assessed for viability levels by PI staining and flow cytometry. 
 
To determine if AIF plays a role in regulating intracellular signal transduction associated 
with this growth phenotype, we evaluated the activation status of MAPK signaling molecules 
following AIF ablation. Upon stimulation by a variety of signals including oxidative stress, 
MAP3Ks phosphorylate and activate MAP2Ks, which subsequently phosphorylate and activate 
MAPKs (Figure 5.5). MAPKs can additionally be activated when their endogenous inhibitors, 
the MAPK phosphatases (MKPs), are suppressed (Figure 5.5). This MAPK phospho-activation 
allows activity levels to be assessed by immunoblot. When AIF expression was suppressed, 
phosphorylation levels of three MAPKs (JNK, p38, ERK), as well as the JNK target c-Jun, were 
markedly reduced under basal conditions (Figure 5.6A, B). When upstream factors (MLK1, 
MKK4/SEK1) of the MAP2K and MAP3K families were assessed, neither protein levels nor 
phosphorylation were altered. We additionally evaluated protein levels of the endogenous 
MAPK inhibitor dual specificity phosphatase 4 (DUSP4). DUSP4 dephosphorylates JNK, p38, 
and ERK to suppress their activities, but is inactivated and degraded under conditions of 
oxidative stress [171]. Notably, DUSP4 protein levels increased two-fold following AIF ablation 
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(Figure 5.6A, B). This observation may be an indicator of decreased oxidative stress levels and a 
possible explanation for MAPK impairment when AIF expression is suppressed. 
 
Figure 5.5. MAPK signal transduction. 
MAP3Ks (e.g., MLK1) phosphorylate and activate MAP2Ks (e.g., MKK4/SEK1), which 
subsequently phosphorylate and activate MAPKs (JNK, p38, ERK). MAPK activity is 
suppressed by dephosphorylation mediated by MKPs (e.g., DUSP4/MKP2).  
 
We additionally tested the response of JNK and p38 to the chemical MAPK activator 
anisomycin [172] following AIF ablation. Anisomycin-stimulated phosphorylation of both JNK 
and p38 required AIF expression (Figure 5.6C), suggesting that AIF is required for MAPK 
activation both under basal and stimulated conditions. We further explored the AIF-dependent 
phosphorylation capacity of MAPKs by overexpressing apoptosis signal-regulating kinase 1 
(ASK1), a redox-sensitive MAP3K that phosphorylates both JNK and p38 under conditions of 
oxidative stress [173] but that is activated in a ROS-independent manner when overexpressed 
[53]. HA-tagged ASK1 was transfected into PC3-derived cells followed by immunoblot for HA 
to verify overexpression (Figure 5.6D). When ASK1 was overexpressed, phosphorylation of 
JNK and p38 increased both in the presence and absence of AIF (Figure 5.6D). This strongly 
suggests that while AIF ablation impairs MAPK activation, the intrinsic activity of neither JNK 
nor p38 is inherently compromised. 
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Figure 5.6. AIF knockdown impairs MAPK signaling. 
A) PC3-derived cells were seeded at equal densities and then subjected to immunoblot using the 
indicated antibodies. (B) Replicate immunoblots from panel a were quantified and normalized to 
β-actin. Phosphoprotein quantities were normalized both to their corresponding total protein 
quantities and β-actin. Data are presented as average ± standard deviation. *p<0.05. C) Cells 
treated with increasing concentrations of anisomycin for assessed for the indicated proteins by 
immunoblot. D) PC3-derived cells were transfected with either empty control (CTL) or ASK1-
HA encoding plasmids and then assessed by immunoblot using the indicated antibodies. 
 
Redox-dependent JNK phosphorylation requires AIF 
Based upon its ROS-generating enzymatic activity [60] and having observed that AIF 
influences multiple levels of MAPK signaling pathways, we then questioned whether AIF 
influences signal transduction under conditions of redox stimulation, concentrating our efforts on 
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activation of JNK in a broad panel of cell types derived from both normal and cancerous tissues: 
PC3 (prostate cancer), HPAC (pancreatic cancer), MRC-5 (normal lung), HCT 116 (colorectal 
cancer), and MIA PaCa-2 (pancreatic cancer). Following acute, nonlethal redox stimulation with 
increasing concentrations of tert-butylhydroquinone (tBHQ), we assessed levels of 
phosphorylated JNK. While the exact patterns of JNK phosphorylation with respect to oxidative 
stress sensitivity varied among cell lines, AIF was required for this oxidant-induced 
phosphorylation in all cells tested (Figure 5.7). 
AIF-dependent changes in JNK phosphorylation were observed under basal conditions, 
under oxidative stress conditions, or both.  Cell lines exhibited variable JNK sensitivity to tBHQ, 
with some cells readily phosphorylating JNK at low doses and others requiring substantially 
higher tBHQ concentrations.  PC3, HPAC, and HCT 116 cells exhibited modest basal phospho-
JNK levels that further increased with treatment; when AIF was suppressed cells were unable to 
phosphorylate JNK following tBHQ stimulation. Conversely, in MIA PaCa-2 and MRC-5 cells 
JNK was relatively insensitive to the treatment conditions used yet showed AIF-dependent 
changes at the highest levels of tBHQ tested (Figure 5.7). However, despite cell type-specific 
differences in basal phospho-JNK levels and pre-existing differences in sensitivity to tBHQ, AIF 
was critical for all cell types to phosphorylate JNK. This suggests the ability of AIF to regulate 
JNK phosphorylation is widespread among cell types. 
To determine if altered phosphorylation was involved with subcellular redistribution of 
JNK, we subjected PC3-derived cells to acute tBHQ treatment and then separated cells into 
cytosolic and nuclear extracts. Total levels of JNK1 and JNK2 were unchanged in both cytosolic 
and nuclear fractions, but within both fractions levels of phospho-JNK were decreased in AIF-
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deficient cells (Figure 5.8). This suggests that AIF ablation does not affect distribution of total 
JNK, but that altered JNK phosphorylation occurs in both the cytosol and nucleus. 
 
Figure 5.7. AIF is required for oxidative stress-induced JNK phosphorylation. 
AIF proficient (shLacZ, shGFP) and deficient (shAIF) cells derived from the indicated cell lines 
were treated with increasing concentrations of tBHQ as follows: 0, 0.2, 0.5, 1, 2 mM (PC3); 0, 
0.1, 0.25, 0.5, 1 mM (HCT 116, HPAC, MIA PaCa-2, MRC-5). Following treatment 
immunoblots were performed with the indicated antibodies and quantified by densitometry.  
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Figure 5.8. AIF promotes cytosolic and nuclear JNK phosphorylation without influencing 
JNK redistribution. 
PC3-derived cells treated with either 0 or 2 mM tBHQ were separated into cytosolic and nuclear 
fractions followed by immunoblot for phospho-JNK, JNK1, and JNK2. GADPH and histone H3 
were used as cytosolic and nuclear markers, respectively.  
 
AIF enzymatic activity promotes the activation of JNK1 
Since the enzymatic activity generates ROS in vitro [60] and elevates cellular ROS levels 
(Figure 5.1A, B), we then questioned whether this enzymatic activity is responsible for oxidative 
stress-induced JNK phosphorylation (Figure 5.7). Therefore PC3-, HPAC-, and RWPE-1-shAIF 
cells stably infected with either empty-hygro lentivirus, AIF
WT
, and AIF
TVA
 were treated with 
tBHQ and then assessed for JNK phosphorylation by immunoblot. As shown in Figure 5.9A, 
restoration of AIF-deficient PC3 cells with AIF
WT
, but not AIF
TVA
, increased phospho-JNK 
levels in all cell types following tBHQ stimulation and demonstrated that the enzymatic activity 
of AIF is required for oxidant-induced JNK phosphorylation. 
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JNK proteins are encoded by three separate genes (JNK1, JNK2, JNK3) that give rise to 
one of ten different isoforms, and alternative splicing of the carboxyl terminus results in their 
long (54 kD) and short (46 kD) molecular weight variants for all three JNK species. JNK1 and 
JNK2 are ubiquitously expressed, whereas JNK3 is expressed primarily in the brain and to a 
lesser extent in the heart and testis [174]. To determine which JNK isoform responds to AIF 
activity, we first employed constitutively active forms of JNK (CA-JNK) fused with the JNK 
activator MKK7 that have been characterized previously [166]. Under basal conditions the 
introduction of CA-JNK1 and CA-JNK2 enhanced proliferation, and AIF was required for CA-
JNK1 to drive cell growth (Figure 5.9B, left). Immunoblot for Flag epitope confirmed 
comparable transfection efficiency within cell lines (Figure 5.9B, right). To determine which 
endogenous JNK isoform is under AIF control, we then used an isoform non-specific antibody to 
precipitate total phosphorylated JNK from tBHQ-treated cells followed by isoform specific 
immunoblotting for JNK1 and JNK2. Only JNK1 was phosphorylated in response to acute 
oxidant stimulation, suggesting JNK1 is the target of tBHQ. Additionally, this phosphorylation 
event was AIF-dependent (Figure 5.9C), demonstrating that AIF is required for the activity of 
JNK1 but not JNK2. 
Discussion 
AIF regulates cellular ROS levels 
The NADH-oxidase activity of AIF has been studied in vitro [60], but the biochemical 
consequences of AIF-mediated superoxide production within cells and the contribution of AIF 
ROS signaling to disease have remained largely descriptive. Experiments described here show 
that elevation of ROS by AIF is required for cellular redox signaling, and it is conceptually 
 121 
satisfying that this activity controls signaling pathways well known for both pro- and anti-
apoptotic downstream effects. 
Data presented in this study show decreased ROS levels following loss of AIF, consistent 
with altered antioxidant responses that are largely decreased in a manner that depends on cell 
type and context. It is notable that AIF ablation moderately protected cells from the oxidative 
stress agents menadione, antimycin A, and tBHQ. While this indicates a pro-death function for 
AIF, cell death is likely due to toxic ROS levels, rather than AIF nuclear translocation. Indeed, 
AIF has been shown to trigger cell death under lethal oxidative stress conditions induced by 
menadione without translocating to the nucleus [168], which is in agreement with our findings. 
Impact of AIF-mediated ROS in cancer  
A large body of data demonstrating AIF upregulation in tumors [51, 52, 83-88, 175] 
suggest a possible role for AIF-mediated redox signaling in the context of cancer. One possibility 
is that within normal cells AIF functions as a ROS sensor that mediates responses to oxidative 
stress, and can be harnessed by cancer cells to promote tumorigenesis. In addition to AIF-
mediated metabolic control, the ability of AIF to regulate cellular redox signaling provides 
further insight into overexpression levels. For example this may explain why AIF elevation in 
cancer rarely exceeds 2-fold compared to normal cells [51, 52]. Rather than AIF nuclear death 
activity it may instead be AIF ROS amplification, uncoupled from the “classic” death 
mechanism, which must be held in check by tumors. 
Effects of AIF redox activity upon MAPK signaling 
In addition to promoting oxidative stress and the antioxidant response, AIF-mediated 
redox signaling induces MAPK phosphorylation. It is notable that MAPKs can both promote and 
inhibit cell death, depending on phosphorylation levels and context [80]. Under oxidative stress 
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conditions, JNK1 is phosphorylated in an AIF-dependent manner in a variety of cell types. In 
PC3 cells, overexpression of CA-JNK1 promotes proliferation that requires AIF, suggesting that 
JNK1 serves as a pro-tumor molecule under AIF control. Based on the wide range of cellular 
activities regulated by JNK and other MAPKs, it is tempting to speculate a variety of phenotypes 
that result from AIF-dependent signal transduction. For example, increased invasiveness due to 
elevated AIF levels observed in advanced prostate cancer cells [51] could be due to JNK-induced 
changes in metastatic genes (explored in chapter 7). 
Summary 
Collectively the data here form a mechanistic starting point for AIF-mediated regulation 
of growth and survival [51, 52, 54], suggesting that through its catalytic function AIF primes 
MAPK activity by moderating cell redox state. It is likely that the biological consequences of 
AIF-induced signaling are diverse and dependent upon intracellular contexts [51, 52]. Oncogene 
status, cellular metabolic activity, and levels of oxidative stress proteins (e.g., superoxide 
dismutase) and MAPK regulators are potential factors in the variability of AIF-mediated redox 
signaling. While a number of outcomes for AIF-mediated ROS production can be envisioned, 
experiments here demonstrate for the first time that AIF serves as an essential signal transduction 
protein. 
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Figure 5.9. The enzymatic activity of AIF promotes JNK1 phosphorylation and activity. 
A) AIF-deficient PC3, HPAC, and RWPE-1 cells (shAIF) restored with either empty vector, 
AIF
WT
, or AIF
TVA
 were treated with tBHQ as follows: 0 or 2 mM (PC3), 0 or 0.25 mM (HPAC), 
or 0.5 mM (RWPE-1); treatment was followed by immunoblot for phosphorylated JNK. 
Replicate immunoblots were quantified and normalized to total JNK and β-actin. B) PC3-shLacZ 
or shAIF cells were transfected with either control plasmid or plasmids expressing either CA-
JNK1 or CA-JNK2. 48 h post-transfection totals cells were determined by Coulter
TM
 counting.  
Change in growth relative to empty control plasmid is shown. Protein expression was verified by 
immunoblot for Flag epitope. C) Total phosphorylated JNK was enriched from PC3-derived cells 
treated with 0 or 2 mM tBHQ by immunoprecipitation using an isoform non-specific P-JNK 
antibody, and precipitated material was analyzed by immunoblot for JNK1 and JNK2. Phospho-
JNK was quantified by normalizing precipitated material to JNK1 or JNK2 and β-actin of input 
samples. Data are presented as average ± standard deviation. *p<0.05. 
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VI. AIF SIGNALS JNK1 TO INDUCE THE CADHERIN SWITCH, A KEY 
METASTATIC EVENT THAT IS LETHAL IN THE ABSENCE OF AIF-MEDIATED 
METABOLIC CONTROL 
Abstract 
AIF is a mitochondrial regulator of cellular homeostasis that controls both metabolic state 
and oxidative stress levels. Through the ROS-generating enzymatic activity of AIF, cells can 
activate signaling proteins and regulate the expression of nuclear genes. Therefore we sought to 
define AIF-mediated signaling pathways and their impact upon cell phenotype. Here we show 
that AIF regulates the expression of a variety of genes associated with the epithelial-
mesenchymal transition (EMT) through JNK-dependent and independent mechanisms. 
Strikingly, by activating JNK1, AIF promotes the cadherin switch, an important metastatic event 
in cancer cells in which E-cadherin levels are reduced and N-cadherin levels increase. Inducing 
the cadherin switch causes AIF-deficient cells to undergo apoptosis, and this cell death 
corresponds to changes in glucose consumption and phosphorylation of the metabolic signaling 
molecule known as AMPK. Collectively, these data suggest that AIF loss-induced apoptosis 
occurs due to a metabolic imbalance with cancer cell aggressiveness. Therefore these 
observations highlight the ability of AIF to promote tumorigenesis by driving metastatic 
progression while simultaneously supplying its heavy energetic demand. 
Introduction 
AIF is an essential mitochondrial regulator of both cellular metabolic and redox 
conditions [73]. In addition to its involvement in cell death and critical role in maintaining 
mitochondrial ETC components, AIF additionally possesses an intrinsic enzymatic activity [60] 
that increases cellular ROS levels. These AIF-induced ROS control both antioxidant responses 
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and MAPK phosphorylation (Chapter 5). However, the downstream effects of AIF-dependent 
signaling, their impact upon tumorigenesis, and their balance with AIF-mediated metabolism 
remain unknown. 
A variety of cellular effects for signaling by AIF can be envisioned. A potential 
downstream process of particular significance to tumorigenesis is the epithelial-mesenchymal 
transition (EMT), which can be influenced by ROS levels, mitochondrial signaling, metabolic 
conditions, and MAPK activation [176, 177]. These stimuli are not the only factors contributing 
to the series of biochemical changes involved but are shared with AIF and point to a possible 
role for AIF in the process of EMT. 
During an EMT, a polarized epithelial cell undergoes extensive biochemical alterations in 
order to acquire a mesenchymal phenotype. The basement membrane interacting with the cell is 
then degraded, while the mesenchymal cell migrates away from the epithelial layer. EMTs serve 
to segregate cells, occurring in a variety of physiological events including embryonic 
implantation and formation, organ development, wound healing, tissue regeneration, and organ 
fibrosis. Cancer cells can additionally employ the EMT machinery to acquire an invasive and 
metastatic phenotype. This cancer-associated EMT is capable of promoting metastasis, 
migration, chemoresistance, metabolic alterations, immune evasion, and tumor cell interactions 
[177, 178]. Therefore the EMT represents a pivotal tumorigenic event capable of substantially 
increasing patient mortality. 
EMTs are induced by a variety of stimuli including growth factors, cytokines, 
extracellular matrix conditions, and ROS. The sequence of cellular events occurring upon these 
cues involves dissociation of cell junctions, loss of polarity, cytoskeletal reorganization, 
upregulation of matrix metalloproteinases (MMPs), basement membrane degradation and 
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subsequent invasion. These events require a large-scale change in gene expression, with some of 
the central molecular players involved including β-catenin, Snail, Slug, Twist, Vimentin, Zeb1, 
E-cadherin, and N-cadherin. While the signaling and genetic events associated with EMT are 
complex, a key event of this process is the cadherin switch. During the cadherin switch, cells 
decrease expression of the tumor suppressor E-cadherin and increase levels of the mesenchymal 
marker known as N-cadherin, representing an important transition point at which cells gain 
further aggressiveness. This phenotype associated with the cadherin switch is due to 
inappropriate protein interactions with intra- and extracellular signaling molecules and altered 
communication with neighboring cells [176-178]. 
Here we show that AIF ablation alters EMT-associated genes both at the RNA and 
protein levels. Notably, the cadherin switch reverses when AIF is suppressed, due to impaired 
JNK1 signaling. Reversal of E-cadherin levels in AIF-deficient cells induces apoptosis, which 
may be due to a failure to metabolically adapt to E-cadherin ablation. Interestingly, the pattern of 
death observed corresponds to changes in phosphorylation of AMP-activated protein kinase 
(AMPK), a central regulator of metabolic signaling. Therefore this study links AIF to a variety of 
novel signaling molecules involved in both EMT and metabolism, further expanding the breadth 
of cellular activities mediated by AIF. 
Materials and methods 
Materials, plasmids and antibodies 
DMEM, RPMI 1640, GlutaMAX, horse serum, trypsin, 4–12 % bis-tris polyacrylamide 
gels, nitrocellulose membranes, fetal bovine serum (FBS), phosphate buffered saline (PBS), and 
Pierce ECL 2 Western Blotting Substrate were from Thermo Fisher Scientific; Matrigel™ was 
from BD Biosciences; Matrigel recovery solution was from Corning; protease inhibitor tablets 
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were from Roche Applied Science; bVAD-fmk was from Enzyme Systems Products; all other 
materials were from Sigma. 
Lentiviral plasmids FG12-shLacZ-GFP, FG12-shAIF-GFP, FG12-shLacZ-puro, and 
FG12-shAIF-puro were described previously [51, 52, 121, 147]. Lentiviral packaging plasmids 
pHCMV-G, pRRE, and pRSV-rev are as described [123]. Additional constructs pcDNA3-Flag-
MKK7β2-JNK1α1 and pcDNA3-Flag-MKK7β2-JNK2α2 [166] were provided by Dr. Roger 
Davis (Addgene plasmids #19726 and 19727). Lentiviral pLKO plasmids were obtained as 
follows: psPAX2 and pMD2.G-vsv-G from Dr. Didier Trono (Addgene plasmids #12260 and 
12259); pLKO.1-puro-scramble [149] from Dr. David Sabatini (Addgene plasmid #1864); and 
pLKO.1-puro-shE-cadherin [179] from Dr. Robert Weinberg (Addgene plasmid #18801); 
pLKO.1-puro-shJNK1 (DTRCN0000010580) and pLKO.1-puro-shJNK2 (TRCN0000000945) 
were from Dharmacon. All shRNA sequences have been rigorously assessed for off-target 
effects and used as described previously [51, 52, 121, 122, 179-183]. 
Antibodies were obtained as follows: anti-AIF (Santa Cruz, sc-13116), anti-β-actin 
(Sigma, A5316), anti-phospho-JNK T183/Y185 (Cell Signaling, 4668), anti-JNK (Cell 
Signaling, 9252), anti-JNK1 (Cell Signaling, 3708), anti-JNK2 (Cell Signaling, 9258), anti-
phospho-c-Jun S73 (3270), anti-E-cadherin (Cell Signaling, 4065), anti-N-cadherin (Cell 
Signaling, 4061), anti-β-Catenin (Cell Signaling, 8480), anti-Vimentin (Cell Signaling, 5741), 
anti-Claudin-1 (Cell Signaling, 13255), anti-Snail (Cell Signaling, 3879), anti-Slug (Cell 
Signaling, 9585), anti-Zeb1 (Cell Signaling, 3396), anti-Zeb2 (Santa Cruz, sc-271984), anti-ZO-
1 (Cell Signaling, 8193), anti-AMPKα (Cell Signaling, 4186), anti-phospho-AMPKα T172 (Cell 
Signaling, 2535), anti-AMPKα/β (Cell Signaling, 4150), anti-phospho-AMPKβ1 S182 (Cell 
Signaling, 4186), anti-ETS-1 (Santa Cruz, sc-350), horseradish peroxidase (HRP)-conjugated 
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anti-Flag (Sigma, A8592), HRP-conjugated anti-mouse IgG (Amersham Biosciences, NA391B), 
and HRP-conjugated anti-rabbit IgG (Amersham Biosciences, NA934B). 
Cell culture 
Cells were cultured in an atmosphere of 95% air and 5% CO2 at 37 °C. All media 
formulations were supplemented with 2 mM GlutaMAX. HEK293T and MRC-5 cells were 
cultured in DMEM supplemented with 10% FBS; PC3, and LNCaP cells in RPMI 1640 medium 
supplemented with 10% FBS; and MIA PaCa-2 cells in DMEM supplemented with 10% FBS 
and 2.5% horse serum. Cells were harvested by trypsinization, washed in PBS, and seeded at 
equal densities and then allowed to attach overnight prior to all assays. 
Transfections 
Plasmids were transfected into cells using Lipofectamine™ 2000 as described by the 
manufacturer. Cells were then harvested 48-72 h following transfection and assessed as 
indicated. 
Drug treatments 
Cells were treated with SP600125 at 0-40 μM for 72 h, or bVAD-fmk at 50 μM at time of 
seeding and then every 48 h for 7 days. Following treatment cells were harvested and assessed in 
assays as described below. 
Lentiviral production and stable infection of cell lines   
To establish cell lines stably suppressing or overexpressing AIF, lentiviral particles were 
produced by transfecting equal amounts of pHCMV-G, pRRE, pRSV-rev, and FG12- or pSL4-
derived plasmids into HEK293T cells using the calcium phosphate method [124]. Following 
incubation at 37 °C for 48 h, supernatants were collected, filtered using 0.45 μm-pore size Millex 
HV PVDF filter units (Millipore) and concentrated by centrifugation at 20,000 x g. Viral pellets 
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were then resuspended in PBS at 4 °C overnight. Resuspended virus was added to cells in the 
presence of 4 μg/mL polybrene for 4 h at 37 °C in an environment of 93% air and 7% CO2. Cell 
lines used for stable RNAi targeting of AIF were infected with either control lentivirus or 
lentivirus harboring an AIF target sequence as follows: shLacZ-puro or shAIF-puro (PC3, MRC-
5) followed by selection with 1 μg/mL puromycin, shLacZ-GFP or shAIF-GFP (LNCaP, MIA 
PaCa-2). LNCaP-derived cells were established as described previously [51]. 
For establishment of cell lines stably suppressing JNK1, JNK2, or E-cadherin, pLKO.1-
based lentiviruses were generated by transfecting HEK293T cells with pMD.2, psPAX2, and 
pLKO-shRNA using the calcium phosphate method. Viral supernatant was collected at 48 h and 
72 h post-transfection and then filtered using 0.45 μm-pore size Millex HV PVDF filter units. 
Target cells were then incubated with viral supernatant and 8 μg/mL polybrene for 24 h. Stably 
infected cells were selected using 1 μg/mL puromycin. 
Cell lysis, SDS-PAGE and immunoblot analysis 
Cell lysates were prepared in radioimmune precipitation assay (RIPA) lysis buffer (PBS 
containing 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM dithiothreitol, 1 mM 
PMSF, 1 mM sodium fluoride, 1 mM sodium orthovanadate, and 1 protease inhibitor mixture 
tablet per 10 mL) or Laemmli buffer (62.5 mM tris-HCl pH 6.8, 2% SDS, 10% glycerol, and 5% 
β-mercaptoethanol). Protein samples were separated by SDS-PAGE using 4-12% gradient SDS-
polyacrylamide gels followed by electrotransfer to nitrocellulose membranes. Membranes were 
blocked with 5% milk or bovine serum albumin in tris-buffered saline containing 0.02 to 0.2% 
Tween-20 and then incubated with the indicated primary antibodies. Membranes were then 
washed three times and incubated with HRP-conjugated anti-mouse or anti-rabbit followed by 
visualization using enhanced chemiluminescence. 
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Replicate immunoblots were quantified at multiple exposures for linearity using 
myImage Analysis™ software (Thermo Scientific). Band intensities for phosphorylated proteins 
were divided by intensities for the corresponding total proteins; all protein values and phospho-
protein/total protein ratios were then normalized to β-actin values. To determine fold changes 
among lanes, all ratios were then normalized to control lanes (leftmost lanes). 
Quantitative RT-PCR 
Gene expression analysis was carried out as described [167] using the relative standard 
curve method for quantification.  Briefly, real time PCR was carried out on the ABI Prism 7000 
sequence detection system (Applied Biosystems, Foster City, CA). Total RNA was isolated from 
the indicated cell lines using TRIzol reagent according to the manufacturer's instructions. 30 μg 
of RNA isolated from each sample was treated with 30 units of DNase I (Promega) for 30 min at 
37 °C. After DNase I digestion, RNA was purified using an RNeasy mini purification kit 
(Qiagen) following the manufacturer's protocol. An oligo (dT) primer was used in cDNA 
synthesis. 200 ng of RNA was reverse transcribed in a total volume of 50 μl using the TaqMan 
reverse transcription reagents kit (Applied Biosystems). To make a standard curve, serial 
dilutions of RNA from one sample (160, 40, 10, and 2.5 ng/μL final concentrations) were added 
to the RT reaction. Aliquots (3.5 μl) of cDNA were added to a 31.5-μl reaction mixture 
containing 17.5 μl of 2× SYBR® Green PCR Master Mix (Applied Biosystems) and 200–400 
nm primers; quadruplicate samples were prepared for each RNA source. Absence of DNA 
contamination was verified by performing amplification from cDNA without reverse 
transcriptase. The primers for PCR were designed with IDT PrimerQuest software (Integrated 
DNA Technologies, Inc.). Primer sequences are shown in Table D1. Primers to either β-Actin or 
GAPDH were used in order to determine normalization factors between AIF proficient (shLacZ) 
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and AIF deficient (shAIF) cell lines, and variation in β-actin/GAPH levels between cell lines was 
less than 10% in all cases. 
Phase contrast microscopy 
Images were captured by phase contrast microscopy using the 10× objective of a Nikon 
TS100F microscope equipped with a Nikon DS-Fi1 digital camera detection system and NIS 
Elements 4.0 software. 
Matrigel™ experiments 
Equal volumes of cold Matrigel™ were added to each well in 24-well plates and then 
allowed to solidify at 37 °C for 1 h. Cells were added to Matrigel™ layers at equal densities and 
exposed to substrate conditions for 3-7 days in the absence or presence of bVAD-fmk. Detached 
cells were collected and quantified by Coulter™ counting; attached cells were extracted from 
substrate using Matrigel recovery solution (Corning) and either lysed as described above or 
quantified by Coulter™ counting. Percent death was defined as the number of detached cells 
divided by total cells. 
Results 
AIF promotes the cadherin switch 
Through control of redox signaling, AIF is capable of inducing the phosphorylation of 
JNK. As a central signaling hub at the convergence of cellular programs regulating death, 
survival, proliferation, and differentiation [184], JNK contributes to a variety of tumorigenic 
processes when phosphorylated. An important cellular activity influenced by JNK in cancer is 
the epithelial-mesenchymal transition (EMT) [176], a large-scale series of gene expression 
changes that increase the metastatic proclivity of cells. A key event of EMT is the cadherin 
switch, whereby cells reduce expression of the tumor suppressor E-cadherin and elevate N-
 132 
cadherin to invade distal tissues [185]. To determine if AIF and JNK are involved with control of 
EMT, we assessed expression levels of EMT-associated genes in AIF deficient PC3 cells via RT-
PCR. AIF ablation did not globally alter EMT transcripts, but we observed a striking elevation in 
E-cadherin mRNA (25-fold increase, Figure 6.1A) that was confirmed at the protein level by 
immunoblot in PC3 and MRC-5 cells (Figure 6.1). To further determine the role of AIF in the 
cadherin switch, we probed lysates for N-cadherin and observed decreased levels following AIF 
ablation in both cell types (Figure 6.1B). The effects of AIF upon the cadherin switch were also 
examined in LNCaP and MIA PaCa-2 cells (Figure 6.1B). As a cell line derived from a less 
aggressive (androgen sensitive) prostate cancer [186], LNCaP cells do not exhibit a cadherin 
switch, expressing high levels of E-cadherin and low N-cadherin. Since pre-existing cadherin 
levels in LNCaP cells are similar to those associated with AIF ablation in PC3 and MRC-5 cells, 
cadherin levels expectedly did not change with AIF knockdown in LNCaP cells (Figure 6.1B). 
This is consistent with our previous observations that LNCaP cells are metabolically insensitive 
to the loss of AIF [51].  In contrast, MIA PaCa-2 cells displayed a cadherin profile similar to 
PC3 and MRC-5 cells but that was unaffected by suppression of AIF (Figure 6.1B). We 
previously demonstrated that MIA PaCa-2 cells do not rely on either their mitochondria or AIF 
to survive and grow [52], thus it was not surprising that cadherin levels were unaffected by AIF 
ablation in this cell type. 
AIF ablation and JNK suppression converge to similar molecular phenotypes and reveal 
novel AIF signaling targets 
To determine if JNK is responsible for the cadherin switch in PC3 cells, we suppressed 
JNK activity by two independent approaches: pharmacological inhibition or genetic knockdown. 
For chemical inhibition experiments, AIF proficient and deficient PC3 cells were treated with the 
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pan-JNK inhibitor SP600125 [187]. AIF deficient cells exhibit subtle differences in morphology 
when compared to controls that may represent a more epithelial phenotype [51].  Notably, 
exposure to SP600125 induced morphological changes in AIF proficient cells, including 
increased size and length, converging on the appearance of PC3-shAIF cells (Figure 6.2).  JNK 
inhibition by SP600125 was confirmed by immunoblot for phospho-c-Jun (Figure 6.3A). c-Jun 
phosphorylation in AIF-deficient cells was expectedly reduced prior to treatment and further 
impaired by SP600125 to a greater extent than in AIF proficient cells; this corresponds to our 
observations that AIF is an upstream effector of JNK (Chapter 5). 
 
Figure 6.1. AIF promotes the cadherin switch. 
A) Transcript levels of EMT-associated genes in PC3-derived cells were assessed by qPCR. Data 
acquired by A.S. Wilkinson. B) Protein levels of E-cadherin and N-cadherin in the indicated cell 
types were determined by immunoblot analysis. Data are presented as average ± standard 
deviation. *p<0.05.  
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To further characterize the observed changes in morphology at the molecular level, 
immunoblots were performed for 11 proteins linked to both morphological phenotype and EMT: 
E-cadherin, N-cadherin, β-catenin, vimentin, claudin-1, Snail, Slug, Zeb1, Zeb2, ZO-1, and ETS-
1 (Figure 6.3A). Similar to the biochemical effects of AIF ablation, SP600125 increased E-
cadherin and decreased N-cadherin protein to levels comparable to those associated with AIF 
deficiency, demonstrating their regulation by both AIF and JNK. Furthermore, our screen 
revealed 7 additional genetic targets of AIF-mediated mitonuclear signaling: vimentin, a 
cytoskeletal molecule expressed in mesenchymal cells that maintains cell shape and integrity 
[188]; Snail, Slug, Zeb1, Zeb2, and ZO-1, which are central transcriptional regulators of EMT 
[176]; and ETS-1, an EMT-associated factor linked to mitonuclear retrograde signaling that 
regulates invasion by controlling the expression of matrix metalloproteinases [150, 176]. 
  
Figure 6.2. AIF ablation and JNK inhibition converge to similar cellular morphologies. 
PC3-derived cells  were treated with 0, 10, and 40 μM SP600125 for 72 h and then imaged by 
phase contrast microscopy. 
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Figure 6.3. AIF ablation and JNK suppression converge to similar molecular phenotypes 
and reveal novel AIF signaling targets.   
(A) PC3-derived cells were treated with 0, 10, and 40 μM SP600125 for 72 h, lysed and probed 
with the indicated antibodies by immunoblot analysis. B) Stable knockdown of JNK1 and JNK2 
in PC3 cells and their effects on E-cadherin and N-cadherin were determined by immunoblot 
analysis. C) Venn diagram depicting the convergence of AIF-dependent and JNK-dependent 
signaling determined from panels A and B. 
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To further assess the involvement of JNK in the cadherin switch and to define isoform 
specificity, we next generated PC3 cells stably deficient in JNK1 or JNK2 by lentivirus-mediated 
shRNA induction (Figure 6.3B). In agreement with the effects of SP600125, we observed 
changes in E-cadherin and N-cadherin following JNK knockdown that were isoform specific. 
Knockdown of JNK2 decreased N-cadherin expression, while the loss of JNK1 phenocopied the 
previously observed effects of AIF ablation, triggering both an elevation in E-cadherin and a 
reduction in N-cadherin levels (Figure 6.3B). 
Taken together, these data suggest that AIF functions upstream of JNK, and through JNK 
activity AIF can control the cadherin switch as well as expression of specific morphological and 
EMT-associated genes. As an example of this specificity, AIF and JNK suppress E-cadherin 
without affecting levels of β-catenin (Figure 6.3A), a critical reciprocal regulator of E-cadherin  
[189]. Notably, while levels of not all AIF-dependent proteins required JNK, all JNK-dependent 
proteins identified were also dependent upon AIF (Figure 6.3C). This further demonstrates that 
AIF is essential for basal JNK activity, and also reveals the existence of additional AIF-
dependent signaling pathways. 
AIF-mediated signal transduction triggers the cadherin switch via JNK1 
Collectively these data show that AIF enzymatic activity induces JNK1 signaling, and 
that AIF and JNK1 share E-cadherin as a target. The ability of AIF to promote both JNK1 
activation and the cadherin switch raised the possibility that if JNK1 functions as a conduit for 
AIF-mediated signaling, then restoration of JNK activity in AIF-deficient cells would reverse E-
cadherin to control levels. In order to restore JNK activity in the absence of AIF, we employed 
constitutively active forms of JNK (CA-JNK) fused with the JNK activator MKK7 and tagged 
with Flag epitope that have been characterized previously [166]. Plasmids encoding CA-JNK1 or 
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CA-JNK2 were transfected into PC3-shLacZ and PC3-shAIF cells followed by immunoblot for 
Flag and phospho-c-Jun (Figure 6.4), demonstrating both expression and activity of each CA-
JNK protein. When CA-JNK1 was introduced into PC3-shAIF cells, E-cadherin reversed to near- 
control (shLacZ) levels (Figure 6.4), confirming that AIF regulates the cadherin switch by 
activating JNK1. 
Failure to induce E-cadherin causes AIF-deficient cells to undergo apoptosis 
We have shown previously that AIF ablation severely impairs tumorigenesis [51, 52]. 
Seeking to link these results to our current data defining an AIF-dependent signaling pathway, 
we employed the use of a Matrigel™-based assay as an in vitro approximation of molecular 
responses that may occur in vivo. We began by growing PC3-shLacZ and PC3-shAIF cells in 
Matrigel™ followed by extraction from substrate after 3 days. Similar to our data acquired from 
cells grown under nutrient-rich conditions in vitro, phosphorylation of JNK was impaired in AIF-
deficient cells grown in Matrigel™ (Figure 6.5A). This suggests that AIF-mediated JNK 
phosphorylation occurs under physical and chemical environments encountered by tumor cells in 
vivo. 
Since we observed that AIF ablation leads to a loss of JNK1-mediated control of E-
cadherin, we then explored the effects of reverting E-cadherin to control levels in AIF-deficient 
cells. Lentiviruses harboring either control scramble shRNA or shRNA against E-cadherin [179] 
were generated and then used to infect PC3-shLacZ and PC3-shAIF cells. Stable knockdown of 
E-cadherin in AIF-deficient PC3 cells (PC3-shAIF/shE-cadherin) increased levels of N-cadherin 
(Figure 6.5B), suggesting N-cadherin levels can be altered by E-cadherin [179] in an AIF-
dependent manner. 
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Figure 6.4. AIF signals JNK1 to downregulate E-cadherin. 
PC3-derived cells were transfected with either empty control (CTL) plasmids or plasmids 
encoding either CA-JNK1-Flag or CA-JNK2-Flag, followed by immunoblot analysis with the 
indicated antibodies. 
 
To determine if E-cadherin is involved with these changes, we next subjected PC3-
shLacZ/scramble, PC3-shAIF/scramble, and PC3-shAIF/shE-cadherin cells to Matrigel™. Cells 
were seeded at three different densities (low, medium, high) and then incubated at 37 °C for 7 
days (Figure 6.5C, D). In agreement with our previous observations [51], AIF proficient cells 
(PC3-shLacZ/scramble) demonstrated population increases ranging from 4-8 fold, indicating an 
ability to survive growth stress conditions.  As expected, PC3-shAIF/scramble cells showed no 
increase in total viable numbers, with seed populations remaining essentially unchanged over the 
duration of the experiment.  Notably, this AIF-deficient phenotype was further exacerbated in 
PC3-shAIF/shE-cadherin cells, which exhibited net reductions of 25-75% compared to controls 
(Figure 6.5C, D).    
During this incubation, significant fractions of PC3-shAIF/scramble cells condensed and 
detached from the substrate (hallmarks of cell death), and the severity of this phenotype 
increased for PC3-shAIF/shE-cadherin cells.  This raised the possibility that the absence of AIF  
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Figure 6.5. Suppression of E-cadherin reverses N-cadherin levels and triggers apoptosis in 
AIF-deficient PC3 cells in Matrigel™ environment. 
A) Immunoblot analysis of phospho-JNK in PC3 shLacZ and shAIF cells recovered from 
Matrigel™ substrate. B) PC3-derived cells were stably infected with lentiviruses harboring either 
control scramble shRNA or shE-cadherin followed by immunoblot for AIF, E-cadherin, and N-
cadherin. C) Phase contrast images of PC3-derived cells seeded at high, medium, and low 
densities in Matrigel™ substrate and grown for 7 days. D) Following 7 days of growth on 
Matrigel™, attached cells were recovered from and then quantified by Coulter™ counting. 
*p<0.05 compared with shLacZ scramble cells seeded at respective initial densities; ‡p<0.05 
compared with shAIF scramble cells at corresponding seed populations. E) Cells were seeded in 
Matrigel™ substrate and treated with 50 μM bVAD-fmk immediately following seeding and 
then every 48 h for 7 days. Attached and detached cells were then recovered and quantified by 
Coulter™ counting; percent death is defined as the fraction of detached cells within each sample. 
All quantitative data are presented as average ± standard deviation.  
shAIF + scramble shAIF + shE-Cadherin
F
o
ld
 c
h
a
n
g
e
 in
 s
e
e
d
 p
o
p
u
la
tio
n
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
2.00
High 
Medium 
Low 
shLacZ + scramble
F
o
ld
 c
h
a
n
g
e
 i
n
 s
e
e
d
 p
o
p
u
la
ti
o
n
0
1
2
3
4
5
6
7
8
9
10
* **
‡‡‡
shLacZ + scramble shAIF + scramble shAIF + shE-Cadherin
L
o
w
M
e
d
iu
m
H
ig
h
P-JNK
β-Actin
s
h
L
a
c
Z
s
h
A
IF
51
39
39
51
39
JNK
s
h
L
a
c
Z
s
c
ra
m
b
le
s
h
A
IF
s
c
ra
m
b
le
s
h
A
IF
s
h
E
-C
a
d
h
e
ri
n
E-Cadherin
N-Cadherin
AIF
β-Actin
A B
C D
 140 
leads to an active form of cell death under growth stress conditions that is amplified by E-
cadherin loss.  To test this possibility, we repeated the Matrigel™ experiment in the absence and 
presence of the caspase inhibitor bVAD-fmk. Detached populations of Matrigel™-exposed cells 
were harvested and viability was quantified (Figure 6.5D).  PC3-shLacZ/scramble cells did not 
demonstrate appreciable cell death, and therefore were insensitive to caspase inhibition.  In 
contrast, the cell death observed for both PC3-shAIF/scramble and PC3-shAIF/shE-cadherin 
cells was substantially reduced following caspase inhibition.  These results strongly suggest that 
under growth stress conditions Apoptosis-Inducing Factor ablation triggers apoptosis that is 
made more severe by the inability to upregulate E-cadherin. Altogether these data show that 
when activated by the enzymatic activity of AIF, JNK1 suppresses E-cadherin to promote 
invasiveness, but suppression of AIF-dependent E-cadherin levels in the absence of AIF is lethal. 
AIF and E-cadherin ablation-induced cell death corresponds to changes in AMPK 
phosphorylation and glucose consumption 
Following the observations that AIF ablation induces apoptosis that is increased by 
knockdown of E-cadherin in Matrigel™ (Figure 6.5), we hypothesized that E-cadherin serves to 
inhibit cell death in the absence of AIF-mediated ATP production [51]. A pivotal endogenous 
sensor of cellular energetic state that is also linked to mechanotransduction (e.g., due to 
Matrigel™-induced stresses) is the heterotrimeric protein complex known as AMP-activated 
protein kinase (AMPK). Notably, AMPK functions downstream of E-cadherin, stimulating 
glucose consumption and ATP production that allow the cell to resist mechanical forces imposed 
by the physiological environment [190]. In contrast to this pro-glycolytic role for AMPK 
associated with E-cadherin, the loss of AMPK triggers a metabolic switch to aerobic glycolysis 
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[191], which is consistent with the notion of a shared metabolic regulatory pathway between 
AMPK and AIF. 
  
Figure 6.6. Loss of AIF and E-cadherin alters AMPK phosphorylation and glucose 
consumption. 
A) The indicated cell lines were lysed and assessed for the indicated proteins by immunoblot. B) 
Replicate immunoblots from panel a were quantified and normalized to total AMPKα or 
AMPKβ1,2 and β-actin. C) Equal densities of cells were plated in fresh media, and total glucose 
was measured using the QuantiChrom™ Glucose Assay Kit (BioAssay Systems) 72 h after 
seeding. Total numbers of cells in each well were used to determine glucose consumption per 
cell. All quantitative data are presented as average ± standard deviation.  
 
Based on the shared pathways of AIF, E-cadherin, and AMPK, the status of AMPK was 
then evaluated in the context of AIF and E-cadherin ablation. While many regulatory 
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mechanisms for AMPK have been identified, two notable post-translational modifications are 
essential for protein activity and localization. The α subunit of AMPK is phosphorylated by 
LKB1 at T172 in the activation loop, and this phosphorylation is required for activation [192-
194]. AMPK activity is additionally regulated through protein localization; phosphorylation at 
S182 of the β1 subunit inhibits nuclear redistribution without affecting enzyme activity [195]. 
Therefore phosphorylation levels of AMPKα T172 and AMPKβ1 S182 were assessed by 
immunoblot analysis in PC3-derived cell lines (shLacZ/scramble controls, shAIF/scramble, and 
shAIF/shE-cadherin). Interestingly, AIF-deficient cells exhibited substantial decreases in 
AMPKα phosphorylation (Figure 6.6A, B), which may be a potential trigger for the metabolic 
switching event that occurs following AIF ablation [51, 192-194]. It is notable that this 
phosphorylation was further reduced upon loss of E-cadherin (Figure 6.6A, B), consistent with 
an exacerbated AIF-deficient apoptotic phenotype observed above (Figure 6.5). No substantial 
changes in phosphorylation levels of AMPKβ1 S182 were observed, suggesting that this residue 
is not strongly involved with either AIF or E-cadherin signaling. Collectively these data strongly 
correlate with the pattern of cell death observed and suggest that AMPK responds both to AIF 
ablation and AIF/E-cadherin ablation, in particular with respect to phospho-activation at α-T172. 
If AMPK is associated with the protective function of E-cadherin in the context of AIF 
ablation, why do cells die despite further dephosphorylation of AMPK when E-cadherin is 
suppressed? We wondered if following AIF ablation cells have met a glycolytic threshold that 
cannot be exceeded upon additional metabolic demand, for example when E-cadherin growth 
suppressive activity is lost. If this is the case, AMPK could respond to such a change (through 
further phosphorylation change) yet still fail to protect cells. To test the validity of this idea, 
glucose consumption levels were assessed in PC3-derived cells. AIF-deficient cells increased 
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glucose uptake levels (Figure 6.6C), consistent with previous data [51] that indicate an 
upregulation of glycolysis to meet ATP demands. Notably, ablation of E-cadherin in AIF-
deficient cells did not further increase glucose consumption (Figure 6.6C). This observation 
provides evidence that loss of E-cadherin induces death in AIF-deficient cells due to a drastic 
loss of metabolic plasticity. 
Discussion 
Identification of a novel signal transduction pathway under AIF control 
This study is the first both to define the steps of an AIF-dependent signaling pathway and 
to show AIF promotes the cadherin switch. The reversal of the cadherin switch following AIF 
ablation in some cells raises the possibility that AIF may influence metastasis [51] by triggering 
E-cadherin suppression and N-cadherin elevation. Experiments presented here focus primarily on 
the cadherin switch in the context of altered AIF/JNK activity, but all MAPKs (JNK, p38, and 
ERK) have been implicated in the cadherin switch and metastatic progression [176]; whether and 
how AIF can regulate cadherin levels through p38 and ERK represent significant future 
questions. 
In light of the wide diversity of cell functions mediated by JNK, a variety of different 
signaling activities for AIF as an upstream messenger can be envisioned. In addition to the EMT 
and cadherin switch, JNK is additionally involved with apoptosis, differentiation, proliferation, 
survival, inflammation, and DNA repair. Through control of JNK activity, AIF is positioned to 
serve as a regulator as one or more of these activities and could therefore function in a 
significantly greater range of cellular activities than originally assumed.  
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Balance of AIF-mediated signaling with metabolism 
Interestingly, we observed that while AIF promotes the cadherin switch via JNK1 
activation, reversing this switch in AIF-deficient cells is lethal under Matrigel™ growth 
conditions. AMPK, a regulator of both metabolism and E-cadherin signaling, exhibits decreased 
phosphorylation following AIF loss that is further impaired when E-cadherin is suppressed, 
while glucose consumption cannot further increase with dual knockdown. This suggests that 
induction of the tumor suppressor E-cadherin following AIF ablation is a potential survival 
adaptation in the absence of AIF-mediated mitochondrial ATP production [51]. This might occur 
to slow cell growth to rates that can match metabolic availability of macromolecules and cell fuel 
sources [196], altogether demonstrating the roles of AIF, JNK, and E-cadherin as double-edged 
swords in cancer [197-199]. Cancer cells may use AIF to activate pro-tumor signaling pathways 
(such as JNK1-mediated suppression of E-cadherin), but their activation in the absence of AIF 
can in some situations be lethal, possibly due to altered AIF-dependent metabolism [25, 51, 52]. 
In the context of our experiments, AIF loss-induced upregulation of E-cadherin (due to impaired 
JNK activity) could serve as a brake on cell growth, which must remain in check when cells are 
unable to meet the metabolic demand of survival and invasion in growth substrate. Cells may 
alter AMPK status in response to dual knockdown of AIF and E-cadherin, but glycolysis cannot 
further increase with E-cadherin loss if a maximal level of glycolytic activity is already met 
following AIF ablation. 
Summary 
Experiments here show that through JNK1 activity AIF promotes the cadherin switch. 
Loss of AIF and subsequent impairment of JNK signaling induce E-cadherin upregulation, and 
knockdown of E-cadherin induces apoptosis when AIF is suppressed. This cell death observed 
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appears to be related to a loss of balance between growth and metabolic demand; these data merit 
further investigation to confirm this hypothesis. Altogether, these findings define a novel 
signaling pathway comprising AIF, JNK1, and E-cadherin, and highlight their roles in 
controlling metabolism and redox signals with significant impact upon decisions of cell fate. 
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VII. AIF-MEDIATED REDOX SIGNALING IS UNCOUPLED FROM STABILIZATION 
OF THE MITOCHONDRIAL RESPIRATORY CHAIN 
Abstract 
The mitochondrial flavoprotein AIF controls both cellular metabolism and redox 
signaling. Regulation of metabolism and oxidative stress levels are often related, and it remains 
unknown if the redox effects of AIF ablation are due to altered metabolism, or if these effects are 
independent of AIF-mediated metabolic control. Suppression of AIF in 13 different cell lines 
from a variety of cancer types and tissues reveals that AIF-mediated stabilization of the 
respiratory chain is restricted to cell type, which is in contrast to the widespread role of AIF in 
redox-dependent activation of JNK. Interestingly, in cells that do exhibit complex I deficiency 
following AIF ablation, complex I levels are variably dependent upon the enzymatic activity of 
AIF, and further metabolic analysis shows that mitochondrial activity and abundance are not 
substantially impaired. Since no correlation appears to exist between metabolic sensitivity to AIF 
ablation and impaired redox signaling, this strongly suggests that AIF-mediated metabolism and 
oxidative stress responses are independent. We confirm this model by enhancing ETC activity 
with the yeast oxidoreductase NDI in AIF-deficient cells, which restores glucose consumption 
but not JNK signaling or the cadherin switch. Altogether these data demonstrate functional 
uncoupling of AIF-mediated control of the respiratory chain from AIF-dependent redox 
signaling. 
Introduction 
Cellular metabolic and redox states are closely related. The pentose phosphate pathway 
(PPP) is a metabolic route diverging from glycolysis that generates NADPH which can be used 
to detoxify free radicals. The ETC generates ROS during respiration due to electron leakage. 
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Additionally, ROS can inhibit various control points of glucose oxidation. Therefore changes in 
cellular metabolic conditions are frequently accommodated by changes in oxidative stress levels.  
This raises the question of whether impaired redox signaling following AIF ablation is due to 
loss of AIF or alteration of cellular metabolism. 
AIF is a mitochondrial oxidoreductase that controls both metabolism and cellular ROS 
levels with substantial impact upon intracellular signaling. Following AIF ablation, cells 
decrease protein levels of complex I subunits and exhibit a metabolic shift from OXPHOS to 
glycolysis that is reflected by increased glucose uptake and lactate secretion accompanied by 
decreased oxygen consumption. When AIF is suppressed, glycolysis increases in order to 
generate ATP in the absence of mitochondrial energy production. Additionally, it is thought that 
impaired growth is in part due to a downregulation of the PPP, which normally supplies the cell 
with macromolecular precursors for biosynthetic reactions. Rather than shuttling into the PPP, 
glycolytic intermediates may be instead destined for pyruvate so that ATP is generated at a level 
sufficient for survival. 
This metabolic switching event adds complexity to the observation that AIF enzymatic 
activity promotes cellular redox signaling. While AIF generates ROS in vitro, a number of 
explanations for decreased ROS levels and altered redox signaling following AIF suppression are 
possible. The ability of AIF enzymatic activity to produce ROS directly is one potential 
explanation for AIF-dependent ROS changes in cells; however, it is also plausible that changes 
in ROS and redox signaling stem from changes in complex I levels. Since complex I functions at 
the start of the ETC, loss of complex I could lead to decreased ROS levels due to decreased 
transport of electrons. Alternatively, ETC malfunction can also increase ROS levels due to 
electron backup within the ETC. In addition to AIF enzymatic activity and AIF-dependent 
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complex I levels, a third rationale for altered oxidative state can be envisioned. Since glycolysis 
is upregulated following AIF ablation, changes in the PPP would likely alter NADPH levels, 
which could consequently have significant impact upon cellular redox state. 
Interestingly, not all cells exhibit ETC deficiency or metabolic switching following AIF 
knockdown. This selective metabolic sensitivity to AIF loss seems to depend upon cellular 
metabolic preferences. Therefore assessment of redox signaling and metabolic status in cells that 
are metabolically insensitive to AIF ablation may clarify whether AIF-mediated redox signaling 
results from AIF metabolic regulation. Moreover, in cells that exhibit a metabolic switch 
following AIF ablation, reversal of this switch followed by evaluation of redox signaling would 
further establish a relationship between AIF-mediated metabolism and redox control. 
To address the relationship between AIF enzymatic activity, AIF-dependent complex I 
levels, and AIF-mediated redox signaling, experiments here focus on mitochondrial responses to 
AIF ablation, followed by assessment of JNK activity in the context of AIF ablation and altered 
metabolism. Remarkably, AIF-dependent signal transduction is uncoupled from stabilization of 
the mitochondrial respiratory chain and cellular metabolism. Altogether these findings show 
functional independence of the metabolic and redox activities of AIF, further demonstrating the 
versatility of AIF in homeostatic control and tumorigenesis. 
Materials and methods 
Materials, plasmids and antibodies 
MEM, DMEM, RPMI 1640, DMEM/F12, GlutaMAX, horse serum, insulin, transferrin, 
epidermal growth factor, trypsin, 4–12 % bis-tris polyacrylamide gels, nitrocellulose membranes, 
fetal bovine serum (FBS), phosphate buffered saline (PBS), and Pierce ECL 2 Western Blotting 
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Substrate were from Thermo Fisher Scientific; QuantiChrom™ Glucose Assay kit was from 
BioAssay Systems; all other materials were from Sigma. 
Lentiviral plasmids FG12-shLacZ-GFP, FG12-shAIF-GFP, FG12-shLacZ-puro, and 
FG12-shAIF-puro were described previously [51, 52, 121, 147]. To generate RNAi-resistant AIF 
restoration pSL4-hygro plasmids, AIF cDNA was subcloned from pEBB-siMut-AIF
WT
 and 
pEBB-siMut-AIF
TVA
 [51] into pSL4-hygro [164]. Lentiviral packaging plasmids pHCMV-G, 
pRRE, and pRSV-rev are as described [123]. pMXs-NDI1 [200] was from Dr. David Sabatini 
(Addgene plasmid #72876). To generate pEBB-NDI1-Flag, NDI1 cDNA was amplified by PCR 
from pMXs-NDI1 using primers containing NotI and KpnI restriction sites (sequences available 
upon request) and then inserted into the pEBB-Flag backbone using standard cloning techniques. 
Lentiviral pLKO plasmids were obtained as follows: psPAX2 and pMD2.G-vsv-G from Dr. 
Didier Trono (Addgene plasmids #12260 and 12259); pLKO.1-puro-scramble [149] from Dr. 
David Sabatini (Addgene plasmid #1864); and pLKO.1-puro-shE-cadherin [179] from Dr. 
Robert Weinberg (Addgene plasmid #18801).  
Antibodies were obtained as follows: anti-AIF (Santa Cruz, sc-13116), anti-NDUFA9 
(Invitrogen, 459100), anti-NDUFB8 (Invitrogen, 459210), anti-citrate synthase (Cell Signaling, 
14309), anti-β-actin (Sigma, A5316), anti-phospho-JNK T183/Y185 (Cell Signaling, 4668), anti-
JNK (Cell Signaling, 9252), anti-E-cadherin (Cell Signaling, 4065), anti-N-cadherin (Cell 
Signaling, 4061), anti-Flag (Sigma, F3165), HRP-conjugated anti-mouse IgG (Amersham 
Biosciences, NA391B), and HRP-conjugated anti-rabbit IgG (Amersham Biosciences, NA934B). 
Cell culture 
Cells were cultured in an atmosphere of 95% air and 5% CO2 at 37 °C. All media 
formulations were supplemented with 2 mM GlutaMAX, except for K-SFM as described below. 
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HEK293T, MRC-5, PANC-1, PL45, and HeLa cells were cultured in DMEM supplemented with 
10% FBS; PC3, DU145, LNCaP, BxPC-3, and HCT 116 cells in RPMI 1640 medium 
supplemented with 10% FBS; HPAF-II cells in MEM supplemented with 10% FBS; MIA PaCa-
2 cells in DMEM supplemented with 10% FBS and 2.5% horse serum; and HPAC cells in a 1:1 
mixture of DMEM and Ham’s F12 medium supplemented with 5 % FBS, 2 μg/mL insulin, 5 
μg/mL transferrin, 40 ng/mL hydrocortisone, and 10 ng/mL EGF. RWPE-1 cells were cultured in 
K-SFM (Thermo Scientific, 17005042) supplemented with 0.05 mg/mL bovine pituitary extract 
and 5 ng/mL EGF. Cells were harvested by trypsinization, washed in PBS, and seeded at equal 
densities and then allowed to attach overnight prior to all assays. 
Transfections 
Plasmids were transfected into cells using Lipofectamine™ 2000 as described by the 
manufacturer. Cells were then harvested 48-72 h following transfection and either lysed as 
described below or quantified by Coulter™ counting. 
Drug treatments 
Cells were subjected to chemical treatments as follows: tBHQ at 0-2 mM for 1 h, and 
staurosporine at 1 μM for 16 h. Following treatment cells were harvested and assessed in assays 
as indicated. 
Lentiviral production and stable infection of cell lines   
To establish cell lines stably suppressing or overexpressing AIF, lentiviral particles were 
produced by transfecting equal amounts of pHCMV-G, pRRE, pRSV-rev, and FG12- or pSL4-
derived plasmids into HEK293T cells using the calcium phosphate method [124]. Following 
incubation at 37 °C for 48 h, supernatants were collected, filtered using 0.45 μm-pore size Millex 
HV PVDF filter units (Millipore) and concentrated by centrifugation at 20,000 x g. Viral pellets 
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were then resuspended in PBS at 4 °C overnight. Resuspended virus was added to cells in the 
presence of 4 μg/mL polybrene for 4 h at 37 °C in an environment of 93% air and 7% CO2. Cell 
lines used for stable RNAi targeting of AIF were infected with either control lentivirus or 
lentivirus harboring an AIF target sequence as follows: shLacZ-puro or shAIF-puro (PC3, 
HPAC, MRC-5, RWPE-1, HeLa, PANC-1, BxPC-3, PL45, HPAF-II) followed by selection with 
1 μg/mL puromycin; shLacZ-GFP or shAIF-GFP (DU145, LNCaP, HCT 116, MIA PaCa-2). To 
establish “restoration” cell lines (PC3, HeLa) expressing either wild-type AIF or a catalytically 
impaired mutant, cells were infected with empty vector, AIF
WT
, or AIF
TVA
 and then selected with 
500 μg/mL (PC3) or 1000 μg/mL (HeLa) hygromycin B. 
For establishment of cell lines stably suppressing E-cadherin, pLKO.1-based lentiviruses 
were generated by transfecting HEK293T cells with pMD.2, psPAX2, and pLKO-shE-cadherin 
using the calcium phosphate method. Viral supernatant was collected at 48 h and 72 h post-
transfection and then filtered using 0.45 μm-pore size Millex HV PVDF filter units. Target cells 
were then incubated with viral supernatant and 8 μg/mL polybrene for 24 h. Stably infected cells 
were selected using 1 μg/mL puromycin. 
Cell lysis, fractionation and immunoblot analysis 
Cell lysates were prepared in radioimmune precipitation assay (RIPA) lysis buffer (PBS 
containing 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM dithiothreitol, 1 mM 
PMSF, 1 mM sodium fluoride, 1 mM sodium orthovanadate, and 1 protease inhibitor mixture 
tablet per 10 mL). Mitochondrial extracts were prepared as described [201]. Briefly, cells were 
resuspended in buffer A (250 mM sucrose, 20 mM HEPES-KOH pH 7.9, 10 mM KCl, 1.5 mM 
MgCl2, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, 1 mM PMSF, and 1 protease inhibitor 
mixture tablet per 10 mL) and equilibrated on ice for 20 min, followed by homogenization with a 
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Dounce tissue grinder (Kimble™ Kontes™). Samples were then centrifuged at 400 x g for 10 
min at 4 °C. Supernatants were then collected and further centrifuged at 10,000 x g for 10 min at 
4 °C. Precipitated material (constituting the mitochondrial fraction) was then washed in buffer A 
and resuspended in NP-40 lysis buffer (1% NP-40, 10% glycerol, 25 mM HEPES pH 7.9, 100 
mM NaCl, 1 mM EDTA, 1 mM dithiothreitol, 1 mM sodium fluoride, 1 mM sodium 
orthovanadate,1 mM PMSF, and 1 protease inhibitor tablet per 10 mL). 
For immunoblot experiments, protein samples were separated by SDS-PAGE using 4-
12% gradient SDS-polyacrylamide gels followed by electrotransfer to nitrocellulose membranes. 
Membranes were blocked with 5% milk or bovine serum albumin in tris-buffered saline 
containing 0.02 to 0.2% Tween-20 and then incubated with the indicated primary antibodies. 
Membranes were then washed three times and incubated with HRP-conjugated anti-mouse or 
anti-rabbit followed by visualization using enhanced chemiluminescence. 
Replicate immunoblots were quantified at multiple exposures for linearity using 
myImage Analysis™ software (Thermo Scientific). Band intensities for phosphorylated proteins 
were divided by intensities for the corresponding total proteins; all protein values and phospho-
protein/total protein ratios were then normalized to β-actin values. To determine fold changes 
among lanes, all ratios were then normalized to control lanes (leftmost lanes). 
Measurements of mitochondrial ΔΨm and abundance 
Staining for mitochondrial membrane potential was carried out as described previously 
[104] by resuspending harvested cells in PBS containing 200 nM TMRM followed by flow 
cytometry. Staining for mitochondrial abundance was carried out by incubating cells with 100 
nM MitoTracker™ Red at 37 °C for 20 min. Cells were then harvested and resuspended in PBS, 
followed by assessment of stain intensity using an Accuri C6 flow cytometer. 
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Glucose consumption measurements 
Following transfections, fresh media was replenished, and cells were grown at 37 °C for 
72 h. Media glucose levels were then assessed using the QuantiChrom™ Glucose Assay kit 
(BioAssay Systems). Cells in each sample were quantified by Coulter™ counting and used to 
determine glucose consumption levels per cell. 
Results 
AIF-mediated respiratory chain stabilization is limited to cell type 
Our data demonstrate that AIF-mediated signaling promotes a JNK1-dependent cadherin 
switch. In addition to this activity, AIF is essential for mitochondrial homeostasis under healthy 
cellular conditions [25, 26, 62]. AIF controls both protein levels within mitochondrial complex I 
and metabolic flux, yet the role of AIF-mediated redox control in these metabolic activities 
remains unclear. Moreover, it is presently unclear whether the ability of AIF to influence 
mitochondrial metabolism (through complex I protein expression) and redox/ROS signaling are 
related properties, or if these are separate features of AIF activity that govern distinct cellular 
responses.  To begin addressing this question, we evaluated AIF-mediated control of complex I 
and mitochondrial activity (potential sources of intracellular ROS) in a broad panel of human cell 
lines. Suppression of AIF protein by lentivirus-mediated RNAi was verified by immunoblot 
(Figure 7.1A), and following ablation of AIF we observed cell line specific losses of complex I 
subunits NDUFA9 and NDUFB8 (Figure 7.1A). Previously we have tested the effect of AIF 
ablation on respiratory chain protein levels [51, 52] in some cell types employed here (PC3, 
DU145, LNCaP, PANC-1, BxPC-3, HPAC, HPAF-II, MIA PaCa-2), which are consistent with 
our current data. Following AIF ablation 7 of the 13 cell lines (MRC-5, PC3, DU145, PANC-1, 
BxPC-3, HPAC, PL45) exhibited reductions in levels of complex I subunits NDUFA9 and 
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NDUFB8 to variable extents, whereas in HeLa cells a reduction of only NDUFB8, but not 
NDUFA9, was observed. In the remaining 5 cell lines (RWPE-1, HCT 116, LNCaP, HPAF-II, 
MIA PaCa-2), levels of neither NDUFA9 nor NDUFB8 were affected following suppression of 
AIF (Figure 7.1A), indicating AIF is not universally required to maintain expression of 
respiratory chain proteins. 
AIF enzymatic activity variably controls complex I levels 
To determine if AIF-mediated control of respiratory protein levels is dependent on AIF's 
NADH-oxidase activity, we next generated AIF restoration cell lines expressing either wild type 
AIF (AIF
WT
) or a catalytically inactive AIF mutant [51, 54] containing the substitutions T263A 
and V300A (AIF
TVA
). Lentiviruses harbored cDNA constructs with a silent mutation resistant to 
shRNA-mediated targeting of AIF [51], and the introduction of hygromycin B resistance was 
used to select stably infected cells. Expression of both wild type AIF and the enzymatically 
deficient mutant restored complex I to control levels in PC3 cells (Figure 7.1B), suggesting that 
the NADH-oxidase activity of AIF is not required for complex I protein expression. These 
findings are in agreement with our previously derived PC3 cell lines in which GFP and 
puromycin resistance were used as selection markers [51]. Interestingly, when AIF was 
reintroduced to HeLa-shAIF cells (which exhibited a reduction of only NDUFB8), AIF
TVA
 failed 
to restore NDUFB8 to control levels (Figure 7.1B). This indicates that the enzymatic activity of 
AIF is essential for complex I regulation only for certain ETC subunits and/or in specific cell 
types. While the mechanism of AIF-mediated mitochondrial control remains poorly understood, 
the above analyses show that the ability of AIF to control respiratory chain subunit levels is 
highly variable and dependent upon context. 
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Figure 7.1. AIF-mediated control complex I levels is restricted to cell type and variably 
requires AIF enzymatic activity. 
A) Immunoblot analysis was performed on a panel of AIF proficient (shLacZ) and deficient 
(shAIF) human cell lines from diverse tissue types.  Antibodies recognizing AIF, complex I 
subunits NDUFA9 and NDUFB8, and citrate synthase were employed; β-actin was used as a 
loading control. B) Immunoblot analysis for AIF, NDUFA9, NDUFB8, and β-actin was 
performed as in panel A on “restored” PC3 and HeLa cell lines. 
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Table 7.1. Effect of AIF ablation on mitochondrial ΔΨm and abundance. 
  
Change in  
ΔΨm  (%) 
p 
Change in 
abundance (%) 
p 
HeLa 20.9 0.020 9.7 0.587 
HPAC 16.3 0.007 34.2 0.002 
MRC-5 15.5 0.007 19.6 0.026 
DU145 13.9 0.064 23.4 0.147 
MIA PaCa-2 13.7 0.128 -13.8 0.212 
HCT 116 12.6 0.079 21.7 0.315 
PL45 8.5 0.149 30.2 0.120 
BxPC-3 8.5 0.001 26.2 0.004 
PANC-1 5.6 0.178 -12.7 0.007 
LNCaP 4.7 0.553 -13.2 0.376 
PC3 -2.0 0.595 2.6 0.272 
RWPE-1 -7.7 0.040 -2.6 0.168 
HPAF-II -10.5 0.389 -0.2 0.987 
Staurosporine 
treatment 
-59.3 0.000 -30.1 0.045 
Staining with either TMRM or MitoTracker™ Red was used to determine ΔΨm and abundance 
of mitochondria, respectively, in cells proficient (shLacZ) and deficient in AIF (shAIF). Changes 
following AIF ablation compared to control cells are shown; p-values were determined by two-
tailed homoscedastic Student’s t-tests. Changes between staurosporine-treated and control-
treated cells were used as a comparative reference to the effects of AIF ablation (bottom row). 
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AIF is not critical for general mitochondrial fitness 
Since some cell types exhibited complex I deficiency following AIF ablation, we 
evaluated mitochondrial status in our panel of cell lines to determine if mitochondrial function 
and/or biogenesis (possible triggers for oxidative stress signaling) were impaired. Citrate 
synthase, a mitochondrial matrix enzyme and marker for mitochondrial abundance, was 
unchanged when AIF was suppressed (Figure 7.1A). Furthermore, assessment of mitochondrial 
status by staining with tetramethylrhodamine ester (TMRM, an indicator of mitochondrial ΔΨm) 
and MitoTracker™ Red (an indicator of mitochondrial abundance) suggests that AIF ablation 
does not substantially dissipate the mitochondrial electrochemical gradient nor decrease 
mitochondrial abundance in any cell types tested (Table 7.1). It is therefore likely that while AIF 
controls complex I in some cell types, AIF is not critical for mitochondrial fitness. Strikingly, all 
cell types examined required AIF for JNK signaling (Chapters 5, 6) regardless of whether AIF 
deficiency led to changes in complex I (Figure 7.1A). 
 
Figure 7.2. NDI1 reduces glucose consumption in AIF-deficient cells. 
Glucose consumption levels of PC3-derived cells transfected with either control plasmid (CTL) 
or NDI1 were measured using the QuantiChrom™ Glucose Assay kit (BioAssay Systems) and 
normalized to cell numbers. Data are presented as average ± standard deviation. *p<0.05. Inset: 
Protein expression levels of NDI1 in transfected PC3-derived cells were determined by 
immunoblot for Flag epitope in mitochondrial extracts. 
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Figure 7.3. NDI1 does not affect JNK phosphorylation in AIF-deficient cells. 
A) PC3-derived cells transfected with either control plasmid or NDI1 were treated with 0 or 2 
mM tBHQ followed by immunoblot for phosphorylated JNK. B) Replicate phospho-JNK 
immunoblots from panel a were quantified and normalized to total JNK and β-actin. *p<0.05 
compared with shLacZ CTL plasmid + 0 mM (CTL CTL). Data are presented as average ± 
standard deviation. 
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through complex I. Therefore we sought to restore functionality of ETC/OXPHOS while 
maintaining knockdown of AIF. To accomplish this, we expressed an epitope-tagged form of 
NDI1 in AIF proficient and deficient cells.  NDI1 is a single-subunit NADH:ubiquinone 
oxidoreductase expressed by yeast and known to enhance and/or restore mitochondrial  
respiratory activity in human cells with complex I defects.  NDI1 can therefore be used to 
determine if an AIF-deficient phenotype is due to the specific loss of AIF or the more general 
loss of complex I function [202-204]. Control vectors and NDI1 plasmids were transfected into 
PC3-derived cells and then assessed for NDI1 expression. Immunoblot of mitochondrial extracts 
for Flag epitope showed that NDI1 protein is expressed in transfected PC3-derived cells (Figure 
7.2). A critical metabolic effect of AIF ablation is an increase in glucose consumption that 
supports energy production required for cell survival [51, 52]. When NDI1 was transfected into 
AIF-deficient PC3 cells, glucose consumption decreased significantly (Figure 7.2) and indicates 
an improvement in mitochondrial metabolic activity resulting from the introduction of a 
functional NDI1 protein. 
Despite restoration of the ETC with NDI1, oxidant-induced JNK phosphorylation 
remained unaffected by respiratory enhancement (Figure 7.3), and changes in the cadherin 
switch were not altered when AIF-deficient cells were transfected with NDI1 (Figure 7.4). 
Therefore, in addition to the finding that JNK requires AIF enzymatic activity across cell types 
regardless of AIF-dependent complex I status, these data demonstrate that AIF redox signaling is 
uncoupled from its roles in control of complex I and cellular metabolism. 
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Figure 7.4. The cadherin switch is unaffected by NDI1 introduction in AIF-deficient cells. 
A) PC3-derived cells transfected with either control plasmid or NDI1 were subjected to 
immunoblot for E-cadherin and N-cadherin. B) Replicate immunoblots from panel a were 
quantified and normalized to β-actin. E/N-cadherin upper band, E/N high; lower band, E/N low. 
*p<0.05 compared to shLacZ CTL. Data are presented as average ± standard deviation. 
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Does AIF directly promote ROS or are decreased ROS following AIF ablation due to altered 
metabolism? 
AIF promotes redox signaling independently of metabolic state 
It is notable that AIF ablation does not substantially decrease mitochondrial ΔΨm, which 
could be maintained by low but remaining complex I levels and/or ETC activity initiated by 
complex II or fatty acid β-oxidation. Similarly, AIF does not appear to substantially control 
mitochondrial abundance, a potential ROS source that could activate JNK. The enzymatic 
activity of AIF generates ROS (Chapter 5) in both PC3 and HeLa cells (exhibiting different ETC 
responses following AIF ablation) but does not universally control complex I (Figure 7.1), which 
is the first evidence that the cellular redox effects of AIF result specifically from its enzymatic 
activity and are not only a side-effect of AIF-mediated complex I function. These findings are 
further supported by experiments showing that respiratory chain enhancement in AIF-deficient 
cells restores glucose consumption but not JNK phosphorylation or E-cadherin levels. It is 
striking that the ability of AIF enzymatic activity to promote oxidative stress-induced JNK 
activation is independent of complex I status and cellular metabolic state, especially since 
metabolism and ROS levels are both controlled by this AIF activity. 
Summary 
Altogether this study shows the ability of AIF to promote redox signaling is uncoupled 
from metabolic control. These findings further support a highly multifunctional nature for AIF 
and suggest a significant capacity to separately regulate metabolism and redox state to the benefit 
of tumorigenesis. This finding that AIF regulates both cellular functions through a single 
enzymatic activity highlights the therapeutic promise of targeting AIF enzymatic activity in 
cancer. 
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VIII. AIF BINDING PROTEINS XIAP AND PGAM5 REGULATE DECISIONS OF 
CELL FATE THROUGH UBIQUITINATION-DEPENDENT MUTUAL ANTAGONISM  
Abstract 
AIF is a mitochondrial protein that exhibits dissociable activities in cellular homeostasis 
and caspase-independent cell death. AIF has been implicated in a variety of atypical cell death 
pathways and physically associates with the caspase-independent cell death regulators PGAM5 
and XIAP, but the mechanisms and functional significance of these interactions remain unclear. 
Here we show that the association of PGAM5 with AIF protects AIF from XIAP-mediated 
inhibition, and that PGAM5 triggers PINK1-dependent mitophagic cell death when 
overexpressed. Binding of PGAM5 with Keap1 and Bcl-XL facilitates XIAP-mediated 
ubiquitination and inhibition. Because XIAP ubiquitinates PGAM5 at a C-terminal lysine residue 
unique to the long isoform, XIAP fails to protect against toxicity induced by the short PGAM5 
isoform. Reciprocally, PGAM5 can prevent XIAP from dimerizing and self-ubiquitinating, 
which leads to altered XIAP activity. Overexpression of PGAM5 in embryonic fibroblasts 
demonstrates acute toxicity that is inhibited by XIAP, while long-term overexpression of 
PGAM5 in surviving cells protects against arsenic trioxide through an XIAP-dependent 
mechanism. Altogether these data illuminate a novel AIF-PGAM5-XIAP regulatory triad that 
determines cell fate decisions.  
Introduction 
The mitochondrial flavoprotein known as AIF is essential for cellular metabolism and the 
regulation of oxidative stress [25, 51, 52, 205]. In contrast to these pro-survival activities, AIF is 
additionally involved in cell death when released from the mitochondria [24]. In a caspase-
independent manner, liberated AIF translocates to the nucleus where it binds DNA and 
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associates with other factors (Endonuclease G, H2AX, Cyclophilin A) to form active DNase 
complexes, inducing chromatin condensation and internucleosomal DNA cleavage [24, 31, 32, 
36-43]. 
AIF-mediated chromatin degradation is inhibited by the multifunctional survival 
molecule known as XIAP. While serving as a potent suppressor of caspase activation and the 
execution of apoptosis, XIAP exhibits additional roles in copper homeostasis and the modulation 
signaling cascades including TGF-β, NF-κB, and JNK [48]. XIAP possesses an E3 ubiquitin 
ligase activity involved in a variety of activities including the regulation of cell death. Notable 
death-associated ubiquitination targets of XIAP include XIAP itself, Smac, and AIF [49, 206, 
207]. XIAP ubiquitinates AIF at a lysine residue essential for DNA binding, and this 
ubiquitination event occurs through alternative linkages that do not induce protein degradation 
[50]. Similar to AIF, the mitochondrial phosphatase PGAM5 is another non-degradative 
ubiquitination target of XIAP. Interestingly, PGAM5 is an AIF-associated factor [53], suggesting 
that AIF, PGAM5, and XIAP may form a regulatory axis that mediates decisions of cell fate.  
As the name indicates, PGAM5 contains a PGAM domain yet lacks mutase activity. 
PGAM5 is only distantly related to the phosphoglycerate mutase family, with the characteristic 
phosphohistidine motif within the PGAM domain poorly conserved in PGAM5 [208]. The 
closest relatives of PGAM5 are STS-1 and STS-2, which are ubiquitin-binding phosphatases 
involved in receptor-mediated signaling [209, 210]. Rather than functioning as a mutase, 
PGAM5 uses the PGAM catalytic region to operate as a phosphatase. While the purpose of 
PGAM5 phosphatase activity is unclear, PGAM5 has been shown to dephosphorylate ASK1, 
leading to the activation of JNK and p38 [211], consistent with initially characterized roles for 
PGAM5 in cell death and oxidative stress responses [212-214]. 
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PGAM5 was first identified as a Bcl-XL binding partner [214], and the first functional 
studies of PGAM5 revealed that PGAM5 is a substrate for Keap1-dependent ubiquitination 
[212]. PGAM5 regulates antioxidant responses within a mitochondrial ternary complex 
containing Keap1 and Nrf2 (also a Keap1 target), and Keap1-mediated ubiquitination leads to 
PGAM5 degradation that is inhibited by conditions of oxidative stress. 
A number of studies have argued disparate functions for PGAM5 in controlling cell 
survival, apoptosis, mitophagy, and necroptosis [215-220]. These activities might be reconciled 
by the physical and functional associations of PGAM5 with AIF and XIAP, all of which can 
mediate atypical forms of cell death and may comprise a novel regulatory axis determining cell 
fate. The functional significance of the AIF-PGAM5 interaction remains unclear, and points of 
regulation within the PGAM5 death pathway have not been identified. Moreover, how XIAP and 
PGAM5 are associated through ubiquitination and consequences upon cell death and survival 
may explain different outcomes of PGAM5 activity.  
We have identified PGAM5 as a trigger for cell death when overexpressed. PGAM5-
induced cell death is associated with mitophagy [53], a mitochondria-specific form of autophagy 
that normally serves to remove damaged mitochondria, modify mitochondrial abundance in 
response to metabolic needs, regulate steady-state mitochondrial turnover, and mediate 
erythrocyte differentiation [221]. Mitophagy is initiated by the stabilization of PINK1, which 
recruits the E3 ligase Parkin to the mitochondria [222, 223]. Parkin then ubiquitinates 
mitochondrial proteins leading to the engulfment of mitochondria into isolation membranes that 
fuse with lysosomes [221].  PGAM5-induced cell death is accompanied by hallmark features of 
mitophagy including severe structural abnormalities of the mitochondria, loss of mitochondrial 
membrane potential (ΔΨm), and elevated PINK1 protein levels [53]. 
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In this study we identify a functional role for PGAM5 in protecting AIF from XIAP-
mediated inhibition. Further, PGAM5 and XIAP regulate each other with different outcomes 
depending on cell type and context, likely due to differences in levels and types of non-canonical 
ubiquitination. Altogether this study identifies a novel PGAM5-XIAP axis and highlights 
significant roles for PGAM5 and XIAP in control of atypical cell death mechanisms. 
Materials and methods 
Materials, plasmids and antibodies 
DMEM, GlutaMAX, 4–12 % bis-tris polyacrylamide gels, nitrocellulose membranes, 
fetal bovine serum (FBS), phosphate buffered saline (PBS), Ni-NTA agarose, glutathione 
agarose, and Pierce ECL 2 Western Blotting Substrate were from Thermo Fisher Scientific; 
immunoglobulin G-Sepharose was from Amersham; all other materials were from Sigma. 
Antibodies were obtained as follows: anti-AIF (Santa Cruz Biotechnology, sc-13116), 
anti-PINK1 (Cell Signaling, 6946), anti-cleaved caspase-3 (Cell Signaling, 9661), anti-HA 
(Covance, MMS-101P), anti-Myc (Cell Signaling, 2276), anti-XIAP (Enzo, AAM-050), anti-
PGAM5 (Abcam, ab126534), HRP-conjugated anti-HA (Sigma, H6533), HRP-conjugated anti-
FLAG (Sigma, F3165), anti-β-actin (Sigma, A5316), HRP-conjugated anti-mouse (Amersham, 
NA931V), and HRP-conjugated anti-rabbit (Amersham, NA934V). 
Plasmids encoding PGAM5L mutants (pEBB-PGAM5L-K285A-HA, pEBB-PGAM5L-
K285R-HA, pEBB-PGAM5L-L135E/G139E-HA, pEBB-PGAM5L-E79A/S80A-HA) were 
generated by site-directed mutagenesis (Stratagene) using pEBB-PGAM5L-HA as a template. To 
generate the lentiviral plasmid pSL4-PGAM5L-puro, PGAM5L cDNA was subcloned from 
pEBB-PGAM5L into the pSL4-puro backbone [224]. Additional plasmids were obtained as 
follows: pLKO.1-shPINK1-puro from Sigma (TRCN0000007101). pLKO.1-puro-scramble [149] 
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from Dr. David Sabatini (Addgene plasmid #1864); and psPAX2 and pMD2.G-vsv-G from Dr. 
Didier Trono (Addgene plasmids #12260 and 12259). All remaining plasmids (pEBB-PGAM5L-
HA, pEBB-PGAM5S-HA, pEBB-PGAM5L-H105A-HA, pEBG-XIAP, pEBB-FLAG-XIAP, 
pEBB-FLAG-XIAP-H467A, pCW7 His6-Myc-Ubiquitin WT, K6R, K11R, K27R, K29R, K48R, 
K63R, pEBB-AIF, pEBB-AIF-FLAG, pEBB-AIF-GST, pcDNA3-Bax, pHCMV-G, pRRE, and 
pRSV-rev) have been described previously [49, 50, 53, 123]. 
Cell culture, transfections, and plasmids 
HEK293T cells were cultured in DMEM supplemented with 10% FBS supplemented 
with 2 mM GlutaMAX at 37 °C in an atmosphere of 95% air and 5% CO2. Wild-type and XIAP-
null MEFs are as described [225]. HEK293T cells were transfected using the calcium phosphate 
precipitation method [53]. Cells were harvested by trypsinization, washed, plated at equal 
densities, and allowed to attach overnight prior to all assays. 
Lentiviral production and stable infection of cell lines 
For establishment of cell lines stably suppressing PINK1, pLKO.1-based lentiviruses 
were generated by transfecting HEK293T cells with pMD.2, psPAX2, and pLKO-shRNA using 
the calcium phosphate method. Viral supernatant was collected at 48 h and 72 h post-transfection 
and then filtered using 0.45 μm-pore size Millex HV PVDF filter units. Target cells were then 
incubated with viral supernatant and 8 μg/mL polybrene for 24 h. Stably infected cells were 
selected using 1 μg/mL puromycin. 
To establish cell lines stably overexpressing PGAM5L, lentiviral particles were produced 
by transfecting equal amounts of pHCMV-G, pRRE, pRSV-rev, and FG12- or pSL4-derived 
plasmids into HEK293T cells using the calcium phosphate method. Following incubation at 37 
°C for 48 h, supernatants were collected, filtered using 0.45 μm-pore size Millex HV PVDF filter 
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units (Millipore) and concentrated by centrifugation at 20,000 x g. Viral pellets were then 
resuspended in PBS at 4 °C overnight. Resuspended virus was added to cells in the presence of 4 
μg/mL polybrene for 4 h at 37 °C in an environment of 93% air and 7% CO2. Stably infected 
cells were selected using 1 μg/mL puromycin. 
Cell lysis, immunoprecipitation, and affinity precipitations 
Cell lysates were prepared in radioimmune precipitation assay (RIPA) lysis buffer (PBS 
containing 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM dithiothreitol, 1 mM 
PMSF, 1 mM sodium fluoride, 1 mM sodium orthovanadate, and 1 protease inhibitor mixture 
tablet per 10 mL) or urea lysis buffer (8 M urea, 300 mM NaCl, 0.5% NP-40, 50 mM Na2HPO4, 
50 mM Tris pH 8.0, 1 mM PMSF, 1 ng/mL aprotinin, and 10 ng/mL leupeptin). 
For immunoprecipitation experiments, RIPA cell lysates were normalized for protein 
content and then incubated with indicated antibodies for 2 h at 4 °C. Protein G-coupled agarose 
beads were then added and incubated for 1 h. Agarose beads were then recovered by 
centrifugation and washed in RIPA buffer. Precipitated protein was eluted by adding lithium 
dodecyl sulfate sample buffer followed by heating samples at 95 °C for 5 min. Samples were 
then analyzed by immunoblot as described below. 
For glutathione affinity precipitation experiments, RIPA lysates were normalized for 
protein content and then incubated with glutathione agarose for 2 h at 4 °C. Agarose beads were 
then recovered by centrifugation and washed in RIPA buffer. Precipitated protein was eluted by 
adding lithium dodecyl sulfate sample buffer followed by heating samples at 95 °C for 5 min. 
Samples were then analyzed by immunoblot as described below. 
For nickel affinity precipitation experiments, urea lysates were normalized for protein 
content and then incubated with Ni-NTA agarose for 2 h at room temperature. Agarose beads 
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were then recovered by centrifugation and washed in RIPA buffer. Precipitated protein was 
eluted by adding lithium dodecyl sulfate sample buffer followed by heating samples at 95 °C for 
5 min. Samples were then analyzed by immunoblot as described below. 
Immunoblot analysis 
For immunoblot experiments, protein samples were separated by SDS-PAGE using 4-
12% gradient SDS-polyacrylamide gels followed by electrotransfer to nitrocellulose membranes. 
Membranes were blocked with 5% milk or bovine serum albumin in tris-buffered saline 
containing 0.02 to 0.2% Tween-20 and then incubated with the indicated primary antibodies. 
Membranes were then washed three times and incubated with HRP-conjugated anti-mouse or 
anti-rabbit followed by visualization using enhanced chemiluminescence. 
Measurements of mitochondrial ΔΨm 
Staining for mitochondrial membrane potential was carried out as described previously 
[104] by resuspending harvested cells in PBS containing 200 nM TMRM followed by flow 
cytometry. Cells were then harvested and resuspended in PBS, followed by assessment of stain 
intensity using an Accuri C6 flow cytometer. 
Cell viability 
For protein toxicity assays, cells were transfected with either control vectors or the 
indicated plasmids. For ATO sensitivity experiments, cells were untreated or treated with ATO 
at 1 μg/mL for 24. Cells were then harvested, washed, and resuspended in PBS containing 2 
μg/mL propidium iodide. Cell viability was then determined by flow cytometry using an Accuri 
C6 flow cytometer. 
 169 
Results 
Association of PGAM5 with AIF protects AIF from XIAP binding and ubiquitination  
We have previously identified PGAM5 as an AIF-associated factor involved in cell death 
[53]. The PGAM5 gene can be transcribed into one of two different mRNA transcripts encoding 
either a long (PGAM5L) or short (PGAM5S) isoform. PGAM5L and PGAM5S proteins are 
identical from amino acids 1-239, with PGAM5L containing an additional 50 amino acids and 
PGAM5S containing an additional 16 amino acids [212, 214]. Both isoforms of PGAM5 bind 
AIF and trigger cell death when overexpressed in HEK293T cells. However, PGAM5S exhibits 
reduced phosphatase activity and multimerization due to differences between C-terminal amino 
acid residues [53]. Because functional differences between PGAM5L and PGAM5S are unclear, 
both isoforms were assessed as described below. 
Since PGAM5 and XIAP can both bind AIF [49, 53], we questioned if these associations 
can impact one another or occur independently. To determine how PGAM5 and XIAP affect AIF 
interactions with the other protein, a binding assay was performed using GST-tagged AIF. AIF-
GST was transfected into HEK293T cells with XIAP-FLAG and/or PGAM5-HA. Cell lysates 
were then subjected to incubation with glutathione-conjugated agarose, which precipitates GST-
fused proteins.  XIAP and PGAM5 expectedly precipitated with AIF (Figure 8.1), demonstrating 
physical associations with AIF. Notably, when both XIAP and PGAM5 were co-expressed, only 
PGAM5 precipitated with AIF regardless of isoform (Figure 8.1). This indicates that PGAM5 is 
a stronger binding partner for AIF, and that the interaction of PGAM5 with AIF blocks XIAP 
from binding AIF. 
When ubiquitinated by XIAP, AIF fails to induce chromatin degradation during cell 
death [50]. Since XIAP cannot associate with PGAM5-bound AIF, PGAM5 is likely to prevent 
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XIAP from ubiquitinating AIF. Therefore to assess the ability of PGAM5 to inhibit XIAP-
mediated ubiquitination of AIF, a nickel affinity precipitation assay was used. This assay 
employs ubiquitin tagged with polyhistidine (polyHis), which exhibits high affinity for nickel. 
Therefore polyHis-tagged ubiquitin can be precipitated using nickel-conjugated agarose. If 
polyHis-tagged ubiquitin conjugates with a target protein, then the protein can subsequently be 
identified in precipitated material, and detection of protein laddering indicates 
polyubiquitination. When ubiquitinated proteins were precipitated, we observed an increase in 
AIF ubiquitination with XIAP overexpression (Figure 8.2). Notably, overexpression of either 
isoform of PGAM5 suppressed XIAP-mediated ubiquitination of AIF. This indicates that binding 
of either PGAM5L or PGAM5S with AIF prevents XIAP from AIF access/inhibition. Therefore 
through AIF binding, PGAM5 is likely to promote AIF-mediated chromatin degradation [50]. 
  
Figure 8.1. Association of PGAM5 with AIF prevents the AIF-XIAP interaction. 
HEK293T cells were transfected with the indicated plasmids, lysed, and subjected to GST 
pulldown and subsequent immunoblots detecting the indicated protein epitope tags. 
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Figure 8.2. PGAM5 prevents XIAP from ubiquitinating AIF. 
HEK293T cells were transfected with His-ubiquitin (Ub) and the indicated plasmids. Cells were 
then lysed, and ubiquitinated proteins were precipitated with Ni-NTA agarose followed by 
immunoblot. 
 
XIAP prevents PGAM5L from activating PINK1 and the mitophagic death pathway 
The data above show that PGAM5 can protect AIF from XIAP-mediated ubiquitination. 
Similar to AIF, XIAP is capable of inhibiting PGAM5 through a ubiquitination-dependent 
mechanism. PGAM5 can also induce cell death independently of AIF [50, 53]. We have shown 
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activation. In an effort to define the sequence of events within this mitophagic death pathway and 
to determine the points of regulation controlled by XIAP [53], HEK293T cells were transfected 
with PGAM5 isoforms in the absence or presence of XIAP followed by assessment of 
biochemical cell death signals. Cells were first assessed for mitochondrial membrane potential 
(ΔΨm), a negative indicator of MOMP, by staining with tetramethylrhodamine ester (TMRM). 
When TMRM stain intensities were measured by flow cytometry, substantial decreases in cell 
populations with high ΔΨm were observed following PGAM5 overexpression that were 
comparable to those associated with elevated Bax levels (Figure 8.3A). Decreased ΔΨm induced 
by PGAM5L was reversed by the introduction of XIAP, whereas ΔΨm loss triggered by PGAM5S 
was unaffected (Figure 8.3B). This agrees with previous data [53] showing that XIAP 
ubiquitinates and inhibits only the long isoform of PGAM5, indicating that XIAP prevents 
PGAM5L from depolarizing mitochondria. 
Mitochondrial dysfunction often leads to MOMP and subsequent induction of PINK1, 
which is also an effect of PGAM5 overexpression. To determine if XIAP affects PGAM5-
mediated PINK1 signaling, lysates of cells transfected with HA-tagged PGAM5 and FLAG-
tagged XIAP were subjected to immunoblot for PINK1. Similar to observations that XIAP 
inhibits PGAM5L-mediated MOMP and cell death, XIAP suppressed PINK1 induced by 
PGAM5L, and PGAM5S-induced PINK1 was unaffected (Figure 8.3C). 
Induction of PINK1 is required for PGAM5 to kill cells 
Since XIAP prevents PGAM5L from stabilizing PINK1, we then questioned if 
suppression of PINK1 is a mechanism by which XIAP protects cells. Under normal cellular 
conditions PINK1 is perpetually degraded but is stabilized under stress stimuli (e.g., ΔΨm loss), 
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leading to the phosphorylation of Parkin and subsequent recruitment of mitophagic machinery 
that induce mitochondrial degradation via autolysosomes [221]. PGAM5 is a significant stimulus  
 
Figure 8.3. XIAP prevents PGAML from inducing MOMP and PINK1. 
A, B) HEK293T cells were transfected with the indicated plasmids, stained with TMRM, and 
then assessed by flow cytometry. Data are presented as average ± standard deviation. C) PINK1 
levels were assessed by immunoblot in HEK293T cells transfected with the indicated plasmids. 
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for mitophagic cell death, and the observation that PGAM5 induces PINK1 [53] leads to a 
significant open question: in the context of PGAM5 does mitophagy accompany cell death, or 
does PGAM5-induced mitophagy directly cause cell death? To address this question, we sought 
to suppress PINK1 and impair the cell’s ability to trigger the series of molecular events signaling 
for mitophagy. 
Lentiviruses harboring either control nonspecific shRNA (shCTL) or shRNA targeting 
PINK1 (shPINK1) were generated and then used to stably infect HEK293T cells. Following 
selection with puromycin, cells were transfected with either PGAM5L or PGAM5S. Stable 
knockdown of PINK1 was then verified by immunoblot analysis, which demonstrated PINK1 
induction 48 h following PGAM5 transfection in control cells but not shPINK1 cells (Figure 
8.4A). 
To test the hypothesis that PINK1 functions within the PGAM5 death pathway, lysates 
were probed for caspase-3, an executioner protease activated by cleavage and functioning at the 
end of cell death signal cascades. Cleavage of caspase-3 was observed when either PGAM5 
isoform was introduced to control cells but not PINK1-deficient cells (Figure 8.4A). This 
suggests that when PGAM5 is overexpressed, PINK1 induction is required for caspase 
activation, therefore implicating PINK1 as a potential death molecule. 
In order to determine if PINK1 is required for PGAM5-mediated cell death, shCTL and 
shPINK1 cells were transfected with PGAM5, and after 48 h harvested and stained with 
propidium iodide followed by viability measurements using flow cytometry. While both 
PGAM5L and PGAM5S exhibited substantial toxicity in control cells, PINK1-deficient cells were 
resistant to PGAM5 toxicity, showing viability levels essentially unchanged relative to control 
(empty) transfected cells (Figure 8.4B). This confirms that PINK1 is required for death when 
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induced by PGAM5, suggesting mitophagy is the cause of PGAM5 toxicity and demonstrating a 
mechanism by which PGAM5 triggers cell death. 
 
Figure 8.4. Both isoforms of PGAM5 trigger cell death by activating PINK1. 
A) HEK293T cells stably infected with either control shCTL sequences or shPINK1 were 
transfected with the indicated plasmids followed by immunoblot with the indicated antibodies. 
NS, nonspecific signal. B) Cells were stained with PI and then assessed for viability levels by 
flow cytometry. Data are presented as average ± standard deviation. 
 
XIAP interacts with PGAM5 and triggers non-productive hetero-oligomerization 
The data above demonstrate that XIAP prevents PGAM5L from activating cell death 
signals (Figure 8.3) and inducing cellular toxicity. This XIAP-mediated inhibition of PGAM5L 
occurs via XIAP E3 ligase activity that ubiquitinates PGAM5L [53]. If XIAP directly 
ubiquitinates PGAM5, an association between the two would be required for XIAP to access the 
ubiquitination target residue(s) of PGAM5. Notably, XIAP has not been demonstrated to affect 
the short isoform in any assays assessed here or previously [53]. This suggests that only the long 
isoform is a target for ubiquitination by XIAP and may explain why XIAP inhibits only 
PGAM5L. 
To determine if XIAP can bind either PGAM5 isoform, cells were transfected with 
PGAM5 isoforms and/or XIAP, followed by coimmunoprecipitation using an anti-HA (PGAM5) 
antibody and subsequent evaluation of FLAG epitope (XIAP) levels. PGAM5L precipitated with 
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XIAP (Fig 8.5A), suggesting a physical association between the two proteins and further 
supporting a role for XIAP as an E3 ligase for PGAM5L. Following precipitation of PGAM5S, 
XIAP was not detected. However, due to the nature of this assay the possibility of a PGAM5S-
XIAP interaction cannot be ruled out. The hydrophobic character of the C-terminal tail of 
PGAM5S reduces extraction levels (Figure 8.5A) from the mitochondrial membrane [53], and 
use of stronger lysis buffers is likely to disrupt protein interactions with PGAM5S. Since XIAP 
neither causes ubiquitination of PGAM5S nor inhibits PGAM5S-mediated toxicity, either XIAP 
does not bind PGAM5S, or binding does not affect PGAM5S signaling capacity.  
XIAP appears to inhibit the long but not short isoform of PGAM5. Interestingly, we and 
others have previously reported that only the long isoform forms homodimers and/or higher 
order oligomers, corresponding to phosphatase activity levels present in PGAM5L but deficient 
in PGAM5S [53, 226] and demonstrating further isoform-specific differences that may be 
differentially regulated by XIAP. Recent biophysical studies have defined multimeric assembly 
mechanisms for PGAM5L [227, 228], which explain the absence of oligomer formation and 
phosphatase activity in the short isoform of PGAM5. Within PGAM5L, the C-terminal tail 
(different in PGAM5S) stabilizes dimer formation, and six PGAM5 dimers subsequently 
multimerize into a dodecameric ring. Dodecamerization then allosterically activates the 
phosphatase by promoting an ordering of the catalytic loop [227]. PGAM5 dodecameric rings 
can polymerize into filamentous structures within cells [228], similar other death effectors 
including DISCs [229] and necrosomes [230]. PGAM5 polymerization does not affect 
phosphatase activity but appears to play a structural role on mitochondrial membranes [228]. 
Based on the exclusivity of PGAM5L oligomerization and inhibition by XIAP, we 
hypothesized that XIAP might impact the multimeric state of PGAM5L.  To test this hypothesis 
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cells were transfected with PGAM5 plasmids containing separate epitope tags as follows: 
PGAM5L-FLAG + PGAM5S-HA, PGAM5L-FLAG + PGAM5L-HA, and PGAM5S-FLAG + 
PGAM5S-HA, with all pairs in the absence or presence of untagged XIAP. 
Coimmunoprecipitation with a FLAG antibody followed by immunoblot for the HA epitope can 
therefore be used to determine if PGAM5 interacts with other PGAM5 molecules. As shown in 
Figure 8.5B, PGAM5L exhibited robust oligomerization, whereas PGAM5S showed no self-
interaction, in agreement with previous work [53]. Overexpression of XIAP did not influence 
homo-oligomerization of either isoform (Figure 8.5B). However, XIAP strongly enhanced 
hetero-oligomerization of PGAM5L with PGAM5S (Fig 8.5B). Since PGAM5S lacks the capacity 
for self-association, it is possible that XIAP-mediated ubiquitination of PGAM5L could increase 
PGAM5S affinity, leading to the formation of a nonproductive hetero-oligomer and therefore 
inhibiting PGAM5L. 
Because the significance of PGAML-PGAM5S binding is unknown, we assessed 
mitophagy and cell death as markers of PGAM5 activity following co-transfection with both 
PGAM5 isoforms. Interestingly, while both isoforms trigger PINK1 stabilization, PINK1 was not 
induced when PGAM5L and PGAM5S were overexpressed together (Figure 8.5C). Since PINK1 
triggers cell death when PGAM5 is overexpressed, cells were then assessed for death levels. In 
agreement with an inability of PGAM5 to induce PINK1 when both isoforms were co-expressed, 
cells did not exhibit toxicity in the presence of both isoforms despite the ability of each isoform 
to kill on its own (Figure 8.5D). Altogether these data suggest that hetero-oligomerization of 
PGAM5L with PGAM5S causes neutralization of both isoforms. Since XIAP promotes this 
interaction, this could provide further insight into how XIAP can inhibit PGAM5-mediated cell 
death.  
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Figure 8.5. XIAP binds PGAM5L and promotes non-productive hetero-oligomerization 
with PGAM5S. 
A, B) HEK293T cells were transfected with the indicated plasmids, lysed, and subjected to co-
immunoprecipitation assay and immunoblot with the indicated antibodies. Data for panel b were 
acquired by A.S. Wilkinson. C) PINK1 levels were assessed by immunoblot of HEK293T cells 
transfected with the indicated plasmids. D) HEK293T cells were transfected with indicated 
plasmids followed by PI staining and flow cytometry. Data are presented as average ± standard 
deviation. 
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XIAP ubiquitinates PGAM5L at lysine residue 285 via a noncanonical linkage 
Collectively the data so far have shown that XIAP suppresses the long isoform of 
PGAM5 through ubiquitin modification. Ubiquitin is a 76-amino acid protein highly conserved 
across species and used by cells to post-translationally modify proteins. Proteins can be either 
mono- or polyubiquitinated, with polyubiquitination occurring through the attachment of 
additional ubiquitin molecules at different lysine residues. Ubiquitin contains 7 lysines (K6, K11, 
K27, K29, K33, K48, K63), all capable of forming covalent bonds with other ubiquitin units, and 
methionine residue 1 (M1) can additionally be used for ubiquitin modification. 
The well-studied canonical ubiquitination mechanism involves covalent attachment of 
ubiquitin resides to lysine units of target proteins, and extension of polyubiquitin chains 
occurring via linkages at lysine 48 (K48) of ubiquitin residues. K48-linked ubiquitination is a 
common signal for proteasomal recognition and subsequent degradation. However, a variety of 
alternative linkages and functions have been identified [231]. A notable example is the case of 
XIAP-mediated ubiquitination of AIF. XIAP binds and ubiquitinates AIF at residue K255, which 
is required for DNA binding. Notably, this ubiquitin modification is not K48-linked and does not 
target AIF to the proteasome. Rather, XIAP-mediated ubiquitination of AIF occurs through a 
non-canonical linkage (probably K27, K33, or M1), and ubiquitination of AIF at K255 prevents 
DNA binding. As a result of this modification, AIF is inhibited from inducing chromatin 
degradation when involved in cell death [50].  
PGAM5L toxicity is suppressed by the ubiquitin ligase activity of XIAP, and XIAP-
mediated ubiquitination of PGAM5L occurs via a non-degradative mechanism [53]. The ability 
of XIAP to modify activity of the PGAM5 binding partner AIF through non-canonical 
ubiquitination led us to question how XIAP modifies PGAM5. In order to identify ubiquitin 
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residues important for XIAP-mediated ubiquitination of PGAM5, cells were transfected with 
PGAM5L, XIAP, and either wild-type (WT) ubiquitin or one of six different ubiquitin point 
mutants (K6R, K11R, K27R, K29R, K48R, K63R) tagged with polyHis. The indicated lysine to 
arginine point mutations retain a positive charge are but incapable of conjugation with other 
ubiquitin molecules. Transfected cells were lysed and subjected to nickel affinity precipitation, 
followed by assessment of PGAM5L ubiquitination by immunoblot. When compared to WT-
ubiquitin, PGAM5L was modified by XIAP to similar levels when K48R-ubiquitin was used 
(Figure 8.6). This suggests that PGAM5L is not significantly modified by canonical K48-linked 
ubiquitination. Similar levels of ubiquitination were also observed with K6R-, K11R-, and 
K63R-ubiquitin (Figure 8.6). Interestingly, XIAP failed to modify PGAM5L with K27R-
ubiquitin or K29R-ubiquitin (Figure 8.6). While K27R-ubiquitin failed to conjugate with 
PGAM5L, it is possible this occurs as a result of structural destabilization of ubiquitin [50]. 
However, data here suggest that XIAP ubiquitinates PGAM5L via alternative linkage(s) that may 
include K27 and/or K29. Altogether these data narrow the range of possible XIAP-mediated 
ubiquitination mechanisms for PGAM5L and add to the list of non-canonical XIAP activities.  
Having shown that XIAP ubiquitinates PGAM5L via an alternative linkage, we next 
questioned the site of ubiquitination within PGAM5L. Both the long and short PGAM5 isoforms 
exhibit high basal levels of ubiquitination, but only PGAM5L is ubiquitinated by XIAP [53]. The 
observation that XIAP does not ubiquitinate PGAM5S prompted us to hypothesize that XIAP 
ubiquitinates PGAM5L at a long isoform-specific position. PGAM5L and PGAM5S are identical 
in sequence from residues 1-239, with PGAM5L containing an additional 50 C-terminal residues 
and PGAM5S containing an additional 16 C-terminal residues. Assessment of PGAM5 primary 
structures revealed 10 lysine residues shared by both isoforms, and 1 lysine residue (K285) 
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unique to PGAM5L located within the C-terminal tail (Figure 8.7). To test the hypothesis that 
XIAP ubiquitinates PGAM5L at K285, nickel pulldown assays were performed using PGAM5L 
K285 mutants. Residue K285 of PGAM5L was mutated either to alanine (A) or arginine (R), 
with the K285A abolishing potential ubiquitin modifications and K285R retaining positive 
charge, allowing us to determine if either ubiquitination or electrostatic properties are involved 
with PGAM5 activity. Nickel pulldown assay revealed that XIAP increases ubiquitination of 
WT-PGAM5L, but does not affect ubiquitination of either PGAM5L K285 mutant (Figure 8.8A). 
Notably, extensive ubiquitination of PGAM5 occurs for both WT and K285 mutants of 
PGAM5L, suggesting other ubiquitination sites exist within PGAM5 that may not be XIAP 
targets. Altogether these data indicate that XIAP ubiquitinates PGAM5L at residue K285. 
 
Figure 8.6. XIAP ubiquitinates PGAM5L via non-canonical linkage(s). 
HEK293T cells were transfected with PGAM5L-HA and polyHis-Ub variants in the absence or 
presence of XIAP and then subjected to precipitation with Ni-NTA agarose followed by 
immunoblot. 
 
XIAP ubiquitinates PGAM5L and inhibits PGAM5L-mediated cell death via its ubiquitin 
ligase activity. Since this modification occurs at residue K285, we then questioned if XIAP 
would fail to prevent PGAM5L toxicity induced by PGAM5L K285 mutants. Cells were therefore 
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transfected with either WT-PGAM5L, K285A-PGAM5L, or K285R-PGAM5L in the absence or 
presence of exogenous XIAP, followed by assessment cell death using propidium iodide 
staining. Both PGAM5L mutants exhibited toxicity levels comparable to WT-PGAM5L (Figure 
8.8B). Interestingly, both PGAM5L K285A and K285R retained capacity to be inhibited by 
XIAP, suggesting XIAP is capable of suppressing PGAM5L through other mechanisms, and/or 
additional factors are involved. 
 
Figure 8.7. Sequences of PGAM5L and PGAM5S. 
Primary structures of PGAM5 isoforms are shown with lysine residues underlined. Residues 
unique to PGAM5S are italicized. Arrow denotes the lysine residue unique to PGAM5L. 
 
10 20         30         40         50         
PGAM5L MAFRQALQLA ACGLAGGSAA VLFSAVAVGK PRAGGDAEPR PAEPPAWAGG 
PGAM5S MAFRQALQLA ACGLAGGSAA VLFSAVAVGK PRAGGDAEPR PAEPPAWAGG
60 70         80         90         100         
PGAM5L ARPGPGVWDP NWDRREPLSL INVRKRNVES GEEELASKLD HYKAKATRHI 
PGAM5S ARPGPGVWDP NWDRREPLSL INVRKRNVES GEEELASKLD HYKAKATRHI
110        120        130        140        150
PGAM5L FLIRHSQYHV DGSLEKDRTL TPLGREQAEL TGLRLASLGL KFNKIVHSSM 
PGAM5S FLIRHSQYHV DGSLEKDRTL TPLGREQAEL TGLRLASLGL KFNKIVHSSM 
160        170        180        190        200
PGAM5L TRAIETTDII SRHLPGVCKV STDLLREGAP IEPDPPVSHW KPEAVQYYED 
PGAM5S TRAIETTDII SRHLPGVCKV STDLLREGAP IEPDPPVSHW KPEAVQYYED 
210        220        230        240        250
PGAM5L GARIEAAFRN YIHRADARQE EDSYEIFICH ANVIRYIVCR ALQFPPEGWL
PGAM5S GARIEAAFRN YIHRADARQE EDSYEIFICH ANVIRYIVCS IPPLLSAGDF
260        270        280 
PGAM5L RLSLNNGSIT HLVIRPNGRV ALRTLGDTGF MPPDKITRS  
PGAM5S VLLGS
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Figure 8.8. XIAP ubiquitinates PGAM5L at residue K285. 
A) HEK293T cells were transfected with polyHis-Ub and PGAM5L variants in the absence or 
presence of XIAP, lysed, and incubated with Ni-NTA agarose followed by immunoblot analysis. 
B) HEK293T cells transfected with PGAM5L variants in the absence or presence of XIAP were 
stained with PI and assessed by flow cytometry. Data are presented as average ± standard 
deviation.  
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XIAP-mediated ubiquitination and inhibition of PGAM5 is facilitated through binding of 
PGAM5 to Keap1 and Bcl-XL 
In an effort to understand why blocking XIAP-mediated ubiquitination does not affect the 
ability of XIAP to rescue cells from PGAM5 toxicity, we then questioned the involvement of 
other factors that may regulate PGAM5 activity. Since the abilities of PGAM5 to bind Keap1 
and Bcl-XL are known to regulate ubiquitination and cell death [212, 213, 232], the roles of 
Keap1 and Bcl-XL in XIAP-dependent suppression of PGAM5 were assessed. Therefore 
PGAM5L binding mutants were generated: mutation of residues E79 and S80 to alanine 
(E79A/S80A) within the Keap1 binding motif impairs Keap1 binding, and mutation of residues 
L135 and G139 to glutamate (L135E/G139E) within a BH3-like motif impairs Bcl-XL binding 
[213]. 
To determine if Keap1 and/or Bcl-XL binding affect the affinity of PGAM5L for XIAP, 
PGAM5L mutants were transfected into HEK293T cells in the absence or presence of GST-
tagged XIAP followed by precipitation with glutathione-conjugated agarose beads. XIAP 
precipitated PGAM5L L135E/G139E, but not PGAM5L E79A/S80A (Figure 8.9A), suggesting 
that PGAM5L must bind Bcl-XL in order to become physically accessible to XIAP. This 
observation agrees with the well-established pro-survival role for Bcl-XL and indicates Bcl-XL 
might promote survival by facilitating XIAP-dependent inhibition of PGAM5. 
In order to evaluate the significance of Bcl-XL and Keap1 binding to XIAP-mediated 
ubiquitination of PGAM5L, PGAM5L mutants were then transfected into cells in the absence or 
presence of XIAP with polyHis-ubiquitin followed by nickel pulldown assay. Since Bcl-XL 
binding is required for XIAP to bind PGAM5L, the L135E/G139E PGAM5L mutant expectedly 
exhibited low ubiquitination levels despite XIAP overexpression (Figure 8.9B). Strikingly, 
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impairment of PGAM5L binding with Keap1 additionally suppressed the ability of XIAP to 
ubiquitinate PGAM5L (Figure 8.9B). This indicates that association of PGAM5 with Bcl-XL and 
Keap1 is required for XIAP to ubiquitinate PGAM5. It is likely that Bcl-XL stabilizes the XIAP-
PGAM5L interaction, and binding of PGAM5L with Keap1 (notably an adaptor for protein 
ubiquitination) is required for XIAP to ubiquitinate PGAM5L. 
Having found that PGAM5L interactions with Keap1 and Bcl-XL are required for XIAP 
to ubiquitinate PGAM5L, we then tested the ability of XIAP to inhibit PGAM5L-dependent cell 
death when Keap1 and Bcl-xL binding to PGAM5L are impaired. Cells were transfected with 
PGAM5 mutants and/or XIAP, followed by viability measurements. In agreement with the 
observations that XIAP does not ubiquitinate PGAM5L E79A/S80A or PGAM5L G135E/L139E, 
XIAP similarly failed to prevent these mutants from inducing toxicity (Figure 8.9C). Overall 
these data suggest that endogenous Keap1 and Bcl-xL inhibit PGAM5L through binding and 
facilitating ubiquitination by XIAP. Additionally, since mutating the ubiquitation target lysine 
285 of PGAM5L does not affect the ability of XIAP to suppress cell death, it appears that 
PGAM5L associations with Keap1 and Bcl-XL, as well as PGAM5L ubiquitination by XIAP, are 
simultaneous requirements for XIAP to block PGAM5L death induction. 
PGAM5 phosphatase activity confers resistance to XIAP 
The above data indicate that binding of PGAM5 with Keap1 and Bcl-XL do not affect the 
ability of PGAM5 to kill, but are required for XIAP-mediated inhibition of PGAM5L. Since we 
have also observed that the phosphatase activity of PGAM5 is not essential for toxicity, we 
questioned if PGAM5L phosphatase activity exhibits an involvement with XIAP, similar to 
Keap1/Bcl-XL binding. 
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Figure 8.9. XIAP-mediated inhibition of PGAM5L requires PGAM5L binding with Keap1 
and Bcl-XL . 
A) HEK293T cells were transfected with the indicated plasmids , lysed, and incubated with 
glutathione-agarose followed by immunoblot. B) HEK293T cells were transfected with polyHis-
Ub and PGAM5L variants in the absence or presence of XIAP and subjected to affinity 
precipitation using Ni-NTA agarose followed by immunoblot. C) HEK293T cells transfected 
with PGAM5L variants in the absence or presence of XIAP were stained with PI and assessed by 
flow cytometry. Data are presented as average ± standard deviation.  
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Mutation of H105 to alanine within the PGAM domain of PGAM5 renders the protein 
catalytically inactive [211], and the PGAM5 H105A mutant can therefore be used to assess the 
role of PGAM5 phosphatase activity upon XIAP-regulated cell death. Interestingly, co-
precipitation of PGAM5L with XIAP revealed substantially increased XIAP binding when 
PGAM5 phosphatase activity was abolished (Figure 8.9A), suggesting that the phosphatase 
activity of PGAM5 inhibits association with XIAP. Based on this observation, we then 
questioned if PGAM5L H105A exhibits altered XIAP-dependent ubiquitination due to increased 
binding. To test this hypothesis polyHis-tagged ubiquitin was precipitated with Ni-NTA agarose 
following co-transfection with PGAM5L H105A and XIAP. When compared with WT-PGAM5L, 
the PGAM5L phosphatase mutant displayed strongly increased levels of ubiquitination both 
under basal conditions and following overexpression of XIAP (Figure 8.10A). Altogether these 
data suggest that the phosphatase activity of PGAM5 blocks interaction with XIAP, conferring 
resistance to XIAP-mediated ubiquitination. 
PGAM5L H105A is more susceptible to XIAP binding and ubiquitination that WT-
PGAM5L, prompting the hypothesis that PGAM5L phosphatase activity regulates the ability of 
XIAP to block cell death. Cells transfected with PGAM5L variants and/or XIAP were subjected 
to propidium iodide staining and flow cytometry, followed by evaluation of extents of XIAP-
mediated rescue from cell death. In agreement with an increased ability of XIAP to bind and 
ubiquitinate PGAM5L H105A, XIAP protected cells at magnitudes of >1.5x more than WT-
PGAM5L (Figure 8.10B) despite equivalent levels of protein overexpression (data not shown). 
Collectively these data suggest that PGAM5 can trigger cell death in part through phosphatase-
mediated neutralization of XIAP. 
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Figure 8.10. The phosphatase activity of PGAM5L protects against XIAP ubiquitination 
and inhibition. 
A) HEK293T cells were transfected with polyHis-Ub and PGAM5L variants in the absence or 
presence of XIAP, lysed, and subjected to Ni affinity precipitation followed by immunoblot. B) 
HEK293T cells were transfected with PGAM5L variants in the absence or presence of XIAP 
followed by PI staining and flow cytometry. Percent rescue is defined by the percent difference 
in viability between PGAM5+XIAP and PGAM5 only. Data are presented as average ± standard 
deviation.   
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PGAM5 prevents XIAP from protecting cells, but how XIAP activity is suppressed by 
PGAM5 remains unclear. One possibility is that PGAM5 inhibits XIAP auto-ubiquitination, a 
self-regulatory mechanism leading to degradation [48, 206]. XIAP self-ubiquitination has been 
studied in vitro [206], but has not been assessed within cells. Therefore cells transfected with 
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denaturing conditions of urea lysis buffer used make post-lysis ubiquitination artifacts unlikely. 
Immunoblot analysis of nickel precipitate revealed extensive ubiquitination of WT-XIAP, but 
not XIAP H467A (Figure 8.11A). This suggests that the E3 ligase activity of XIAP is required 
for its own ubiquitination, indicative of a potential target for PGAM5 (explored below). 
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Although XIAP induces its own ubiquitination and degradation, it is unknown if XIAP 
can self-ubiquitinate using ubiquitin linkages that do not signal for degradation. Because XIAP 
can ubiquitinate PGAM5 and AIF through non-K48 linkages, it is possible XIAP could also 
mediate its own activity through alternative signaling-related ubiquitination mechanisms. Cells 
were transfected with XIAP and polyHis-tagged ubiquitin variants K6R, K11R, K27R, K29R, 
K48R, and K63R and then assessed for XIAP ubiquitination. Interestingly, all ubiquitin variants 
conjugated to XIAP except for the K27R variant (Figure 8.11B), which may be structurally 
unstable [50]. This indicates that XIAP exhibits flexibility in ubiquitin linkage mechanisms and 
can be polyubiquitinated potentially through mixed linkages. Since these linkages do not induce 
protein degradation, it is possible XIAP may control its own activity levels through such a 
mechanism. This non-canonical ubiquitination is similar to AIF and PGAM5, which are targets 
of XIAP [50, 53]. 
  
Figure 8.11. XIAP auto-ubiquitinates via mixed non-canonical linkages. 
A) The indicated plasmids were transfected into HEK293T cells with polyHis-Ub followed by 
lysis and nickel affinity precipitation assay. Samples were then assessed by immunoblot. B) 
XIAP-FLAG was transfected into HEK293T cells in the absence or presence of the indicated 
polyHis-Ub variants followed by lysis, nickel affinity precipitation assay and immunoblot. 
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PGAM5 phosphatase activity inhibits XIAP dimerization and ubiquitination 
Data presented so far indicate that XIAP regulates PGAM5 through ubiquitination, and 
that the phosphatase activity of PGAM5 can neutralize this inhibition by preventing XIAP 
binding. Based on this ability of PGAM5 to resist XIAP, we wondered if PGAM5 is capable of 
regulating XIAP. Since XIAP regulates PGAM5L through binding and non-canonical 
ubiquitination, this raised the question of whether PGAM5 can act upon XIAP in a similar 
manner. Specifically, can PGAM5 control non-canonical XIAP autoubiquitination? 
To explore this possibility, cells were transfected with GST-tagged XIAP and FLAG-
tagged XIAP in the absence and presence of PGAM5 isoforms. Transfection with two differently 
tagged XIAP plasmids allows co-precipitation assays that can assess self-association of XIAP 
molecules. Following precipitation with glutathione beads, FLAG epitope was present in 
precipitated material (Figure 8.12A), suggesting dimerization that is consistent with previous 
reports [48, 206]. This dimerization was impaired when either isoform of PGAM5 was 
overexpressed (Figure 8.12A), indicating that both PGAM5 isoforms can block dimerization of 
XIAP. 
Since PGAM5 blocks XIAP dimerization, this loss of self-association may lead to a 
decrease in ubiquitination. Moreover, since PGAM5L phosphatase activity protects against 
XIAP-mediated inhibition (Figure 8.10), we hypothesized that the phosphatase activity of 
PGAM5 serves to regulate XIAP activity. Nickel affinity pulldown with polyHis-tagged 
ubiquitin was used to determine the extent of XIAP ubiquitination following the introduction of 
PGAM5 variants. Introduction of either PGAM5 isoform abolished XIAP ubiquitination almost 
completely (Figure 8.12B). Interestingly, PGAM5L H105A fully restored ubiquitination (Figure 
8.12C), strongly suggesting that the phosphatase activity of PGAM5L inhibits ubiquitination of 
 191 
XIAP. Since PGAM5S exhibits very low catalytic activity relative to PGAM5L [53], it is 
particularly notable that PGAM5S H105A partially restored XIAP ubiquitination (Figure 8.12C). 
Given the reduced phosphatase activity of PGAM5S, the observation of any laddering with 
PGAM5S H105A overexpression suggests a high potency of PGAM5 phosphatase activity 
towards XIAP. However, since restoration of ubiquitination by PGAM5S H105A was incomplete 
(Figure 8.12C), PGAM5S is likely to inhibit ubiquitination through other mechanisms and 
indicates that PGAM5L and PGAM5S can function differently within cells. Altogether these data 
show that PGAM5 blocks dimerization and non-canonical autoubiquitination of XIAP, 
suggesting a possible mechanism through which PGAM5 can kill cells. 
The PGAM5-XIAP axis controls cell fate in embryonic fibroblasts 
Experiments so far have shown that PGAM5 and XIAP control cell death through mutual 
antagonism when overexpressed in HEK293T cells. However, the significance of the PGAM5-
XIAP axis to death induction in other cell types and its physiological relevance remain unknown. 
Therefore the roles of PGAM5 and XIAP in cell death control were assessed in mouse 
embryonic fibroblasts (MEFs). 
To test the PGAM5-XIAP axis in MEFs, PGAM5 was overexpressed in the context of 
XIAP loss in order to determine if PGAM5 toxicity is associated with endogenous levels of 
XIAP. While PGAM5S has been identified as an alternative splice variant of the PGAM5 gene, it 
has not been identified at the protein level in cells; whether endogenous PGAM5S protein exists 
remains an open question. Therefore the long isoform of PGAM5 was assessed. MEFs derived 
from wild-type and XIAP knockout mice have been reported previously [225]. Lentiviral vectors 
were generated and then used to deliver PGAM5L into XIAP-proficient and deficient cells 
(Figure 8.13A). Consistent with experiments in HEK293T cells, overexpression of PGAM5L in 
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MEFs induced substantial quantities of cell death (Figure 8.13B). Moreover, XIAP-deficient 
cells exhibited greater sensitivity to PGAM5L (Figure 8.13B), demonstrating that XIAP inhibits 
PGAM5L in MEFs. 
 
Figure 8.12. PGAM5 phosphatase activity inhibits XIAP dimerization and ubiquitination. 
A) HEK293T cells were transfected with the indicated plasmids, lysed, and incubated with 
glutathione beads followed by immunoblot with the indicated antibodies. B, C) HEK293T cells 
were transfected with polyHis-Ub and the indicated plasmids, lysed, and subjected to nickel 
affinity precipitation followed by immunoblot. 
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Figure 8.13. The PGAM5-XIAP axis controls cell fate in MEFs. 
A) Immortalized wild-type (WT) and XIAP-null (KO) MEFs [225] were infected with 
lentiviruses harboring either an empty cassette or PGAM5L, lysed, and assessed for the indicated 
proteins by immunoblot. B) WT and KO MEFs were infected with either an empty lentivirus or 
lentivirus harboring PGAM5L, stained with PI and assessed for viability by flow cytometry. C) 
Surviving WT and KO MEFs that stably express either empty vector or PGAM5L were left 
untreated or treated with arsenic trioxide (ATO) followed by PI staining and flow cytometry. 
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PGAM5 has been linked to control of apoptosis, necroptosis, and mitophagy, leading to 
both death and survival outcomes [215-220]. Since a variety of death and pro-survival roles for 
PGAM5 have been reported, we questioned how PGAM5 and XIAP influence cell fate in cells 
that are resistant to PGAM5 toxicity. Therefore XIAP-proficient and deficient cells were stably 
infected with lentiviruses harboring PGAM5L. As expected PGAM5L induced substantial 
toxicity that was exacerbated by loss of XIAP, but cells that survived were further cultured to 
derive cell lines stably expressing PGAM5L. 
Following the derivation of cells stably overexpressing PGAM5L, cell death was induced 
by arsenic trioxide (ATO), an oxidative stress agent that triggers apoptosis but can also prompt 
necrosis and mitophagy [233-235]. When cells were treated with ATO, PGAM5 protected cells 
in the presence of XIAP, but not in XIAP-deficient cells (Figure 8.13C). Interestingly, this 
suggests that in this context PGAM5 promotes survival by acting upon XIAP. Altogether, these 
data demonstrate alternative activities for PGAM5 that depend on cell context/stimulus and 
XIAP, highlighting the multifunctional nature of PGAM5. 
Discussion 
PGAM5 and XIAP regulate PINK1-dependent mitophagic cell death 
Altogether this study outlines mechanisms through which both isoforms of PGAM5 
induce cellular toxicity and their inhibition by XIAP. PGAM5 and XIAP exhibit an antagonistic 
relationship involving non-canonical ubiquitination. The inhibitory nature of PGAM5 and XIAP 
extends to MEFs and appears to control decisions of cell fate depending on stimulus and intrinsic 
sensitivity to PGAM5 activity. 
While both PGAM5 isoforms induce cell death via PINK1 stabilization, XIAP is capable 
of suppressing the long but not short isoform of PGAM5. This is likely because PGAM5S lacks a 
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key lysine residue within the PGAM5L C-terminal tail that is targeted by XIAP when PGAM5 
binds Keap1 and Bcl-XL.  
The PGAM5-XIAP axis defines cell death and survival mechanisms 
Both isoforms of PGAM5 suppress XIAP dimerization and non-canonical ubiquitination, 
suggesting that PGAM5L and PGAM5S can regulate XIAP activity. PGAM5-mediated 
suppression of XIAP is dependent upon the phosphatase activity of PGAM5L, but likely involves 
other factors when suppressed by PGAM5S activity. The PGAM5-XIAP axis is confirmed with 
PGAM5L overexpression in MEFs: acute upregulation of PGAM5 induces cell death that is 
inhibited by XIAP, whereas long-term overexpression of PGAM5 protects cells from ATO 
through an XIAP-dependent mechanism. Interestingly, other studies have indicated roles for 
PGAM5 in both cell death and survival through mechanisms involving mitophagy and 
necroptosis [215-220]. These disparate findings may be explained by experiments presented 
here, which show that XIAP and PGAM5 serve to balance cell death and survival, inducing 
different cell fate outcomes in response to different stimuli. 
XIAP can autoubiquitinate through a variety of non-canonical linkage types that may 
regulate its own different activities. Similarly, XIAP ubiquitinates PGAM5 through a non-
degradative mechanism, raising the possibility that XIAP may regulate PGAM5 activity, binding 
partners, localization, etc. Since XIAP and PGAM5 regulate each other, these potential 
mechanisms may explain how the XIAP-PGAM5 axis mediates different cellular functions. It is 
notable that XIAP is often upregulated in cancer as a pro-survival protein, contributing to 
aggressiveness and therapeutic resistance. Small molecules targeting XIAP in cancer have shown 
some therapeutic potential and are used as a unique tool for studying the death pathway known 
as necroptosis (Appendix C). The involvement of the XIAP-PGAM5 axis in cancer cell death 
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and survival and their intersection with molecular targeting techniques represent significant 
future directions. 
Summary 
Overall this study shows that the interaction of AIF with PGAM5 serves to protect AIF 
from XIAP-mediated ubiquitination, and defines additional routes through which PGAM5 and 
XIAP further regulate one another in cell death associated with PINK1-dependent mitophagy. 
Therefore these studies add to the growing list of cell death signaling pathways and reveals novel 
mechanisms by which cells control death vs. survival through the XIAP-PGAM5 axis. 
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IX. SUMMARY AND CONCLUDING REMARKS 
AIF survival activity benefits tumorigenesis 
AIF was initially characterized for its role in caspase-independent cell death and once 
thought to function primarily as a death signaling molecule [24]. However, accumulating 
evidence indicates that an essential role for AIF in cell death is cell type and context-specific 
[55-58]. Independent of a role in cell death, AIF possesses an intrinsic NADH-oxidase activity 
[60]. The mechanisms through which AIF enzymatic activity operates in cells are largely 
enigmatic, but demonstrated to play an essential role in cellular metabolism and redox control. 
AIF exhibits a predominant role in promoting survival and homeostasis in healthy cells through 
the regulation of mitochondrial metabolism and redox balance, with loss or mutation of AIF 
leading to a variety of mitochondrial disorders observed in mice and humans [26, 62-68]. AIF 
exerts control of mitochondrial activity through the regulation of ETC protein subunits, 
metabolic flux, and cellular redox state [73]. 
AIF is required for normal mitochondrial function and homeostasis in healthy cells, and 
this role is poised to benefit cancer cell growth and survival. The rapid proliferation and 
aggressiveness exhibited by tumor cells demands a significant rewiring of both metabolism and 
oxidative stress signaling. These tumorigenic processes may be supported by the pro-survival 
activities of AIF in metabolism and redox balance. Indeed, AIF is upregulated at the RNA and 
protein levels in a variety of cancers relative to normal cells [51, 52, 83-88], indicating a 
potentially tumorigenic function. The work of Urbano et al. [54] was the first to demonstrate a 
pro-tumor role for AIF in colorectal cancer, showing that the enzymatic activity of AIF protects 
cancer cells from chemotherapeutic agents and is required for tumorigenic growth. 
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The work of our laboratory then demonstrated a contributory role for the enzymatic 
activity of AIF to prostate tumorigenesis [51]. Transcript levels of AIF are elevated in PCa 
relative to normal prostatic tissues, indicating a potential role in PCa pathogenesis. AIF protein 
levels increase with progression of PCa, and knockdown of AIF suppresses tumorigenesis both 
in vitro and in vivo in advanced but not early-stage PCa cells. This indicates that AIF is a 
significant factor for the progression of PCa to advanced stage and is required for the growth and 
aggressiveness of advanced PCa cells. Moreover, changes in cell growth and survival following 
AIF ablation are accompanied by metabolic changes that are indicative of a metabolic switching 
event from OXPHOS to glycolysis as a predominant source of ATP production. Importantly, 
aggressiveness and metabolism of PCa cells are restored by WT-AIF, but not the enzymatically 
deficient TVA-AIF mutant. Altogether these findings strongly suggest that the enzymatic activity 
of AIF mediates mitochondrial metabolism supporting the growth and survival of advanced PCa 
cells. 
With a tumorigenic role for AIF established, several questions surrounding the 
mechanisms of AIF activity in cancer arose, and the breadth of AIF pro-tumor activity across 
cancer types remained to be determined. Why and how does AIF promote mitochondrial 
metabolism in some cell types but not others? With a metabolic role for AIF demonstrated in 
PCa, the redox role of AIF in cancer cells (and normal cells) was unaddressed. Therefore the 
work presented in Chapters 3-7 sought to determine both the metabolic and redox impacts of AIF 
and their integration across cell types. 
A spectrum of AIF-dependent metabolic effects in PDAC 
Exploration of the intersection of abnormal metabolism and tumorigenesis (Chapter 2) 
led to the striking finding that MIA PaCa-2 PDAC cells are capable of being metabolically 
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reconditioned from a glycolytic to OXPHOS-dependent phenotype. Rather than exhibiting 
mitochondrial impairment as Warburg hypothesized [74], cells appear to intentionally 
downregulate mitochondrial activity. Notably, under conditions of altered metabolic 
requirements cells can adapt by increasing mitochondrial metabolism. Remarkably, this 
metabolic adaptation is reversible but triggers persistent therapeutic resistance, demonstrating the 
paramount importance of metabolism to tumorigenesis. 
Assessment of AIF metabolic activity in the context of PDAC (Chapter 3) revealed an 
important role for AIF-dependent metabolism in pancreatic tumorigenesis. PDAC cell types 
(PANC-1, BxPC-3, HPAC, HPAF-II, MIA PaCa-2) were selected for their diversity of metabolic 
requirements [100]. Stable knockdown of AIF in PDAC cells induced the loss of complex I and 
an increase in glucose uptake, similar to the effects of AIF ablation in PCa cells. Loss of AIF in 
PDAC cells additionally impaired cell growth both in vitro and in Matrigel™ substrate, which 
correlated to metabolic changes observed (complex I levels, glucose consumption, sensitivity to 
2-deoxyglucose). 
Similar to the observations of AIF ablation in PCa, not all PDAC cell types exhibited 
metabolic changes. Interestingly, there appears to be a continuum of metabolic sensitivities to 
AIF ablation that was not identified in PCa. PANC-1 and BxPC-3 cells exhibit changes in both 
growth and metabolism when AIF is suppressed. HPAC cells show changes in metabolism and 
growth, but retain enough metabolic flexibility to survive glycolytic inhibition. HPAF-II cells do 
not exhibit substantial metabolic changes until introduced to Matrigel™ substrate. MIA PaCa-2 
cells show no change in either metabolism or growth following AIF ablation. The spectrum of 
sensitivities to AIF ablation is distinct from observations in PCa, in which cells exhibited A) 
changes in both metabolism and growth, or B) no changes in either metabolism or growth. 
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One explanation for the differences between AIF ablation sensitivity in PCa and PDAC 
may simply be the evaluation of only 3 cells types in PCa vs. 5 cell types in PDAC. A more 
likely explanation is the greater metabolic addiction in PDAC cells vs. PCa cells. Relative to 
other cancers, PDACs often encounter more demanding in vivo metabolic constraints that stem 
from hypovascular and fibrotic microenvironments leading to hypoxia and limited nutrient 
availability [76, 102]. Moreover, PDACs exhibit increased crosstalk with whole-body metabolic 
conditions that lead to additional metabolic signals within tumors. PDAC development is 
influenced by pathological environments such as type II diabetes and obesity, and can also 
trigger further metabolic dysregulation leading to cachexia and diabetes [102]. As a result of this 
more metabolically elaborate setting, AIF is likely to function differently in PDAC when 
compared with PCa. Moreover, AIF may be more important to growth and survival of PDAC 
than PCa. This idea is supported by greater metabolic changes in PDAC and the observation that 
growth is impaired in vitro when AIF is suppressed; in PCa growth rates following AIF ablation 
are unaffected until introduction to growth stress in Matrigel™ or in vivo. 
The stringent metabolic requirements for the survival and growth of PDAC cells makes 
the setting of PDAC an ideal system for studying the role of AIF in different metabolic 
environments and evaluating phenotypes when AIF-dependent metabolic requirements are not 
met (e.g., glucose consumption, growth). PDAC cell types have recently been categorized into 
metabolic subtypes [100] including OXPHOS-dependent and glycolytic subtypes. It is notable 
that complex I is dependent upon AIF only in OXPHOS-dependent cells, suggesting that AIF 
responds to metabolic cues in order to promote ETC stability. The types of signals (e.g., 
NAD
+
/NADH ratios, oxygen availability, ΔΨm) that could influence AIF-mediated complex I 
control remain to be determined. 
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While much work remains in establishing how AIF controls the ETC, Chapter 4 identifies 
a significant role for AIF in mediating translation of mitochondria-encoded genes. AIF interacts 
with both the mitochondrial translation factor TUFM and the MRPL18 subunit of the 
mitoribosome, facilitating their essential interactions with each other. Further, ablation of either 
AIF or TUFM triggers the loss of both mitochondria- and nuclear-encoded ETC protein subunits, 
demonstrating a possible mechanism by which AIF controls the respiratory chain and links the 
extra-mitochondrial environment with mitochondrial activity. 
Altogether experiments of AIF activity in PDAC cells demonstrate an important role for 
AIF in promoting pancreatic tumorigenesis. Importantly, the range of AIF-dependent growth 
changes corresponds to the magnitudes of metabolic sensitivities to AIF ablation. The correlation 
of AIF-mediated metabolic control with cellular energy preferences indicates a possible 
responsiveness of AIF to metabolic requirements, thus expanding our understanding of AIF 
activity in control of mitochondrial metabolism and disease. 
AIF enzymatic activity exhibits control of cellular ROS and redox signals  
The enzymatic activity of AIF promotes homeostasis in normal cells [73] and can be used 
by a variety of cancer cell types to promote a tumor permissive metabolic state supporting 
aggressive phenotypes [51, 52, 54]. The enzymatic activity of AIF has additionally been shown 
to produce ROS in vitro [60], but the in vivo significance of AIF-mediated ROS control has 
remained poorly understood. Chapter 5 of this work assesses the ability of AIF to regulate ROS 
levels in PC3 and HeLa cells, showing for the first time that AIF enzymatic activity is required 
for cells to increase ROS levels in response to oxidative stress triggers. Interestingly, AIF 
appears to control different ROS types depending on cell type, but in both cases AIF ablation 
protects cells from oxidative stress-induced cell death. Given the selective nature of AIF-
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mediated cell death, it is interesting that AIF is required for cell death under heightened oxidative 
stress levels. Since AIF enzymatic activity increases ROS levels in cells, it is likely that AIF-
mediated cell death is actually due to AIF-dependent increases in cellular ROS and not nuclear 
translocation of AIF. 
We additionally show for the first time that through control of redox signaling, AIF is 
capable of regulating nuclear gene expression. Nuclear accumulation of the antioxidant 
transcription factor Nrf2 is dependent upon AIF in HeLa cells but not PC3 cells, which may be 
due to different types and/or levels of AIF-mediated ROS between cell types. In both cell types 
AIF ablation leads decreased levels of a variety of antioxidant transcript levels under both basal 
conditions and oxidative stress stimulation, with several transcripts showing increases that are 
confirmed at the protein level. Altogether these data suggest that AIF-mediated ROS induce 
nuclear responses. 
AIF redox signaling promotes a JNK1-mediated cadherin switch that determines decisions 
of cell fate 
Following the findings that AIF enzymatic activity promotes cellular redox signaling, we 
then questioned the ability of AIF to influence other redox sensitive pathways, focusing on the 
MAPK family of proteins. AIF suppresses DUSP4, an endogenous inhibitor of MAPKs, leading 
to MAPK phosphorylation and activation. The ability of AIF to control JNK-mediated signaling 
events in a variety of cell types was then explored. In Chapter 6 we show that via an oxidative 
stress mechanism, AIF signals JNK1 to induce the cadherin switch and promote cell survival. 
We additionally report the finding of other AIF-dependent EMT genes that are independent of 
JNK activation. These findings reveal a novel function for AIF and confirm its role as a pivotal 
redox signaling molecule (Figure 9.1). 
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Figure 9.1. AIF-mediated control of metabolism and redox signaling in tumorigenesis. 
AIF mediates control metabolism in part by regulating ETC/OXPHOS within the mitochondria. 
Distinct from this metabolic function, AIF enzymatic activity promotes extra-mitochondrial 
redox signals regulating a variety of pathways. 
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Interestingly, loss of AIF induces apoptosis in Matrigel™ substrate, and levels of 
apoptosis significantly increase when E-cadherin levels are reversed (Figure 9.2). This shows 
that AIF suppresses apoptosis, which sharply contrasts its initial characterization and namesake. 
Although less rigorously assessed, we also find that AIF mediates metabolic signaling (Chapters 
4, 6). Specifically, AIF ablation leads to increased levels of the oncogenic regulator of 
metabolism c-Myc and upregulation of a variety of glycolysis enzymes. AIF ablation 
additionally impairs phosphorylation of the metabolic signaling molecule AMPK, and 
knockdown of E-cadherin further inhibits AMPK phosphorylation. An established function of 
AMPK is the regulation of cellular glucose uptake levels, which increase following AIF 
knockdown but do not further change with knockdown of E-cadherin (Chapter 6). This suggests 
that increased apoptosis with dual AIF/E-cadherin knockdown is due to an imbalance of 
metabolism and pro-tumor signaling. 
Functional dissociation of AIF-mediated metabolism and redox signaling 
Chapter 7 assesses the relationship of AIF-mediated metabolism with redox signaling. 
Remarkably, the abilities of AIF to promote mitochondrial metabolism and oxidative stress 
signaling are functionally uncoupled (Figure 9.1), and AIF-mediated control of JNK and E-
cadherin are not due to AIF-dependent complex I activity. While AIF-mediated regulation of 
complex I is cell type specific, AIF-dependent promotion of JNK signaling is widespread and 
occurs independently of complex I levels. JNK phosphorylation, but not complex I, is dependent 
upon the enzymatic activity of AIF in all cell types assessed. Additionally, replacement of 
impaired complex I with yeast NDI1 restores metabolism, but not JNK phosphorylation or E-
cadherin levels in AIF-deficient cells. 
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Figure 9.2. Effects of AIF and E-cadherin on signaling and decisions of cell fate. 
AIF promotes JNK1 activity by transmitting extra-mitochondrial redox cues leading to the 
suppression of E-cadherin and promotion of the cadherin switch. When AIF is suppressed, JNK1 
activity is decreased and E-cadherin levels subsequently increase, leading to impaired growth 
and apoptosis. When E-cadherin is suppressed, AIF-deficient cells undergo apoptosis due to 
unrestrained growth with metabolic demands that cannot be met without AIF. 
AIF association with cell death regulators XIAP and PGAM5 
AIF pro-survival activity is dissociable from its roles in cell death. In addition to 
determining how AIF promotes tumorigenesis through control of cellular metabolism and 
oxidative stress signaling, we also assessed the involvement of AIF with atypical cell death 
pathways through interactions with XIAP and PGAM5. While AIF is not typically pivotal for the 
cell to die (Chapter 3), under certain circumstances alternative death pathways are necessary, and 
through XIAP and PGAM5 activities AIF may regulate these cell death signaling events. 
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AIF is protected from XIAP-mediated ubiquitination by interaction with PGAM5, 
suggesting roles for PGAM5 in mediating alternative cell death mechanisms. Indeed, 
experiments in Chapter 8 demonstrate that PGAM5 induces toxic mitophagy that requires PINK1 
and can be suppressed by noncanonical XIAP-mediated ubiquitination. Further, PGAM5 can 
promote cell death by neutralizing the prosurvival activities of XIAP. Collectively these data 
demonstrate the existence of a novel AIF-XIAP-PGAM5 axis that regulates decisions of cell 
fate. 
Conclusion 
Overall, experiments presented here underscore the role of AIF in mediating the balance 
of cell death and survival and its dysregulation in cancer. We and others have demonstrated that 
in addition to its nuclear activity in cell death, AIF controls mitochondrial energy production by 
regulating respiratory chain protein levels while its NADH-oxidase activity functions as a redox 
conduit that senses and responds to the metabolic and oxidative environment. The unification of 
metabolism, oxidative stress, MAPK signaling, and the cadherin switch by AIF activity raises 
numerous possibilities that include roles in normal physiology, development, redox balance, and 
disease. Altogether we demonstrate a cellular role for AIF-mediated catalysis and the existence 
of AIF-dependent redox pathways (Figure 9.1) that can be uncoupled from ETC control, 
implicating AIF as a fundamental control point for cell signaling and homeostatic regulation. 
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APPENDIX A. CELL DEATH MECHANISMS: AN OVERVIEW 
Cell death and cancer 
Cancer is one of the leading causes of death in the world, arising when cells accumulate 
genomic mutations that render them incapable of controlling their own proliferation. The 
inability of cancer cells to properly regulate their division cycles and their capabilities of 
therapeutic resistance are often due to impairment of cell death, a critical process in multicellular 
organisms. 
As a fundamental requirement for biological homeostasis, cellular death systems serve to 
remove cells that are old, unwanted, damaged, and/or defective. Although many distinct death 
pathways have been defined in various cell types and contexts, cell death is traditionally 
classified into three broad categories: apoptosis (type I or heterophagy), autophagy (type II), and 
necrosis (type III) [11]. Cell death promotes proper organismal development and the prevention 
of disease through a wide variety of biochemical mechanisms and contexts. 
In cancer, the dysregulation of these processes leads to invasiveness and resistance to 
treatment. Therefore developing methods to reactivate death pathways in tumor cells is an 
attractive pharmacological goal, both as a primary method of eliminating cancer cells as well as 
sensitizing them to other therapeutics. 
Cell death types 
Apoptosis 
Type I cell death, the most common and well-studied type of cell death known as 
apoptosis (Greek, "falling away"), was named for the characteristic morphology of cells 
condensing and breaking into smaller apoptotic bodies that are phagocytosed by neighboring 
cells [12]. In contrast to premature or accidental cell death (necrosis), the quiet incorporation of 
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apoptotic bodies into phagocytes allows immune evasion without inducing inflammation [13]. 
Biochemical hallmarks of apoptosis include the activation of pro-apoptotic Bcl-2 protein family 
members and  caspases, permeabilization of the mitochondrial membrane, flipping of 
phosphatidylserine membrane lipids, high ROS levels, DNA fragmentation and degradation, and 
rupture of the cell membrane [14]. Apoptosis is a routine event in multicellular organisms (>1 
million cells per second in humans), promoting normal development (e.g., organ morphogenesis 
and lymphocyte maturation) and eliminating diseased cells, e.g., those infected with pathogens or 
that have accumulated irreparable and potentially tumorigenic mutations [15, 16]. However, 
many cancer cells contain defects or deletions of pro-apoptotic genes and/or upregulated or 
mutationally activated anti-apoptotic genes, leading to therapeutic resistance. 
Autophagic cell death 
Type II cell death, or autophagic death, is defined by characteristic autophagic vacuoles 
in dying cells [236]. Similar to apoptosis, autophagic death does not induce an immune response 
[237].  Autophagy is normally a survival mechanism in response to starvation, stress, or the 
invasion of pathogens. In this tightly regulated catabolic process, eukaryotic cells recycle their 
internal components by degrading macromolecular structures. When autophagy occurs, 
components of the cytoplasm (damaged or excess organelles, macromolecular structures, or 
pathogens) are isolated and sequestered into membrane-bound vacuoles called autophagosomes. 
Autophagosomes then fuse with lysosomes to form autolysosomes, which degrade their contents 
using lysosomal hydrolases [238-240]. While autophagy is an important pathway for cellular 
homeostasis and survival, uncontrolled autophagy can result in death. Unlike apoptosis, cells 
undergoing autophagic death exhibit an abundance of autophagic vacuoles and die independently 
of caspase activation. Currently it is unknown whether autophagy is the cause of death in these 
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cells or an attempt to survive [241]. In cancer, autophagy is considered a double-edged sword; 
while the altered metabolic state and associated signaling pathways are tumor-suppressive by 
nature, some advanced tumors may rely on autophagy to survive [242]. 
Necroptosis 
Distinct from apoptosis and autophagy, necrosis is a premature, accidental, and most 
often detrimental form of cell death. Unlike apoptosis but similar to autophagy, necrosis is 
caspase-independent. Characterized by organelle swelling, membrane rupture, and spillage of 
cellular contents into the extracellular space, necrosis results in inflammation [243]. While 
necrosis has long been viewed as a chaotic type of death that is not genetically programmed in 
the cell, a substantial body of research has begun to show that necrosis can be a structured 
process in some situations [244]. Programmed necrosis, or "necroptosis," can occur as a backup 
form of death when the execution of apoptosis is not possible. Necroptosis is thought to function 
as an anti-viral response system that is carried out when caspases are inhibited or inadequate for 
cell death [245]. By triggering necroptosis, infected cells can call on the immune system for 
assistance in clearing the infection [244]. As a failsafe form of cell death, necroptosis has 
anticancer potential, and defective necroptosis signaling pathways have been observed in a 
number of tumor specimens [246-248]. However, like autophagy, necroptosis also has the 
potential to support cancer. In contrast to the altered metabolic state associated with autophagy, 
necroptosis may play a supportive role in tumorigenesis by inducing inflammation, a process 
known to promote cancer development [249]. 
While cell death is classically viewed as manifesting in one of three different forms, it is 
becoming clear that there are not only three types; rather, cell death involves a highly elaborate 
signaling network whose class and phenotype is defined by the activation and repression of 
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specific sets of signaling molecules. Apoptosis, necroptosis, and autophagy pathways overlap 
with one another with significant crosstalk in response to different stimuli [11]. Furthermore, 
many more related but distinct forms of cell death have been shown including anoikis, mitotic 
catastrophe, pyroptosis, paraptosis, pyronecrosis, cornification, entosis, and parthanatos [14, 250, 
251]. In cancer, cells evade normal death processes due to malfunction of this signaling regime, 
mainly apoptosis, autophagy, and necroptosis. Thus, targeting proteins that play important pro-
survival roles at the crossroads of multiple death pathways is a plausible method for cancer 
therapy. One such family of proteins is the inhibitor of apoptosis (IAP) family, which mediates 
cellular functions crucial to survival, apoptosis, and necroptosis.  In recent years a class of 
molecules known as Smac mimetics has shown promise in reactivating caspases by suppression 
of IAP activity (Appendix C). Several of these synthetic peptides are currently in clinical 
development for the treatment of cancer. 
Caspase control of apoptosis and necroptosis 
When cell death is a physiological necessity or cells become potentially tumorigenic, 
apoptosis is the most frequent biological outcome. Depending on stimulus and context, apoptosis 
can be activated through either an extrinsic or intrinsic pathway. Extrinsic apoptosis involves the 
binding of an external signaling ligand with its cognate receptor, in turn inducing toxic pathways 
within the cell. Intrinsic apoptosis is activated by cellular stresses such as radiation or chemical 
damage that are detected by the mitochondria, which respond by releasing apoptotic molecules 
that activate death pathways in the cytosol. Both extrinsic and intrinsic pathways are mediated by 
cascades of cysteine-aspartate proteases called caspases. Caspases activated by proteolytic 
cleavage serve as the executioners of apoptosis [17]. 
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Extrinsic apoptosis 
In the extrinsic pathway, cells respond to external signaling molecules that bind 
membrane-bound tumor necrosis factor (TNF) receptors (TNFRs). Binding of TNF family 
members, such as Fas, TNFα, and TNF-related apoptosis-inducing ligand (TRAIL), to TNFRs 
from outside the cell permits the recruitment of the adaptor Fas-associated protein with death 
domain (FADD) on the interior side of the membrane. This death-inducing signaling complex 
(DISC) can associate with other proteins that also influence cell fate (i.e., survival or necroptosis, 
discussed later) [252, 253]. To trigger apoptosis, DISC recruits the zymogen procaspase-8 and 
induces its cleavage to form the active initiator caspase-8 [254]. Caspase-8 then cleaves and 
activates caspase-3 and caspase-7 (caspase-7 can also be activated by cleaved caspase-3) [255]. 
Subsequently the effector caspases-3 and 7 cleave many target substrates including nuclear 
lamins and poly-ADP ribose polymerase (PARP) to disassemble the cell at the end of the 
apoptotic pathway [23]. 
Intrinsic apoptosis 
In contrast to extrinsic apoptosis, the intrinsic pathway is activated by nonspecific 
internal stresses that directly or indirectly lead to changes in mitochondrial membrane 
permeability. Under nonstress conditions, the pro-survival proteins Bcl-2 and Bcl-xL maintain 
mitochondrial membrane integrity by inhibiting their pro-apoptotic family members Bax, Bak, 
and Bid [18]. When the cell death pathway is induced, apoptotic proteins are activated through a 
variety of mechanisms relieving these inhibitory interactions. An example of this mitochondrial 
death protein activation can occur via the tumor suppressor p53. Following lethal signals, p53 is 
stabilized and can induce apoptotic genes as a nuclear transcription factor but also promote cell 
death proteins through direct interactions with Bcl-2 family members at the mitochondria [19]. 
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Following apoptotic insult, Bax and Bak oligomerize, causing the formation of pores in the 
OMM that increase its permeability [20]. 
Once the mitochondrial membrane has permeabilized, various death factors are released 
into the cytosol including Smac (second mitochondria-derived activator of caspases) and the 
ETC molecule cytochrome c [21]. Upon release from the mitochondria, Smac binds X-linked 
inhibitor of apoptosis (XIAP), neutralizing its ability to inhibit caspases, while cytosolic 
cytochrome c binds Apaf-1 and induces its oligomerization, forming the death complex known 
as the apoptosome [22]. The apoptosome recruits procaspase-9 and induces its cleavage into 
active caspase-9, which subsequently activates caspases-3 and 7 to mediate cellular disassembly 
[23]. 
Caspase-independent death 
Independent of caspase activation, additional mitochondrial proteins can induce cell 
death when released into the cytosol. These include endonuclease G and the flavoprotein known 
as apoptosis-inducing factor (AIF). In healthy mitochondria, endonuclease G generates RNA 
primers for mitochondrial DNA replication. When cells undergo mitochondria-mediated cell 
death, endonuclease G migrates to the nucleus and cleaves genomic DNA [256, 257]. Like 
cytochrome c, AIF is involved in mitochondrial redox function with a separate role in death 
induction. AIF is an oxidoreductase that is critical for metabolism and redox balance in healthy 
conditions [25, 26, 258]. Prior to release from the mitochondria, AIF is linked to the inner 
membrane by a hydrophobic tether that is cleaved by calpains and/or cathepsins upon specific 
stimuli [32, 36]. Once released into the cytosol, AIF translocates to the nucleus and recruits 
proteins such as endonuclease G to cause chromatin condensation and DNA degradation 
characteristic of programmed cell death [24]. Despite AIF's role in cell death, however, it is 
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worth noting that many cancer cells can exploit AIF's NADH oxidase activity to the benefit of 
their own survival [51, 54]. Because only a change in mitochondrial membrane permeability 
(which does not absolutely require caspases) is necessary for death mediated by AIF and 
endonuclease G, these distinct pathways are considered caspase-independent [259, 260]. 
Caspase-8 and necroptosis   
Caspases play a defining role in apoptosis but also control necroptosis. Specifically, 
caspase-8 inhibits necroptosis, preventing activation of the chaotic failsafe death pathway [261, 
262].  Active caspase-8 prevents this form of death by cleaving cylindromatosis (CYLD) and 
receptor-interacting protein kinases 1 and 3 (RIP1/RIP3), which normally activate TNF-mediated 
necroptosis; only when cell death is required and caspase-8 is unable to induce apoptosis does 
necroptosis occur [262, 263]. Necroptosis begins with the activating phosphorylation of RIP1 
and RIP3, which form a complex known as the necrosome [264-266]. Events downstream of 
necrosome formation are currently not well understood, but a known necroptosis-inducing 
substrate of RIP3 is the protein phosphoglycerate mutase family member 5 (PGAM5), a 
mitochondrial phosphatase capable of promoting survival by regulation of antioxidant pathways 
as well as mediating mitochondrial autophagy (mitophagy) [211-213, 218, 267]. When 
phosphorylated by RIP3, PGAM5 dephosphorylates and activates dynamin-related protein 1 
(Drp1). Activated Drp1 subsequently causes mitochondrial fragmentation that leads to cell death 
by necroptosis [215]. How mitochondrial fragmentation executes necroptosis remains unknown, 
although it has been reported that mitochondria released from cells undergoing necroptosis can 
act as a signal for immune intervention [268]. Thus, caspase-8 is able to divert specific signals 
away from promotion of survival or immunogenic necroptosis and towards the activation of the 
quiet apoptotic death pathway. Because of this esssential role in cell death, reactivation of 
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caspases in cancer is an area of research under investigation, specifically with small molecules 
that promote caspase activation by mimicking the caspase activator Smac (Appendix C). 
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APPENDIX B. TARGETING SUBTYPES OF PANCREATIC CANCER 
Clinical advantage of subtyping 
In this post-genomic era of cancer research, our ability to molecularly define various 
subtypes of cancer raises tremendous promise for the concepts of patient targeted therapies and 
precision medicine.  A particular bright spot in the utility of cancer subtyping is the example of 
breast cancer, which has been well defined at the molecular level: tumor subtypes are currently 
classified based upon the expression of estrogen receptor, progesterone receptor, and human 
epidermal growth factor receptor 2, and current targeted treatment strategies based on subtype 
assessment have increased clinical responses in the last decade [269].  In stark contrast to the 
subtype success achieved in breast cancer analysis is the present state of pancreatic ductal 
adenocarcinoma (PDAC).  PDAC is one of the most lethal malignancies and the fourth leading 
cause of cancer deaths, associated with a dismal 5-year survival rate of only ~5%. This poor 
outlook results from late-stage diagnosis of disease, as non-invasive early detection methods 
remain elusive in the clinic, and current treatment modalities extend patient lifespan by only 
several weeks to months [270].  
Typically PDAC has been treated as a single aggressive form of cancer, because disease 
is detected almost universally at advanced stages. The identification of common druggable 
molecular targets, especially those representing specific subgroups of PDACs, will allow therapy 
to be optimized to increase patient survival.  In recent years genomic expression profiling has 
begun to define separate PDAC subtypes [99, 271], a promising discovery for our efforts in 
treating PDAC. The next major step will therefore be to determine how these subtypes differ in 
clinically relevant ways and use these findings to target PDACs in a more focused and accurate 
approach. Recently Noll et al. reported studies identifying new diagnostic markers for PDAC 
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subtypes and demonstrating the first putative subtype-specific drug resistance mechanism [272]. 
These findings highlight molecular differences among PDAC subtypes and cumulatively 
represent a substantial step forward in understanding the pathogenesis of pancreatic cancer. This 
work is an important starting point for translating molecular studies to the clinic and the 
development of new therapeutics with the potential to achieve a significant improvement in 
patient outcome.  
Subtypes of pancreatic cancer 
Historically subtyping PDAC has been difficult, in large part due to the complex tumor 
microenvironment. In 2011 Collisson et al. [99] reported the existence of three separate 
subtypes—“classical,” “quasimesenchymal,” (QM-PDA), and “exocrine-like”—defined by 
differences in gene expression signatures, KRAS addiction, and drug response. Due to the 
absence of exocrine-like cell lines in vitro, this study only evaluated features of the classical and 
QM-PDA subtypes; the nature of the exocrine-like subtype, and whether this population is a true 
subgroup, has therefore remained an open question. In another study, Moffitt et al. [271] 
employed an approach that subtracted mRNA transcripts associated with normal pancreatic 
tissue that defined only two PDAC subtypes, “classical” and “basal,” the latter subtype showing 
some overlap with the previously defined QM-PDA group [273]. In the recent work of Noll et al. 
[272], patient tumor specimens were implanted into mice used to derive pancreatic 
adenocarcinoma (PACO) cell lines representative of each of Collisson’s subtypes, accompanied 
by histological and RNA profile verification, which confirms the existence of all three subtypes 
defined by Collisson et al. The establishment of cell lines of each subtype is an important 
accomplishment, as the absence of exocrine-like cells in vitro has in the past posed an 
unidentified challenge to accurate assessment of disease representative of all PDAC patients. 
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Identifying molecular and functional differences among these cell types, such as metabolism 
[100], tumor microenvironment [274], drug resistance [99, 272], and immune evasion and 
immunotherapy [275], in future studies will be highly valuable. 
Markers of pancreatic cancer subtypes 
To extend molecular characteristics of each subtype into clinical utility, an important step 
is to determine diagnostic markers for patient stratification. Noll et al. [272] presented surrogate 
protein markers for the PDAC subtypes, showing that hepatocyte nuclear factor 1, alpha 
(HNF1A) and cytokeratin 81 (KRT81) are enriched almost exclusively to exocrine-like and QM-
PDA subtypes, respectively (Table B1). Levels of HNF1A and KRT81 are inversely correlated 
in PDAC, and neither protein is frequently found in the classical subtype. Therefore using 
standard clinical immunohistochemical methods, the classical PDAC subtype can be determined 
by double negative (KRT81
-
HNF1A
-
, DN) status, KRT81
+
HNF1A
-
 for QM-PDA, and KRT81
-
HNF1A
+
 for the exocrine-like group in patients. HNF1A and KRT81 are associated with survival 
and grade: the KRT81
+
 subtype correlates with low mean survival and poor differentiation, 
whereas HNF1A
+
 tumors show the greatest mean survival and cell differentiation, with DN 
tumors lying in between for both survival and differentiation (Table B1). Although subtype 
appears to predict patient prognosis, overall average survival is very low (<5 years), 
underscoring the need to develop improved approaches to targeting PDACs, likely by identifying 
and targeting cellular processes unique to each group. 
CYP3A5 mediates PDAC drug resistance 
While classical and QM-PDA tumors are sensitive to cell death by small molecule 
chemotherapeutics, the exocrine-like subtype is resistant to these agents. Noll et al. go on to 
show that this drug resistance mechanism stems from elevated expression of cytochrome P450 
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3A5 (CYP3A5), a heme-thiolate monooxygenase normally expressed in the liver that mediates 
xenobiotic metabolism to detoxify drugs in the body [276, 277]. Expression of CYP3A5 
correlates positively with HNF1A and inversely with KRT81 in PDAC, and within the exocrine-
like subtype CYP3A5 expression is both elevated and drug-inducible relative to normal tissues, 
QM-PDA, and classical PDAC cells. CYP3A5 mediates resistance against tyrosine kinase 
inhibitors including erlotinib (EGFR inhibitor) and dasatinib (SRC and ABL1 inhibitor), as well 
as the CYP3A5 substrate paclitaxel, a cytoskeletal drug that disrupts microtubule breakdown 
during cell division. Both the pan-CYP inhibitor ketoconazole and shRNA-mediated knockdown 
of CYP3A5 sensitize exocrine-like cells to treatment, while expression of CYP3A4 or CYP3A7 
appear to be neither elevated nor important to PDAC drug resistance, suggesting that CYP3A5 is 
the lone culprit within the CYP family of enzymes. Furthermore, tumors cannot adapt to the loss 
of CYP3A5 following sustained treatment, which suggests that CYP3A5 makes an important 
candidate therapeutic target in exocrine-like tumors. Basal CYP3A5 expression in exocrine-like 
tumors is mediated by the transcription factor HNF4A, while drug-induced CYP3A5 is 
controlled by NR1I2, also known as PXR, and the presence of both CYP3A5-regulating proteins 
appears to have an additive effect in PDAC drug resistance. Therefore targeting these upstream 
regulators of CYP3A5 may also be therapeutically valuable. 
Though CYP3A5 appears to play a predominant role in facilitating cancer cell protection 
against chemotherapy only in exocrine-like tumors, CYP3A5-mediated drug resistance is not 
limited solely to exocrine-like PDACs. Indeed, when classical and QM-PDA tumors acquire 
resistance against therapy, CYPA5 expression and activity are elevated as an adaptation to 
sustained treatment, and ectopic expression of CYP3A5 confers protection to non-exocrine-like 
cells. Tissue microarray analyses suggest that CYP3A5-mediated drug resistance is not only a 
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feature of PDAC but other cancers as well, and these observations were confirmed using cancer 
cells of non-pancreatic origin. This suggests that CYP3A5 is a potential general target in cancer, 
and it will be important to determine its pro-tumor activities in other cancer types. 
Table B1. Characteristics of pancreatic cancer subtypes. 
 
KRT81 HNF1A CYP3A5 
Percentage of 
tumors 
Grade 
Mean 
survival 
Classical  - - - 45% 41.5% grade 3 26.3 months 
QM-PDA + - - 35% 50.6% grade 3 16.5 months 
Exocrine-like - + + 20% 24% grade 3 43.5 months 
 
Clinical potential of pancreatic cancer markers 
The pre-clinical characterization of all three PDAC subtypes in vivo is an important step 
forward in pancreatic cancer treatment. The establishment of PACO cell lines will be useful in 
determining further differences among subtypes, and the application of the finding that CYP3A5 
is a protector of exocrine-like cells will be valuable clinically. Given the known physiological 
roles of the CYPs, it is not surprising that CYP3A5 protects cancer cells from treatment, but its 
now confirmed role as a mediator of exocrine-like tumor drug resistance and its regulatory 
mechanisms in PDAC highlight its value as a potential target. We now have a mechanistic basis 
for differences in drug resistance among the PDAC subtypes (Figure B1), and in light of these in 
vivo studies, development of CYP3A5 drugs is warranted. CYP3A5 is dispensable to normal 
tissues [278, 279], but central to chemoresistance in PDAC. Despite high levels of CYP3A5 in 
tumors relative to healthy tissues, inhibiting the drug clearance activities of CYPs in 
noncancerous tissues presents the possible clinical pitfall of elevating the systemic toxicity of 
other chemotherapies. Therefore the significance of achieving high chemical specificity for 
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CYP3A5, but not other CYPs, is worth noting. An alternative approach to CYP3A5 inhibition 
might instead be to seek out anti-tumor agents that are not metabolized by CYPs and therefore 
circumvent CYP3A5-mediated resistance. Another possibility is the development of small 
molecules that serve as substrates for CYP3A5 (such as a modified form of paclitaxel), with the 
oxidation product functioning as an active form of the drug, thus turning the tumor’s resistance 
mechanism against itself. 
 
Figure B1. Mechanism of CYP3A5-mediated basal and acquired therapy resistance among 
PDAC subtypes. 
In exocrine-like tumors, basal expression of CYP3A5 is regulated by HNF4A while drug-
induced expression is mediated by NR1I2/PXR. Classical and QM-PDA tumors may acquire 
drug resistance via upregulation of CYP3A5 following sustained treatment. 
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Immunohistological detection of HNF1A and KRT81 may prove important to revealing 
which patients are likely to benefit from such therapy. Evaluating the subtype and context 
specificity of CYP3A5 in other cancer types will also be an important goal for therapeutic 
development, as well as determining if the correlation of HNF1A and KRT81 with CYP3A5 
extends to other cancers. Altogether the work of Noll et al. demonstrated a substantial body of 
clinically useful findings, yet the “smoking gun” for PDAC treatment remains elusive.  We can 
only hope that these targets represent three additional straws on the back of PDAC treatment, and 
may one day bring us that much closer to improved therapeutic intervention. 
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APPENDIX C. SMAC MIMETICS AND CELL DEATH 
Competition of inhibitors of apoptosis (IAPs) and caspases 
IAP proteins 
Since caspases can trigger cell death through rapid signal amplification, their apoptosis-
inducing capabilities must be tightly regulated under healthy conditions. The inhibitor of 
apoptosis (IAP) family of proteins prevents caspase-mediated cell death through a broad range of 
mechanisms, both directly and indirectly. IAPs, also known as baculoviral IAP repeat (BIR)-
containing (BIRC) proteins, are defined by characteristic zing finger domains originally 
discovered in baculoviruses that prevent apoptosis from occurring [280, 281]. To date, 8 IAPs 
have been identified, each exerting unique effects on cellular signaling pathways: neuronal 
apoptosis inhibitory protein (NAIP/BIRC1), cellular IAP 1 (cIAP1/BIRC2), cellular IAP 2 
(cIAP2/BIRC3), X-linked IAP (XIAP/BIRC4), survivin (BIRC5), BIRC ubiquitin-conjugating 
enzyme (BRUCE/apollon/BIRC6), melanoma IAP (ML-IAP/BIRC7), and IAP-like protein 2 
(BIRC8) [282]. As promoters of cell survival, it comes with little surprise that IAPs are often 
elevated in cancer, directly contributing to invasiveness and resistance to treatment. Current 
strategies to reactivate caspases in tumor cells focus on cIAP1, cIAP2, and XIAP, which utilize 
really interesting new gene (RING) domains to carry out their respective cellular functions [283]. 
The RING domain of XIAP participates in a range of signaling functions, while in cIAPs these 
domains are linked to BIR function and can inhibit cell death through multiple mechanisms. By 
targeting the BIR domains of IAPs, caspase inhibition can be quickly relieved and allow the cell 
to properly respond to death signals such as chemotherapy. 
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Cellular IAPs 1 and 2 
The survival proteins cIAP1 and cIAP2 promote survival and proliferation through 
ubiquitin mechanisms activating the canonical nuclear factor κB (NF-κB) pathway, which 
downstream results in the transcription of genes involved in inflammation, and many of these 
can be used by cancer cells to their own benefit [284, 285]. Upon binding of TNFα to TNFR1 on 
the cell surface, multiple proteins are recruited on the cytosolic side to form a protein 
supercomplex that includes cIAPs and RIP1. When this complex forms, cIAPs polyubiquitinate 
RIP1 via lysine 63 linkages in a non-degradative manner that results in activation of NF-κB and 
mitogen-activated protein kinase (MAPK) pathways [286-289]. NF-κB and MAPK signaling 
cascades lead to the activation of target genes that promote survival, proliferation, migration, and 
invasion [290]. TNFα can also trigger cell death, but only when cIAPs are inhibited or RIP1 is 
deubiquitinated [291]. Thus, while cIAP-regulated gene expression programs are crucial in cells 
such as lymphocytes during the immune response, cancer cells can often use the pro-survival 
capabilities of cIAPs to promote invasive behavior. By upregulating the activities of cIAPs, 
cancer cells not only prevent apoptosis from occurring but also directly promote growth and 
invasiveness through NF-κB and MAPK cascades, converting a death signal to a survival signal. 
X-linked IAP 
The most notorious of the IAPs in cancer is XIAP, which allows cells to resist many 
death stimuli including TNFα, Fas, ultraviolet radiation, and genotoxic agents [292]. Under 
normal cell conditions, XIAP ubiquitinates protein substrates through its E3 ligase activity to 
modulate signaling cascades of TGF-β, NF-κB, and c-Jun N-terminal kinase, as well as maintain 
copper homeostasis [48, 293-297]. In contrast to the cIAPs, which indirectly prevent caspase 
activation by ubiquitinating RIP1, XIAP is the only known IAP to suppress caspase activity 
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through direct binding, which is accomplished via its BIR domains [298]. The BIR2 domain of 
XIAP binds the active site groove of caspases-3 and 7 [299], while the BIR3 domain recognizes 
and binds the N-terminal Ala-Trp-Pro-Phe of caspase-9 to inhibit caspase action and promote 
cell survival [300, 301]. As a potent suppressor of death pathways, XIAP can also prevent 
caspase-independent cell death. By ubiquitinating AIF at lysine 255 via a non-canonical 
ubiquitin linkage, XIAP is able to prevent AIF from inducing chromatin degradation and 
subsequent cell death [49, 50]. 
HtrA2 
When cells undergo apoptosis, IAP neutralization is necessary for caspases to freely 
activate cell death. Thus, when mitochondrial membrane permeabilization occurs upon death 
stimuli, IAP-neutralizing proteins are released into the cytosol alongside cytochrome c and AIF. 
One of these proteins is the serine protease known as HtrA2 (also known as Omi). The four 
amino acid resides at the N-terminus (AVPS) of HtrA2 are structurally similar to the caspase 
regions necessary for recruitment to cIAP1 and XIAP. Unlike caspase binding, however, 
association of HtrA2 with XIAP both inhibits XIAP and results in its proteolytic cleavage by 
HtrA2, thereby preventing the apoptotic suppression [302-306]. 
Smac/DIABLO 
Another IAP repressor released into the cytosol is the second mitochondria-derived 
activator of caspases, or Smac, also known as direct IAP binding protein with low pI (DIABLO) 
[307, 308]. Smac exists as an elongated homodimer whose quaternary structure is stabilized by 
extensive hydrophobic interactions between its two subunits, an association critical for caspase 
activation [309]. Upon import into the mitochondrial membrane, the mitochondrial import 
peptide at the N-terminus is cleaved from Smac, forming the mature pro-apoptotic form [307, 
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308]. When released into the cytosol, the new N-terminus of Smac, which structurally resembles 
that of caspases, inhibits XIAP. The death-inducing N-terminus consists of four critical amino 
acid residues: Ala1, Val2, Pro3, and Ile4. Similar the XIAP-binding region of caspases and 
HtrA2, the Ala-Val-Pro-Ile (AVPI) motif of Smac recognizes and binds a distinct groove of 
XIAP's BIR3 domain with high affinity. Binding of Smac's AVPI peptide to XIAP's BIR3 
domain is stabilized both by hydrogen bonds and hydrophobic interactions [310]. This binding 
event competes with binding of caspase-9 to XIAP, thereby preventing XIAP inhibition of 
caspase-9 [301, 311]. Additionally, binding of the AVPI motif of one Smac subunit to BIR3 also 
stabilizes the interaction of Smac's second subunit's interaction with the BIR2 domain of XIAP 
(also using the AVPI motif) [283]. Binding of Smac to XIAP's BIR2 domain prevents XIAP 
from inhibiting caspases-3 and 7 [312]. Monomeric Smac is rare, if present at all, in biological 
settings, and the binding affinity to XIAP and efficiency of neutralization by dimeric Smac far 
exceed that of its monomeric form [309, 313]. The discovery of Smac's ability to suppress XIAP 
activity and subsequently promote caspase activation and apoptosis, specifically via its AVPI 
tetrapeptide, has gained significant attention as a potential pharmaceutical tool to promote 
apoptosis in cancer cells. 
Design of XIAP inhibitors to promote caspase activation and cell death 
Exploiting the AVPI peptide for clinical benefit 
A universal characteristic of cancer is an inability of tumor cells to properly undergo 
apoptosis. While many therapeutic strategies aim to induce cell death in tumors through chemical 
stress or death signaling ligands, cancer cells often resist treatment through elevation of anti-
apoptotic molecules. XIAP is often a major culprit in therapy resistance, and Smac levels 
become insufficient to permit proper caspase activation, either due to XIAP upregulation, Smac 
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downregulation, or a combination of the two, all of which directly correlate with cancer 
progression [314]. Thus, peptides that mimic the AVPI motif of Smac, or "Smac mimetics," have 
been proposed to compensate for insufficient Smac levels and inhibit XIAP to aid the cell in 
undergoing apoptosis. 
Smac mimetics 
Because of its widespread capabilities of cell death inhibition and its activity at the 
convergence of multiple death pathways, XIAP theoretically makes an excellent therapeutic 
target. Additionally, the AVPI peptide of Smac, which binds and alters XIAP activity, makes an 
ideal natural template for the design of drugs targeting XIAP. The design of most small 
molecules that can mimic Smac-IAP interactions are based on the crystal structure of Smac, 
specifically the AVPI peptide that binds the BIR3 domain of XIAP. To reproduce Smac-
mediated XIAP inhibition efficiently, Smac mimetics must maintain chemical properties similar 
to those most important for the binding of AVPI to BIR3.  When the N-terminus of mature Smac 
recognizes XIAP's BIR3 domain, the amino group at Smac's N-terminus associates via hydrogen 
bonds with the Glu314 and Gln19 residues of XIAP, while the indole group of XIAP's BIR3 
Trp323 forms a weaker hydrogen bond with Smac's Ala1 carbonyl group. To further stabilize 
binding, the methyl side chain of Smac's Ala1 fits into a hydrophobic pocket of XIAP. While the 
solvent-exposed side chain of Smac's Val2 residue does not interact with XIAP, its amino and 
carbonyl groups hydrogen bond with the carbonyl and amino groups XIAP's Thr308 residue. The 
hydrophobic ring of Smac Pro3 forms stabilizing interactions with XIAP's adjacent Trp323 and 
Tyr324 side chains. The amino group of Smac's Ile4 and XIAP's Gly306 form a hydrogen bond, 
while the side chain of Ile4 inserts into another hydrophobic pocket within XIAP consisting of 
the hydrophobic portions of Leu292, Val298, Lys297 and Lys299 [313, 315]. Overall the AVPI 
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peptide binds XIAP with a Kd of 480 nM [316], and many synthetic peptides that mimic AVPI 
are capable of eliciting potent biological responses. To date numerous small molecules have been 
developed to mimic Smac's N-terminal AVPI peptide. Depending on their precise chemical 
structure, Smac mimetics exert their biological effects through XIAP binding with a range of 
affinities, efficacies, and potencies. While some alterations to the AVPI template are acceptable, 
for example an ethyl group rather than a methyl group in Ala1 (although this does decrease 
affinity), other regions of the peptide are critical for effective binding and IAP neutralization, 
particularly the amine groups. Some modifications have even been found to improve binding 
affinity, notably the alteration of Ala1 to 2-aminobutyric acid or Ile4 to large hydrophobic 
substituents [316, 317]. 
Synthetic peptides based on AVPI bind IAPs with high affinity and effectively induce 
apoptotic pathways. However, these molecules are generally unable to cross cell membranes on 
their own. To promote the internalization of Smac mimetics into cells, several different chemical 
strategies have been used. One method frequently employed uses the cationic poly-arginine. 
Although the mechanism of delivery into cells by this method is not well understood, it is 
thought to involve electrostatic interactions between poly-arginine's positively charged side 
chains and the negatively charged membrane lipid head groups [318]. Indeed, conjugation of 
Smac mimetic peptides with 6-8 arginine units has been demonstrated to permit cellular 
incorporation [319]. In another technique for peptide delivery, Smac mimetic compounds are 
fused with penetratin, a peptide derived from the Drosophila transcription factor antennapedia 
[320]. Penetratin is an established peptide carrier that can effectively deliver molecules into cells 
due to its amphipathic nature [321-323]. Other Smac mimetic delivery methods have been 
demonstrated as well, such as exploiting validated tumor biomarkers like the σ2 receptor. 
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Delivery of Smac mimetics conjugated with the σ2 ligand causes tumor cells to internalize the 
peptides by endocytosis upon ligand-receptor binding [324, 325]. 
Smac mimetics are constructed as one of two forms, monovalent or bivalent, each with its 
own advantages and drawbacks. Monovalent Smac mimetics chemically mimic one AVPI 
peptide and are consequently comparable in size with AVPI. The low molecular weights of 
monovalent Smac mimetics provide desirable pharmacological properties, most notably high 
bioavailability. The primary disadvantage of monovalent Smac mimetic compounds, however, is 
the low potency compared to their bivalent counterparts [326, 327]. The Smac protein inhibits 
XIAP far more effectively as a dimer than a monomer, and for this reason bivalent Smac 
mimetics were developed to more accurately reproduce biological inhibition of XIAP. In contrast 
to monovalent compounds, bivalent Smac mimetics consist of two AVPI analogs tethered by a 
flexible linker [317, 328]. The linkage of two monovalent Smac mimetics to synthesize a 
bivalent compound can be achieved with little difficulty through the use of click chemistry 
techniques [317]. For effective XIAP inhibition by bivalent Smac mimetics, the tether compound 
must attach to each AVPI analog at a site that is solvent-exposed in the Smac protein template so 
not to interfere with XIAP binding. Because bivalent Smac mimetics act like a Smac dimer in 
cells, the efficiency of IAP neutralization by bivalent compounds exceeds that of monovalent 
peptides by 100-1000-fold [327]. Despite the drastic increase in potency compared to 
monovalent Smac mimetics, bivalent Smac mimetics have significantly greater molecular 
weights that result in much lower bioavailability. As a consequence bivalent Smac mimetics 
cannot be administered orally, and alternative routes such as intravenous administration must be 
used in patients [317], an option particularly unfavorable when frequent dosing is required. 
Although no studies have yet found routes to reconcile the advantages and setbacks of the two 
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Smac mimetic classes, it seems feasible that the high bioavailability of monovalent compounds 
and the superior potency of bivalent compounds may be combined. A potential method to 
achieve maximal therapeutic benefit could lie in the administration of a monovalent Smac 
mimetic followed by dimerization within the cell, perhaps via photooxidation methods. To date 
both Smac mimetic forms are in clinical trials. 
 Smac mimetic mechanisms of action: beyond XIAP inhibition 
Effect on cIAPs 
Smac mimetic design was originally based on the interaction between the AVPI motif of 
Smac and the BIR3 domain of XIAP [313, 315, 316]. It was first conceived that Smac mimetics 
would promote apoptosis by inhibiting XIAP and assisting caspase activation. Yet fortuitously, 
Smac mimetics were also found bind the BIR domains of cIAP1, cIAP2, and ML-IAP. In cancer 
cells cIAPs use their ubiquitin ligase activity to ensure that TNFR ligand binding results in 
survival rather than death signaling pathways. However, binding of Smac mimetics to cIAPs 
causes the cIAPs to ubiquitinate themselves, leading to rapid proteasomal degradation. The loss 
of cIAPs promotes the activation of NF-κB and subsequent production and secretion of TNFα 
[329-331]. Since cIAPs are known to promote NF-κB activity, the exact mechanism by which 
cIAP degradation induces NF-κB-activated TNFα production remains controversial. NF-κB 
activates both anti-apoptotic and pro-apoptotic genes, but in most cases the activation of survival 
genes outweighs that of NF-κB's death targets. However, it is suspected that when cIAPs are lost, 
the cell becomes sensitized to the death capabilities of NF-κB. Whatever the actual mechanism 
is, the autocrine signaling that follows TNFα secretion induces apoptosis in cancer cells. When 
autocrine TNFα binds TNFR1 without cIAPs present, RIP1 is no longer ubiquitinated and 
instead forms the DISC with FADD and caspase-8. Caspase-8 then becomes activated, and with 
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XIAP neutralized by Smac mimetic treatment, the caspase cascade can destroy the tumor cell 
free from suppression by IAPs [332]. Originally designed only to neutralize direct XIAP-
mediated caspase inhibition, the actual mechanism is far more elegant: Smac mimetic 
compounds trick cancer cells into secreting the survival factor TNFα, while at the same time 
tackling its IAP defenses to convert TNFα-induced signaling into a death pathway. 
Smac mimetics and necroptosis 
Smac mimetics are powerful activators of apoptosis as single agents in TNFα-sensitive 
cancer cells but can also sensitize resistant cells to chemotherapeutic agents including paclitaxel, 
etoposide, SN-38, doxorubicin, and cisplatin [319, 320, 329-331, 333]. Furthermore, Smac 
mimetic compounds can prime apoptosis-resistant cells for necroptosis [334-337]. Although 
rather infrequent, caspase deficiency has been reported for some cancers [338]. The loss of 
FADD, an important DISC protein, can also promote resistance to apoptosis in some tumors 
[339]. By preventing TNFα-stimulated survival pathways, Smac mimetic compounds can force 
apoptosis-resistant cancer cells to undergo necroptosis as an alternative death pathway. Although 
this pathway is incompletely understood, the induction of necroptosis may be an effective 
strategy in treating particularly aggressive forms of cancer, but the ramifications of necroptotic 
stimulation in clinical settings save not been defined. However, because Smac mimetic 
compounds can sensitize cells to necroptosis, they have become a powerful research tool for 
elucidating the inner workings of this newly identified process in addition to their clinical 
potential. 
Smac mimetics in clinical trials 
Currently 6 Smac mimetics, both monovalent and bivalent, have reached clinical trials: 
GDC-0152 (Genentech), GDC-0917/CUDC427 (Genentech/Curis), SM-406/AT-406/Debio1143 
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(University of Michigan, Ascenta Therapeutics, and Debiopharm), LCL161 (Novartis), 
TL32711/Birinapant (TetraLogic Pharmaceuticals), and AEG40826/HGS1029 (Aegera and 
Human Sciences). 
GDC-0152 and GDC-0917 
Genentech has developed two monovalent Smac mimetics that are currently in clinical 
trials for solid tumors and lymphomas. The first, GDC-0152, binds XIAP, cIAPs, and ML-IAP 
with affinities at the nanomolar level and was administered intravenously. Linear 
pharmacokinetics dosed from 0.049 to 1.48 mg/kg were reported [340]. GDC-0917, also 
monovalent, reached clinical phase I and was administered orally in 42 patients. Tumor biopsies 
showed decreased cIAP1 levels, increased caspase-3 levels, and PARP cleavage; 2 patients had 
unconfirmed complete responses and 4 had stable disease lasting greater than 3 months. Adverse 
effects included diarrhea, nausea, fatigue, vomiting, and constipation [341, 342]. 
SM-406 
SM-406, an orally bioavailable monovalent Smac mimetic, reached clinical phase I trials 
in combination with daunorubicin, cytarabine, carboplatin, paclitaxel, and chemo-radiation 
therapy in advanced solid tumors, lymphomas, acute myelogenous leukemias, and head and neck 
squamous cell carcinomas. Adverse effects were similar to GDC-0152 and GDC-0917, and a 
fraction of patients had stable disease at first evaluation [343]. LCL161, also monovalent and 
administered orally, has shown little toxicity and caused reduction in cIAP levels in biopsy 
samples. LCL161 has been tested in phases I and II trials as a single agent and in combination 
with paclitaxel, gemcitabine, and cyclophosphamide in solid cancers, metastatic pancreatic 
cancer, triple negative breast cancer, multiple myeloma, and leukemia. Partial responses were 
observed in some patients [342, 344, 345]. 
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AEG40826 
AEG40826, a bivalent Smac mimetic compound administered intravenously, has 
undergone phase I dose escalation studies in advanced solid cancers and lymphoid malignancies. 
Like other Smac mimetics in clinical development, AEG40826 rapidly induces cIAP1 
degradation with evidence of apoptosis in tumor specimens. Adverse effects included fever, 
fatigue, vomiting, diarrhea, rash, and anorexia. Of 44 patients enrolled, 2 showed stable disease 
for at least 6 months, while one patient showed tumor regression [342, 346]. 
Birinapant 
Birinapant, developed by TetraLogic Pharmaceuticals, is currently the most advanced 
Smac mimetic compound in clinical development. Birinapant has reached phase II trials both as 
a single agent and in combination with other chemotherapies. Birinapant is a bivalent compound 
delivered via intravenous administration and has the highest claimed efficacy of Smac mimetics 
with more than half of enrolled patients receiving clinical benefit. Birinapant rapidly causes 
cIAP1 degradation and unlike other Smac mimetics does not systemically induce inflammatory 
cytokines, leading to improved tolerability [342, 347-349]. 
Conclusion 
Since the discovery of Smac as a caspase activator and XIAP inhibitor, the application of 
its pro-apoptotic mechanisms by molecular mimicry has achieved results greater than expected 
through the combination of both XIAP inhibition and cIAP degradation, leading both to 
apoptosis induction and sensitization of tumor cells to multiple death pathways. These findings 
have established the use of Smac mimetics as a powerful method for cell death research and a 
potential therapeutic option in clinical settings. Overall Smac mimetics in clinical development 
potently promote cIAP degradation, are generally well tolerated, and suppress tumorigenesis 
 269 
both as single agents and synergistically with other therapies. Consistent with in vitro and 
preclinical studies, Smac mimetics are effective in a subset of cancers, and further research may 
expand the understanding of cell death mechanisms and the optimization of Smac mimetic 
therapy in cancer patients. 
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APPENDIX D. PRIMERS 
Table D1. Primer sequences. 
Gene Forward primer Reverse primer 
AIF 
TACCTCAGCAACTGGACCAT
GGAA 
TACCTTCCTGCCGTCTTTCAG
CTT 
E-Cadherin ACGCATTGCCACATACA CGTTAGCCTCGTTCTCA 
GAPDH CCCACTCCTCCACCTTTGAC TGTTGCTGTAGCCAAATTCGT 
GCLM 
CTGCTGTGTGATGCCACCAG
ATTT 
GTGCGCTTGAATGTCAGGAA
TGCT 
GGT1 
TTCTGCCGGGATAGAAAGGT
GCTT 
TCAGCTCAGCACGGTAGTTG
TTC 
GSR 
ACGAGTGATCCCAAGCCCA
CAATA 
TGTAACCTGCACCAACAATG
ACGC 
GSTM1 
AACGCCATCTTGTGCTACAT
TGCC 
TAGCAGATCATGCCCAGCTG
CATA 
HMOX1 
ATTGCCAGTGCCACCAAGTT
CAAG 
ACGCAGTCTTGGCCTCTTCTA
TCA 
HMOX2 
AATGAGAATGGCTGACCTCT
CGGA 
GATGGTCCTTGTTGCGCTCCA
TTT 
Met GGTCAATTCAGCGAAGTCCT CCAGTGTGTAGCCATTTTGG 
N-Cadherin GAAAGACCCATCCACG CCTGCTCACCACCACTA 
NQO1 
TGCAGCGGCTTTGAAGAAG
AAAGG 
TTCGCAGGGTCCTTCAGTTTA
CCT 
Serpine 
ATTCAAGCAGCTATGGGATT
CAA 
CTGGACGAAGATCGCGTCTG 
Snail 
AATCGGAAGCCTAACTACA
GCG 
GTCCCAGATGAGCATTGGCA 
Twist1 GGAGTCCGCAGTCTTACGAG TCTGGAGGACCTGGTAGAGG 
Vimentin 
ACCAGCTAACCAACGACAA
AG 
GCAGGGTGTTTTCGGCTTC 
Zeb1 
TGCACTGAGTGTGGAAAAG
C 
TGGTGATGCTGAAAGAGACG 
Zeb2 CAAGAGGCGCAAACAAGC GGTTGGCAATACCGTCATCC 
β-Actin 
GCGGGAAATCGTGCGTGAC
ATT 
GATGGAGTTGAAGGTAGTTT
CGTG  
